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ABSTRACT
This thesis investigated the extent to which genetic factors underlie the 
variations observed in fetal haemoglobin (HbF) levels.  This is important as it is 
known that an elevated HbF level can ameliorate the symptoms of many of the 
haemoglobinopathies.  
The frequency and range of hereditary persistence of fetal haemoglobin (HPFH) 
in the UK population was determined which was otherwise unknown.  All 4 
categories of deletion mutations were identified and demonstrated the high 
frequency of deletional HPFH in UK patients.  Four potentially novel deletions 
were identified and 2 fully characterised.  One novel deletion was the first 
reported case of a large β0-thalassaemia deletion mutation in the Afghan
population.  Mutations in the γ-globin gene promoters were identified as a 
frequent (21% of patients) cause of non-deletion HPFH in the UK.  The majority 
of mutations being in white British individuals with elevated HbF levels only, 
probably arisen independently through genetic drift.  The strongest association 
with the three polymorphisms and HbF expression was seen in β-thalassaemia 
trait subjects with the XmnI-HBG2 polymorphism. The SNPs in BCL11A and 
HBS1L-MYB failed to show statistical correlations with HbF.  Heterozygosity for 
ten novel mutations in the KLF1 gene were indentified in patients with a high 
HbF indicating that a single altered KLF1 allele can elevate HbF. The 
identification of a KLF1 mutation in an individual with a particularly mild form of 
sickle cell disease could provide in-vivo evidence that controlled reduction of 
KLF1 expression could be an effective treatment for sickle cell disease.  Finally, 
the finding that Asian Indian newborns undergo haemoglobin switching earlier 
than other ethnic groups was investigated.  Birth weight, gestation and 
chromosomal abnormalities were not responsible and the frequency of the 
4.9kb γ-thalassaemia deletion mutation was determined to be low.   
ii 
ACKNOWLEDGEMENTS 
Firstly I would like to thank my supervisors.  I am very grateful to Dr John Old 
for giving me the opportunity to carry out this research in his laboratory and 
count it a great privilege to have been able to work with him. 
Thanks to Dr Shirley Henderson for guiding me through the process of scientific 
writing and for her enthusiasm for my work.  Special thanks to Dr Tony 
Bradshaw who has been behind me all the way and been a constant source of 
encouragement.  His help and kindness I will not forget. 
Thanks to all my colleagues in the Molecular Haematology Department who 
have been very supportive and to the staff in the Life Sciences Department at 
Oxford Brookes University. 
Finally and most importantly I want to thank Olly, Zoë and Sam who have 
tirelessly encouraged me and got me through some of the most difficult times. 
To my family and friends I must say a huge thank you for your understanding 
and putting up with me never being around. 
  iii 
LIST OF ABBREVIATIONS 
ANOVA analysis of variance 
ARMS  amplification refractory mutation system 
BCL11A B-cell lymphoma/leukemia 11A  
bp  base pair 
CAP  catabolite activator protein 
oC  degrees centigrade 
CDA  congenital dyserythropoietic anaemia 
CP1  Cysteine proteinase-1 
CDP  CCAAT displacement protein 
cnLOH copy neutral loss of heterozygosity 
DNA  deoxyribonucleic acid 
DNase deoxyribonuclease 
dNTPs deoxynucleotide triphosphates 
DTT  dithiothreitol  
EDTA  ethylenediaminetetraacetic acid 
EKLF  erythroid kruppel-like Factor 
kb  kilobase 
KCL  potassium chloride 
KHCO3 potassium hydrogen carbonate 
KLF  kruppel-like factor 
FBC  full blood count 
FC  f cell 
fl  femtolitre 
FOG  friend of GATA 
g  gram 
g/dl  gram per decilitre 
g/L  gram per litre 
GATA  GATA binding-factor 
Glu  glutamic acid 
GWAS genome wide association study 
Hb  haemoglobin 
HbA  adult haemoglobin 
HbF  fetal haemoglobin 
HbS  sickle haemoglobin 
HBS1L HBS1-like (S. cerevisiae) 
Hct  hematocrit 
HGVS  human genome variation society 
HMIP  HBS1L-MYB intergenic polymorphism 
HPFH  hereditary persistence of fetal haemoglobin 
HPLC  high performance liquid chromatography 
HS  Dnase I hypersensitive site 
HS 1-5 Dnase I hypersensitive site 1-5 
HS-40  Dnase I hypersensitive site -40 
HVR  hypervariable region 
IVS  intervening sequence 
IEF  isoelectric focusing 
LCR  locus control region 
Lys  lysine 
  iv 
M  molar 
Mb  megabase 
MCV  mean cell volume 
MCH  mean cell haemoglobin 
mg  milligram 
µg  microgram 
min  minute 
µl  microlitre 
mM  millimolar 
µM  micromolar 
ml  millilitre 
MgCl2  magnesium chloride 
MgSO4 magnesium sulphate 
MLPA  multiplex ligation-dependent probe amplification 
mRNA  messenger RNA 
MYB  myeloblastosis gene 
NaCl  sodium chloride 
NaOH  sodium hydroxide 
NF-E2  nuclear factor erythroid 2 
NF-E3  nuclear factor erythroid 3 
ng  nanogram 
NH4Cl  ammonium chloride 
OD  optical density 
OCT-1 octamer transcription factor 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
pg  picogram 
pI  isoelectric point 
pmole  picomole 
QTL  quantitative trait locus 
RBC  red blood cell 
RE  reticuloendothelial system 
RFLP  restriction fragment length polymorphism 
RNA   ribonucleic acid 
rpm  revolutions per minute 
RT  room temperature 
SD  standard deviation 
SDS  sodium dodecyl sulphate 
sec  second 
SIFT  software implemented fault tolerance 
SNP  single nucleotide polymorphism 
SOX6  SRY (sex determining region Y)-box 6 
Sp1  specificity protein 1 
SS  sickle cell disease 
SSP  stage selector protein 
TBE  tris-borate-EDTA 
TE  tris-EDTA 
TF  transcription factor 
TRIM  tripartite motif gene 
TRIS  2-amino-2-(hydroxyl)-1, 3-propanedol 
  v 
U  unit 
UCSC  university of California, Santa Cruz 
UK  United Kingdom 
UPD  uniparental disomy 
UV  ultra violet 
V  volt 
Val  valine 
WHO  world health organistion 
Zn  zinc
  vi 
LIST OF FIGURES 
 
Figure 1.1 Synthesis of individual globin chains in prenatal and postnatal life. .. 3 
Figure 1.2 The α- and β-globin clusters.............................................................. 5 
Figure 1.3 Long-range chromatin looping in the -globin locus.......................... 7 
Figure 1.4 Proposed mechanisms of HbF production. ..................................... 14 
Figure 1.5 Transcription factor binding regions and positions of known 
mutations in the γ-globin gene promoters. ...................................... 26 
Figure 1.6 Genomic organisation of the β-globin gene cluster with the different 
polymorphic restriction enzyme sites. ............................................. 30 
Figure 1.7 Model of BCL11A silencing of the γ-globin genes. .......................... 35 
Figure 1.8 KLF1 regulates globin switching...................................................... 37 
Figure 3.1 HPFH-2 deletion mutation by MLPA and Gap-PCR. ....................... 59 
Figure 3.2 The human β-globin gene cluster on chromosome 11p. ................. 62 
Figure 4.1 MLPA results for deletion 1 (β-globinxs MLPA Kit; ServiceXS). ....... 69 
Figure 4.2 Gap-PCR amplification products in deletion 1................................. 70 
Figure 4.3 Sequence analysis results (β-globin gene) for deletion 1. ............... 71 
Figure 4.4 β-globin gene cluster MLPA results for deletion 2. .......................... 74 
Figure 4.5 Schematic representations of the MLPA probes deleted in deletion 2.
....................................................................................................... 75 
Figure 4.6 Analysed sequence data (Mutation Surveyor®) on the mother 
showing the deletion breakpoint. .................................................... 76 
Figure 4.7 Diagram showing the size and location of the 1,393bp deletion in 
relation to the β-globin gene. .......................................................... 77 
Figure 4.8 ServiceXS MLPA results for deletion 3............................................ 79 
Figure 4.9 Schematic representation of the probes reduced in height in deletion 
3 (ServiceXS MLPA set). ................................................................ 80 
Figure 4.10 Microarray (iScan) results for deletion 3........................................ 81 
Figure 4.11 Schematic representation of the probes reduced in height in 
deletion 3 (ServiceXS) with the size of the deletion from the 
microarray....................................................................................... 82 
Figure 4.12 Diagram showing the pedigree of the Asian Indian family with 
(εγδβ)0-thalassaemia (deletion). ...................................................... 85 
Figure 4.13 ServiceXS MLPA results for deletion 4.......................................... 86 
Figure 4.14 Schematic representation of the probes reduced in height in 
deletion 4 (ServiceXS). ................................................................... 87 
Figure 4.15 SNP microarray (iScan) results for deletion 4. .............................. 88 
Figure 5.1 Positions of point mutations in the Gγ-globin gene promoters.......... 95 
  vii 
Figure 5.2 Positions of point mutations in the Aγ-globin gene promoters. ......... 96 
Figure 5.3 Map of the UK showing where the 12 patients with the British  -198 
Gγ point mutation originate. Adapted from www.map-of-UK.com.... 99 
Figure 6.1 Association between rs7482144 genotypes and the proportion of 
HbF............................................................................................... 107 
Figure 6.2 Association between rs9399137 genotypes and the proportion of 
HbF............................................................................................... 109 
Figure 6.3 Association between rs11886868 genotypes and the proportion of 
HbF............................................................................................... 111 
Figure 7.1 Diagram showing the position of the mutations identified in the KLF1 
gene.............................................................................................. 124 
Figure 7.2 HPLC and IEF results for case 12. ................................................ 129 
Figure 7.3 SNP array B allele frequency plots for case 12. ............................ 131 
Figure 7.4 Diagram showing the inheritance of uniparental disomy. .............. 132 
Figure 8.1 Histogram and boxplot showing HbA levels in each ethnic group. 139 
Figure 8.2 Histogram and boxplot showing the birth weight (g) at 38-40 weeks 
gestation in each ethnic group...................................................... 141 
Figure 8.3 Schematic representation of deletional γ-thalassaemia................. 143 
Figure 8.4 β-globin gene cluster MLPA results (ServiceXS) on the Asian Indian 
family. ........................................................................................... 145 
Figure 8.5 Gap-PCR showing the 4.9kb γ-thalassaemia deletion mutation. ... 147 
Figure 9.1 Summary of results showing the frequency of deletional and non 
deletion HPFH in the UK population. ............................................ 160 
Figure 9.2 Summary of results showing the frequency of non deletion HPFH in 
both patients with high HbF only and patients with a 
haemoglobinopathy and an unexplained raised HbF level. .......... 161 
  viii 
LIST OF TABLES 
Table 1.1 Classification of genetic disorders of haemoglobin........................... 10 
Table 1.2 Reported δβ-thalassaemia mutations*.............................................. 18 
Table 1.3 Reported deletional HPFH mutations*.............................................. 22 
Table 1.4 Reported non-deletion HPFH point mutations*................................. 24 
Table 3.1 Haematological indices and MLPA results of common β- globin 
cluster deletions confirmed by Gap-PCR........................................ 60 
Table 3.2 Haematological indices and MLPA results of rare/novel β− globin 
cluster deletions.............................................................................. 61 
Table 4.1 Haematological parameters for deletion 1. ....................................... 68 
Table 4.2 Haematological parameters on the mother in deletion 2. ................. 73 
Table 4.3 Haematological parameters on deletion 3. ....................................... 78 
Table 4.4 Haematological parameters for the pedigree with deletion 4............ 84 
Table 5.1 Haematological parameters and genotypes in patients with mutations 
detected in the Gγ globin gene promoter region. ............................. 93 
Table 5.2 Haematological parameters and genotypes in patients with mutations 
detected in the Aγ globin gene promoter region. ............................. 94 
Table 6.1 Mean value of HbF % associated with the rs7482144 (XmnI) 
polymorphism for each SNP genotype. ........................................ 108 
Table 6.2 Mean value of HbF % associated with the rs9399137 (intergenic 
region of HBS1L-MYB) polymorphism with each SNP genotype.. 110 
Table 6.3 Mean value of HbF % associated with the rs11886868 (on the 
BCL11A gene) polymorphism with each SNP genotype............... 112 
Table 7.1 Haematological parameters and genotypes in subjects with mutations 
detected in the KLF1 gene............................................................ 123 
Table 7.2 HiSeq 2500 whole exome sequence analysis results for case 12. . 133 
Table 8.1 HbA % in newborns from Caucasian, Asian Indian and black African 
origins ........................................................................................... 138 
Table 8.2 Average birth weight at term (38-40 wks gestation) from Caucasian, 
Asian Indian and black African newborns ..................................... 140 
Table 8.3 Haematological data in family with γ-thalassaemia......................... 144 
 
 
 
 
  ix 
CONTENTS 
ABSTRACT ................................................................................................i 
ACKNOWLEDGEMENTS .........................................................................ii 
LIST OF ABBREVIATIONS .....................................................................iii 
LIST OF FIGURES ...................................................................................vi 
LIST OF TABLES...................................................................................viii 
LIST OF TABLES...................................................................................viii 
CONTENTS ..............................................................................................ix 
CHAPTER ONE: INTRODUCTION...........................................................1 
1.1 Introduction ...............................................................................................1 
1.2 Haemoglobin.............................................................................................2 
1.2.1 Structure and genetic control of normal human haemoglobin ............ 2 
1.2.2 α-globin cluster................................................................................... 4 
1.2.3 β-globin cluster ................................................................................... 4 
1.2.4 Haemoglobin switching ...................................................................... 5 
1.3 Inherited disorders of haemoglobin...........................................................8 
1.3.1. Structural haemoglobin variants........................................................ 9 
1.3.2 The thalassaemias ........................................................................... 11 
1.4 Fetal Haemoglobin (HbF)........................................................................12 
1.5 Acquired increases in HbF levels in adults .............................................13 
1.6 Genetic disorders increasing HbF levels in adults ..................................15 
1.6.1 Secondary increases in HbF levels .................................................. 15 
1.6.2 Primary increases in HbF levels ....................................................... 16 
1.7 Deletional HPFH .....................................................................................22 
1.8 Non-deletion HPFH.................................................................................23 
1.8.1 γ-globin gene promoter mutations .................................................... 23 
1.8.2 γ-globin gene rearrangements.......................................................... 25 
1.8.3 Swiss type of non-deletion HPFH..................................................... 27 
1.9 Therapeutics for HbF induction...............................................................39 
1.10 Thesis aims...........................................................................................40 
CHAPTER TWO: MATERIALS AND METHODS...................................41 
2.1 Introduction .............................................................................................41 
2.2 Haematological analysis .........................................................................41 
2.2.1 Full blood count (FBC) ..................................................................... 41 
2.2.2 High performance liquid chromatography (HPLC)............................ 41 
2.2.3 Isoelectric focusing (IEF).................................................................. 42 
2.3 Extraction of genomic DNA.....................................................................42 
2.3.1 Manual phenol-chloroform DNA extraction from whole blood .......... 42 
2.3.2 Automated chemagen DNA extraction from whole blood ................. 43 
2.3.3 Extraction of DNA from hair follicles ................................................. 44 
2.3.4 Extraction of DNA from dried blood spots ........................................ 44 
2.4 Measurement of DNA concentration by nanodrop ..................................44 
2.5 Polymerase chain reaction (PCR)...........................................................45 
2.5.1 Long range PCR............................................................................... 46 
  x 
2.5.2 Gap-PCR for the common β-globin gene cluster deletion mutations 47 
2.6 Agarose gel electrophoresis of DNA.......................................................47 
2.7 DNA sequence analysis..........................................................................48 
2.7.1 PCR product purification .................................................................. 48 
2.7.2 Cycle sequencing............................................................................. 48 
2.7.3 Ethanol precipitation......................................................................... 49 
2.7.3 Analysis of sequence data by mutation surveyor ............................. 50 
2.8 Pyrosequencing assays for the SNPs in BCL11A and HBS1L-MYB ......50 
2.9 Multiplex ligation-dependent probe amplification (MLPA) .......................51 
2.10 Genome-wide SNP array ......................................................................52 
2.11 Next-generation whole exome sequencing ...........................................53 
CHAPTER THREE: BETA GLOBIN GENE CLUSTER DELETIONS 
ASSOCIATED WITH INCREASED HBF LEVELS IN ADULTS .............54 
3.1 Introduction .............................................................................................54 
3.2 Detecting β-globin gene deletions...........................................................55 
3.3 Study subjects ........................................................................................56 
3.4 Laboratory procedures............................................................................56 
3.5 Results....................................................................................................57 
3.6 Discussion ..............................................................................................63 
CHAPTER FOUR: MAPPING OF PRECISE BREAKPOINTS IN NOVEL 
DELETIONS ............................................................................................67 
4.1 Introduction .............................................................................................67 
4.2 Deletion 1................................................................................................67 
4.3 Deletion 2................................................................................................73 
4.4 Deletion 3................................................................................................78 
4.5 Deletion 4................................................................................................83 
4.6 Discussion ..............................................................................................90 
CHAPTER FIVE: GAMMA GLOBIN GENE PROMOTER MUTATIONS 
ASSOCIATED WITH INCREASED HBF LEVELS IN ADULTS .............91 
5.1 Introduction .............................................................................................91 
5.2 Study subjects ........................................................................................91 
5.3 Laboratory procedures............................................................................92 
5.4 Results....................................................................................................92 
5.5 Discussion ..............................................................................................97 
CHAPTER SIX: DNA POLYMORPHISMS ASSOCIATED WITH 
INCREASED HBF LEVELS IN ADULTS..............................................103 
6.1 Introduction ...........................................................................................103 
6.2 Study subjects ......................................................................................103 
6.3 Laboratory procedures..........................................................................104 
6.4 Results..................................................................................................104 
6.4.1 rs7482144 XmnI-HBG2 .................................................................. 105 
6.4.2 rs9399137 HBS1L-MYB ................................................................. 105 
6.4.3 rs11886868 BCL11A ...................................................................... 106 
6.5 Discussion ............................................................................................113 
  xi 
CHAPTER SEVEN:  KLF1 GENE ASSOCIATED WITH INCREASED 
HBF LEVELS IN ADULTS ....................................................................118 
7.1 Introduction ...........................................................................................118 
7.2 Study subjects ......................................................................................119 
7.2.1 Elevated HbF level and matched control group.............................. 119 
7.2.2 Sickle cell disease.......................................................................... 120 
7.3 Laboratory procedures..........................................................................120 
7.4 Results..................................................................................................121 
7.4.1 Elevated HbF subjects ................................................................... 121 
7.4.2 Sickle cell anaemia subjects .......................................................... 122 
7.4.3 Tolerated SNPs.............................................................................. 122 
7.5 Discussion ............................................................................................125 
7.6 Case 12 – KLF1 mutation in a sickle cell disease patient .....................128 
CHAPTER EIGHT: HAEMOGLOBIN SWITCHING OCCURS EARLIER 
IN ASIAN-INDIAN NEWBORNS THAN NEWBORNS FROM OTHER 
ETHNIC GROUPS.................................................................................135 
8.1 Introduction ...........................................................................................135 
8.2 Differences in haemoglobin switching in newborns ..............................135 
8.3 Accurate HPLC quantitation of haemoglobins in newborns ..................136 
8.4 Study subjects and laboratory procedures............................................137 
8.5 HbA levels in Caucasian, Asian Indian and black African newborns born 
at 38-40 weeks gestation............................................................................138 
8.6 Birth weight ...........................................................................................140 
8.7 γ-thalassaemia ......................................................................................142 
8.7.1 Identification of γ-thalassaemia by MLPA....................................... 143 
8.7.2 Case of γ-thalassaemia in an Asian Indian family .......................... 144 
8.7.3 Identification of γ-thalassaemia by Gap-PCR ................................. 146 
8.7.4 Chromosomal abnormalities........................................................... 148 
8.8 Discussion ............................................................................................149 
CHAPTER NINE: DISCUSSION ...........................................................153 
9.1 Summary of findings .............................................................................153 
9.2 Conclusions ..........................................................................................158 
9.3 Future work...........................................................................................162 
REFERENCES ......................................................................................163 
APPENDICES .......................................................................................185 
APPENDIX 1: Diagram showing the principle of the MLPA technique........185 
APPENDIX 2: Schematic representation of β-globin gene cluster MLPA probe 
set designed by Harteveld et al (2005). ......................................................186 
APPENDIX 3: Pyrosequencing assay design rs 11886868 ........................187 
APPENDIX 4: Pyrosequencing assay design rs 9399137 ..........................188 
APPENDIX 5: Statistical analysis ...............................................................189 
APPENDIX 6: Publications arising from this work.......................................190 
  1 
CHAPTER ONE: INTRODUCTION 
1.1 Introduction 
 
Fetal haemoglobin (HbF, α2γ2) is the major haemoglobin (Hb) produced during 
intrauterine life.  As both fetal and adult Hb (HbA, α2β2) contain α-globin chains, 
the switch from fetal to adult Hb production is essentially that of the replacement 
of γ-globin with β-globin gene expression.   After birth the percentage of HbF 
progressively falls over several months to less than 1% of the total haemoglobin 
(97% HbA, 3% HbA2).  By six months of age mutations which affect the β-globin 
gene such as β-thalassaemia and sickle cell disease become clinically 
apparent.  However, in some individuals the HbF levels do not fall to <1% and 
remain elevated.  These conditions are known as hereditary persistence of fetal 
haemoglobin (HPFH) and δβ-thalassaemia.  In a proportion of cases the genetic 
reasons for HPFH disorders are understood; however, in many cases the 
molecular basis of the HPFH disorder remains obscure. 
 
The degree of HbF persistence varies greatly between individuals and this 
variability is largely genetically controlled (Garner et al., 2000). Whilst 
persistence of high levels of HbF production have no clinical consequences in 
healthy individuals, high HbF levels have immense clinical benefits associated 
with milder disease progression and fewer complication in patients with sickle 
cell disease and β-thalassaemia (Thein and Menzel, 2009).  Even a relatively 
modest increase in production of HbF is known to significantly benefit 
haemoglobinopathy patients.  Major advances have been made in our 
understanding of the molecular mechanisms and pathophysiology of these 
haemoglobinopathies.  However, problems still arise in genetic counselling and 
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clinical management as predicting the disease severity remains difficult.  The 
ability to be able to identify the different genetic factors involved could provide 
more precise estimates of disease severity and increasing our knowledge of the 
molecular mechanisms could reveal new targets for therapeutic intervention 
(Thein, 2008).  With this in mind, this project was aimed at trying to establish the 
genetic reasons responsible for the variation in HbF levels seen in the UK 
population and provide further understanding of the molecular mechanisms 
involved. 
1.2 Haemoglobin 
 
Haemoglobin is a vehicle for transporting oxygen.  It picks up oxygen as the red 
cell passes through the lungs and releases oxygen when the red cell reaches 
the capillaries of the tissues.   
 
1.2.1 Structure and genetic control of normal human haemoglobin Human 
haemoglobin was one of the first proteins to have its amino acid structure and 
DNA sequence identified and has been intensely studied partly due to its 
abundance in blood.  All normal haemoglobin molecules have a tetrameric 
structure consisting of two different pairs of identical peptide chains, either α-
like or β-like globin chains.  The α-like peptide chains (α and ζ) are made up of 
141 amino acids whereas the β-like chains (ε, γ, δ and β) each consist of 146 
amino acids.  The structure of haemoglobin changes throughout development 
(Figure 1.1) giving rise to embryonic, fetal and adult haemoglobins.  In the 
embryo there are three types of haemoglobin, HbPortland (ζ2γ2), HbGower 1 
(ζ2ε2) and HbGower 2 (α2ε2).  Fetal haemoglobin (α2γ2) replaces the embryonic 
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haemoglobins by 10 weeks post-conception (Figure 1.1).  HbF is comprised of 
two different types of γ-chains, Gγ and Aγ, differing only at amino acid position 
136 which is either glycine or alanine respectively.  Adult haemoglobin (HbA) 
has two α-chains combined with two β-chains (α2β2).  The β-globin gene is 
expressed at low levels during early fetal life with the main switch to adult 
haemoglobin occurring 3-6 months after birth (Figure 1.1).  In addition to HbA, 
adults also have a minor haemoglobin component HbA2 (α2δ2).  HbA2 is a 
haemoglobin without an obvious physiological function and it has been 
suggested that the δ-gene will eventually end up as a pseudogene (Steinberg & 
Nagel, 2009) Normal adult haemoglobin consists of HbA (~96%), HbA2 (~3%) 
and a small amount of HbF (~1%).   
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Figure 1.1 Synthesis of individual globin chains in prenatal and postnatal 
life. The sites of haemopoiesis at different stages of development and the levels 
of expression of the different globin chains at various gestational ages are 
shown (adapted from Hoffbrand et al., 1993). 
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Genetic analysis has established that the genes responsible for globin synthesis 
lie in two developmentally regulated multigene clusters on separate 
chromosomes known as the α-globin and the β-globin clusters. 
1.2.2 α-globin cluster 
The α-globin cluster is over 70 kilobases long and is on the short arm of 
chromosome 16 (16p13.3).  The cluster has three functional genes ζ2, α1 and 
α2, two non-transcribed pseudogenes ψζ1, ψα1, the θ and recently designated 
 αD gene.  Both θ and  αD are transcribed but no protein or haemoglobin 
products have been detected (Albitar et al., 1992).  The pseudogenes are highly 
homologous to their corresponding genes but they do not direct protein 
synthesis due to changes within their sequences acquired during evolution.  
The genes are arranged on the cluster in the order in which they are expressed 
during development 5- ζ2,- ψζ1- αD- ψα1- α2 - α1- θ -3 (Figure 1.2).  There are 
normally two functional copies of the α-globin gene per chromosome in humans 
and therefore normal individuals will inherit four α-globin genes in total, written 
as αα/αα.  Around 40kb upstream of the ζ2 gene lies the HS-40 site which is an 
important binding site for several transcription factors.The HS-40 site was found 
to be an enhancer and critical for the expression of the downstream α-globin 
genes. 
1.2.3 β-globin cluster 
The β-globin cluster spans a region of 50kb and is located on the short arm of 
chromosome 11 (11p15.5).  It has five functional genes ε, Gγ, Aγ, δ, β and one 
non-functional gene ψβ.  Like the α-globin cluster the genes are arranged in the 
order in which they are expressed during development 5-ε-Gγ-Aγ-ψβ-δ- β-3 
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(Figure 1.2).  Upstream of the β-globin cluster is the β-locus control region  
(β-LCR) which consists of five DNase I hypersensitive sites (HS1-5) (Tuan et 
al., 1985).  The β-LCR is important for the expression of the β-like globin genes 
as it maintains an open chromatin domain and acts as an enhancer element; in 
its absence the level of gene expression is low. 
3’
ζ2 ψζ1 ψα1 α2 α1 θ
HS-40
αD
5’
β-globin gene cluster – chromosome 11p15.5
α-globin gene cluster – chromosome 16p13.3
5’ 3’ε Gγ Aγ ψβ δ β
β-LCR
4 2 1 3’HS
HbF HbA2 HbA
35
 
 
 
Figure 1.2 The α- and β-globin clusters.  HS-40 = DNase1-hypersensitive site 
at -40kb relative to the ζ-globin gene.  β-LCR= β-locus control region. 
 
1.2.4 Haemoglobin switching 
An important and extensively studied event that occurs in the β-globin gene 
cluster is the so-called haemoglobin switching process, the suppression of the 
γ-globin genes accompanied by the complementary rise in the expression of the 
previously silent β-globin gene (Stamatoyannopoulos et al., 2001).  While the  
α-like globin genes have a single switch (embryonic ζ → fetal/adult α), the  
β-globin genes undergo two switches (embryonic ε → fetal γ → adult β).  In the 
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β-globin gene cluster the expression of the globin genes is regulated by 
complex interactions between the β-LCR and the promoters of the globin genes 
themselves.  The β-LCR and the promoter regions of the globin genes are 
bound by either repressing or activating proteins called transcription factors 
(Stamatoyannopoulos, 2005).   
 
Each HS of the β-LCR contains genetically conserved domains for the 
transcription factors to bind.  Binding sites for transcription factors have also 
been identified in the promoter regions immediately upstream of each of the 
globin genes (Cao et al., 2002).  These sequences include a TATA box at 
position -30, CCAAT box at position -70, CACCC box at position -90 and an 
AGATAT box at position -345 relative to the CAP site.  As the β-LCR is bound 
by activating transcription factors (such as GATA1 and KLF1) the associated 
chromatin then becomes activated (Fraser et al., 1998).  Individual globin gene 
promoters and their associated chromatin might also become activated or 
repressed by the binding of different transcription factor complexes.  In the later 
stages of erythropoiesis the β-LCR and the globin gene promoters appear to 
interact via a looping mechanism (Figure 1.3).  This interaction causes the 
recruitment and activation of RNA polymerase II, which is needed to transcribe 
the gene into mRNA.  This nuclear RNA is then processed into messenger RNA 
(mRNA) transported into the cytoplasm of erythroblasts and translated into the 
globin chains (Higgs et al., 2012). 
 
It is suggested that the switch between embryonic, fetal and adult globins relies 
on the competition between the globin gene promoters for access to their 
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activating upstream regulatory elements in the β-LCR.  The ability of the 
promoters to compete might in turn rely on changes in the activating or 
repressing transcription factors that they bind (Sankaran & Orkin, 2013).  For 
example in fetal life the γ-promoter binds an activating complex that 
preferentially interacts with the β-LCR.  Yet in adult life the γ-globin genes are 
bound by repressive factors (BCL11A) whereas the β-genes are bound with 
activating factors (KLF1).   
1
2 3 4
LCR
δ
β
G γ
A γ
ε
Adult globins
Embryonic /Fetal globins
5
 
Figure 1.3 Long-range chromatin looping in the -globin locus.  
The β-LCR and adult -globin gene come into close proximity in adult stage erythroid 
cells in which the gene is actively transcribed. The embryonic and fetal expressed 
genes that are silent at this stage of development are excluded from the close contacts. 
(Adapted and modified from Kiefer et al., 2008) 
 
Understanding the control of this process has obvious therapeutic implications 
for the therapy of β-thalassaemia and sickle cell disease. The γ-globin gene can 
functionally substitute for the defective β-globin gene in these diseases; 
therefore any advancement in the comprehension of the Hb switching process 
could benefit therapies based on the reactivation of the γ-globin gene 
(Weatherall and Clegg, 2001).   
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1.3 Inherited disorders of haemoglobin 
 
The haemoglobinopathies are the most common single gene disorders in 
humans (Weatherall and Clegg, 2001).  It is believed that their high prevalence 
in certain parts of the world reflects the heterozygote advantage of many of 
these disorders against severe malaria.  The World Health Organisation (WHO) 
has estimated that close to 7% of the world’s population i.e. 270 million are 
carriers for these conditions (especially α- and β-thalassaemia, HbS, HbC and 
HbE).  There are approximately 300-400,000 affected babies born each year 
with severe forms of these diseases (WHO 1994).  There is currently no 
definitive cure for any haemoglobinopathy apart from bone marrow 
transplantation which is expensive and available only to patients with 
compatible donors.  Patients with these disorders often require lifelong 
treatment.  Therefore the haemoglobinopathies pose a major health and 
economic burden to countries where they are common.  These conditions are 
indigenous to tropical and subtropical regions where most of the developing 
countries are located however with the increasing frequency of population 
migration into the Western world, continents such as Australia, Europe and 
North America are identifying these disorders (Weatherall, 2000).  Although 
improvements have been seen in overall infant mortality worldwide, these 
inherited disorders will still be an ever increasing haematological problem as 
these infants will require life long treatment and care.   
 
The haemoglobinopathies are a diverse group of autosomal recessive 
disorders. They can be divided into two common types, the structural 
haemoglobin variants and the thalassaemias. 
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1.3.1. Structural haemoglobin variants 
The structural haemoglobin variants are caused by single amino acid 
substitutions in either the α- or β- globin chains and the thalassaemias are a 
result of reduced production of one or more of the globin chains which leads to 
imbalanced globin chain synthesis.  Over 900 structural variants have been 
reported so far with the majority being harmless and rare (Giardine et al., 2007) 
(Table 1.1).  Clinically, the most important are HbS (sickle haemoglobin,  
β-globin codon 6, A→T, Glu→Val), HbE (β-globin codon 26, G→A, Glu→Lys) 
and HbC (β-globin codon 6, G→A, Glu→Lys) because they have reached high 
frequencies in some populations.  HbS has reached high frequencies in parts of 
Africa, Saudi Arabia and India whereas HbC is mainly restricted to West Africa.  
Homozygosity for HbS (HbSS) and compound heterozygosity for HbS and HbC 
(HbSC) cause sickle diseases that pose significant health problems for the 
countries in which they are endemic.  Yet, HbE which is the most common 
variant globally is not harmful in the homozygous state but when it interacts with 
β-thalassaemia it produces a thalassaemia phenotype which can range in 
severity from thalassaemia intermedia to transfusion dependant thalassaemia 
major (as explained in section 1.3.2). HbE is extremely common in Asia with 
frequencies reaching 50% in some areas and therefore in regions where  
β-thalassaemia is also prevalent this disorder has caused a significant health 
burden. 
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Table 1.1 Classification of genetic disorders of haemoglobin* 
I. Structural variants – > 900 described.  Mainly due to single amino-acid substitutions 
II. Thalassaemias – Disorders due to defective and imbalanced globin production. 
(1) α- thalassaemias – result from > 80 different deletions or point mutations in the α-globin genes. 
          1. α0-thalassaemia (--/) 
          2. α+-thalassaemia (-α/) 
               - Deletional (-α/) 
               - Non-deletional (ααT) 
    (2) β-thalassaemias – result from over 200 different mutations in the β-globin genes. 
          1. β0- thalassaemia 
          2. β+-thalassaemia 
             - variants with unusually high level of HbF or HbA2 
             - normal HbA2 
             - ‘silent’ 
             - dominant 
             - unlinked to β-gene cluster 
    (3) δβ-thalassaemias 
         1. (δβ)+ - thalassaemia 
         2. (δβ)0 - thalassaemia 
         3. (αγδβ)0 - thalassaemia 
    (4) γ-thalassaemia 
    (5) δ-thalassaemia 
         1. δ0 - thalassaemia  
         2. δ+ - thalassaemia 
    (6) εγδβ-thalassaemia 
III. Structural variants that result in a thalassaemic phenotype 
IV. Hereditary persistence of fetal haemoglobin (HPFH)  
    (1) Deletional – (δβ)0 
    (2) Non-deletional – linked to β-globin gene cluster (γ-gene rearrangements and promoter mutations) 
                                  - unlinked to the β-globin gene cluster (H-MYB, BCL11A) 
*Modified from Weatherall 2001 
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1.3.2 The thalassaemias 
The thalassaemias are classified depending on which globin gene is defective 
(α, β, δβ and εγδβ) (Table 1.1).  The α- and β-thalassaemias are found at high 
frequencies in some populations with the δβ and εγδβ being much rarer. The  
α- and β-thalassaemias can be further subdivided according to the amount of 
globin chain production.  In α+- and β+-thalassaemia, decreased quantities of  
α- or β-globin chains are produced, whereas in α0- and β0- thalassaemia α- or 
β-globin production is absent. The α-thalassaemias can be divided into three 
clinically important types: α+ -thalassaemia, a mild form in which only one of the 
linked α-globin genes is inactive (-α/); α0-thalassaemia, a severe form in which 
both α-globin genes are inactive (--/); and HbH disease, compound 
heterozygosity of α+- and α0-thalassaemia in which there is only one functional 
α-globin gene (-α/--). The clinical picture of HbH disease is that of a chronic 
haemolytic anaemia of variable severity often requiring transfusion. The loss of 
all α-globin genes (--/--) is lethal and is referred to as HbBart’s hydrops fetalis 
syndrome.  Approximately 25% of the fetuses die in utero and the rest at 
delivery or soon after, although there are cases of hydropic infants who have 
been kept alive with regular transfusions (Joshi et al., 2004, Singer et al., 2000). 
Clinically β-thalassaemias are classified into thalassaemia major, thalassaemia 
intermedia and thalassaemia trait/minor according to their severity.  
Thalassaemia major results in a severe anaemia requiring regular blood 
transfusions and usually results from the interaction of two β0 mutations or a 
β0  mutation and a severe β+ mutation. The intermedia phenotype is less severe 
and usually results from the interaction of two β+ mutations or a β+ mutation and 
  12 
a β0  mutation.  The carrier state (β-thalassaemia trait) is usually asymptomatic. 
Clinically the most important forms of thalassaemia worldwide are  
β-thalassaemia major HbE/β-thalassaemia, HbH disease and HbBarts hydrops 
fetalis.  Cases of thalassaemia have been found in most parts of the world but 
principally they are found in South China, Southeast Asia, the Mediterranean, 
Indian sub-continent, Africa and the Pacific Islands.  
1.4 Fetal Haemoglobin (HbF) 
 
The switch from γ- to β-globin gene expression at birth is also reflected by the 
change in the relative ratio of the two γ-globin chains.  During intra-uterine life 
and at birth the G γ/A γ ratio is about 70:30 but during the first months of life the 
ratio changes gradually to 40:60.  Although HbF is replaced by adult 
haemoglobin by 1 year after birth, small amounts of HbF continue to be 
synthesized throughout adult life.  This small amount of HbF is not evenly 
distributed but concentrated to a subset of erythrocytes termed F cells (FCs) 
(Boyer et al., 1975).   FCs are not similar to fetal cells either in the amount of 
HbF per cell or in other characteristics which distinguish fetal and adult red cells 
(Wood, 1993).  Studies have shown that FCs and non-FCs are derived from the 
same stem cell population and that FCs represent the progeny of erythroid 
progenitor cells that have undergone an ‘accelerated’ pathway of erythroid 
differentiation.  Under normal circumstances very few cells follow this pathway 
but in conditions in which erythroid demand is increased, a higher proportion of 
erythroid cells follow such a pathway and hence a transitory increase in FCs 
occurs (Stamatoyannopoulos et al., 1987) (Figure 1.4).  Various acquired and 
genetic disorders can increase HbF and FC levels in adult life. 
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1.5 Acquired increases in HbF levels in adults 
 
In most acquired disorders the increased HbF production is due to perturbation 
of erythropoiesis; and increased demand for red cells leads to ‘stress’ 
erythropoiesis with preferential production of FCs.  Increased HbF production is 
often seen in situations of acute erythroid expansion as in severe iron deficiency 
anaemia following treatment, in normal individuals following acute blood loss, in 
bone marrow regeneration after bone marrow transplantation, in cytotoxic 
treatment and in pregnancy, particularly in early second trimester when the 
blood volume increases sharply (Rochette et al., 1994).  Two hypotheses for the 
increased HbF in pregnancy have been put forward; 1) a possible response of a 
placental or fetal inducer of HbF entering the maternal circulation and 2) the 
secretion of hormones which effect HbF production.  Patients with haemopoietic 
malignancies such as juvenile chronic myeloid leukaemia and myelodysplastic 
syndromes often show a striking increase in HbF levels caused by a gross 
distortion in the regulation of erythropoiesis.  Increased HbF levels have also 
been reported sporadically in patients with choriocarcinoma, testicular cancer, 
bronchogenic carcinoma, hepatoma and thyrotoxicosis (Rochette et al., 1994).  
The exact mechanism for the increased HbF seen in patients with solid tumours 
and cancers is being widely studied.  In adult life the inactivated γ-genes in 
erythroid cells are methylated and the theory is that there are factors able to 
induce DNA demethylation and therefore activation of the γ-globin genes (Wolk 
et al., 2006).  It is also thought that the expression of HbF in cancer prior to 
treatment may be a strategy of the cancer to gain increased access to oxygen, 
since HbF has a higher affinity for oxygen than adult haemoglobin and therefore 
HbF can be used as a potential marker for malignancy (Wolk et al, 2012). 
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Figure 1.4 Proposed mechanisms of HbF production. 
 
A) Normal fetal and adult haemoglobin are produced by cells from the same lineage i.e. 
haemoglobin switching occurs through a change in transcription program within the 
same cell.  A change in transcription program occurs with erythropoietic differentiation, 
from one that predominantly supports γ-globin expression to one that supports only  
β-globin expression.  FC represents the progeny of erythroid progenitor cells that 
terminate early before the change in transcription occurs.  Two plausible mechanisms 
of HbF modulation have emerged from biological studies of trans-acting factors: 
 
B) Direct effect on γ-globin gene expression.  Where there is activation of γ- globin 
transcription or inhibition of γ-globin gene repression, thereby increasing the amount of 
HbF in each normal erythrocyte without producing more F cells. 
 
C) Indirect via perturbation of kinetics of erythropoiesis such as in severe anaemia and 
the acquired disorders which increase HbF production by increasing the number of F 
cells produced. (Adapted and modified from Stamatoyannopoulos, 2005) 
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1.6 Genetic disorders increasing HbF levels in adults 
 
Increased HbF production may occur as a primary genetic disorder or 
secondary to other inherited disorders. 
1.6.1 Secondary increases in HbF levels 
1.6.1.1 Increased HbF levels in sickle cell anaemia 
Carriers for the sickle cell gene have normal HbF levels but in sickle cell 
homozygotes HbF levels can range from 1-20%.  Factors that account for this 
striking variation include the preferential survival of HbF cells and the variability 
in the intrinsic capacity for HbF synthesis.  Polymerisation of HbS leads to 
irreversibly sickled cells, which will be removed from the circulation by the 
reticuloendothelial (RE) system.  HbF can effectively reduce the intracellular 
concentration of HbS so that the formation of HbS polymers becomes less 
likely.  High HbF containing red cells gain this advantage and thus have a 
higher chance of survival.   
 
1.6.1.2 Increased HbF levels in β-thalassaemia 
Slightly increased HbF levels are often seen in patients heterozygous for  
β-thalassaemia as a result of the selective survival of HbF containing red cells.  
In homozygous β-thalassaemia HbF levels range from 10% to 100% depending 
on mutations.  Despite this increase in γ-globin gene transcription, which is a 
response to erythropoietic stress, and the selective survival of HbF containing 
red cells, the majority of patients homozygous for β-thalassaemia (either β+ or 
β0) have very low Hb levels (3-5g/dl) and require regular blood transfusions for 
their survival.  This is because the increase in HbF production is insufficient to 
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compensate for the reduced HbA production. However some individuals who 
are homozygous for β0-thalassaemia produce more HbF and are able to 
maintain Hb levels of 8-10g/dl without a blood transfusion and therefore have a 
β-thalassaemia intermedia phenotype. Family studies have shown that in some 
cases the high HbF determinant segregates independently of the β-globin 
complex, indicating that trans-acting factors are involved (Wood, 1993).   
1.6.2 Primary increases in HbF levels 
The inherited disorders in which the underlying mutation is a direct cause of 
increased HbF production have been traditionally classified into two groups;  
δβ-thalassaemia and HPFH (deletion and non-deletion).  Both δβ-thalassaemia 
and deletional HPFH are caused by deletions of the δ- and β-globin genes and it 
is apparent that the size and positions of the deletions do not correlate to the 
overall phenotype and that both disorders are closely related.  They are 
classified depending on the level of HbF and whether the phenotype in the 
homozygous state is clinically affected or not.  Therefore as there is overlap 
between the two disorders it has been suggested that they should be classified 
as one group. However, this reclassification has not happened as the precise 
mechanisms responsible for the increased HbF levels in these conditions are 
not fully understood and it is hoped that with increased knowledge a new 
classification might emerge naturally. 
 
1.6.2.1 Increased HbF levels in δβ-thalassaemia 
Heterozygotes for δβ-thalassaemia deletions (GγAγ(δβ)0  and Gγ(Aγδβ)0 )   are 
characterised by elevated levels of HbF ranging from 5-20% with a normal HbA2 
value (Table 1.2).  The red cell indices are similar to those of β-thalassaemia 
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trait although the MCH and MCV are slightly higher.  This is because in δ-
thalassaemia the defect in β-chain production is partially compensated by an 
increase in the output of γ-chains from the chromosome carrying the 
thalassaemia determinant (Shiokawa et al., 1988).  Homozygotes have a 
clinical course of thalassaemia intermedia (Galanello et al., 2002).   
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Table 1.2 Reported δβ-thalassaemia mutations*. 
 
Phenotype Mutation HGVS 
nomenclature 
Size 
 (kb) 
%F   
hetero- 
zygote 
Ethnic Origin Reference 
GγAγ(δβ)0 East 
European 
(δβ)0 
- 9.12 13-24 East European (Palena et 
al., 1994) 
GγAγ(δβ)0 Laotian (δβ)0 - 12.58 11.5 Laotian, 
Vietnamese 
(Zhang et 
al., 1988) 
GγAγ(δβ)0 Thai (δβ)0 - 30 10 Thai (Trent et 
al., 1988) 
GγAγ(δβ)0 Macedonian 
GγAγ(δβ)00/Tu
rkish inv- del
 
(δβ)0 
- 11.465+1.5
93del7.6inv 
7-14 Macedonian, 
Turkish 
(Efremov 
et al., 
1986b, 
Kulozik et 
al., 1992) 
GγAγ(δβ)0 Turkish (δβ)0 - 30 15 Turkish (Oner et 
al., 1996) 
GγAγ(δβ)0 Leiden 7.4 
kb (δβ)0 
- 7.4 18.5 Turkish (Phylipsen 
et al., 
2009) 
GγAγ(δβ)0 Thai 11.3 
(δβ)0 
- 11.3 23.2 Thai (Svasti et 
al., 2007) 
GγAγ(δβ)0 Indian (δβ)0 NG_000007.3:g.5
0509_83170del32
662 
32.62 5-15 India (Mishima 
et al., 
1989) 
GγAγ(δβ)0 Japanese 
(δβ)0 
NG_000007.3:g.5
1483_165148del1
13666 
113.63 5-7 Japan (Matsunaga 
et al., 
1985) 
GγAγ(δβ)0 Spanish 
(δβ)0 
NG_000007.3:g.6
0375_153285del9
2911 
115 5-15 Spanish (Feingold 
and Forget, 
1989) 
GγAγ(δβ)0 Black (δβ)0 NG_000007.3:g.6
0530_60730del11
822 
11.77 24.8 African (Anagnou 
et al., 
1985) 
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Phenotype Mutation HGVS 
nomenclature 
Size 
 (kb) 
%F   
hetero- 
zygote 
Ethnic Origin Reference 
Gγ Aγ(δβ)0 Sicilian (δβ)0 NG_000007.3:g.6
4336_77738del13
403 
13.38 4-19 Mediterranean (Henthorn 
et al., 
1990) 
GγAγ(δβ)0 Japanese 2 
(δβ)0 
- 27 - Japan (Yamashiro 
et al., 
2005) 
GγAγ(δβ)0 Senegalese 
(δβ)0 
NG_000007.3:g.(6
3154_63209)_(70
570_70625)del74
17 
74 14.2 Mediterranean (Zertal-
Zidani et 
al., 2001, 
Saller et al. 
2012) 
Gγ(Aγδβ)0 Italian (Aγδβ)0 - 52 12-17 Italian (De 
Angioletti 
et al., 
1997) 
Gγ(Aγδβ)0 Canadian 
(
Aγδβ)0 
- 55.1 9.7-17.3 Canadian (Voruganti 
et al., 
2009) 
Gγ(Aγδβ)0 Leiden 69.5 
(
Aγδβ)0 
- 69.5 10.6 Italian (Phylipsen 
et al., 
2009) 
Gγ(Aγδβ)0 Asian (Aγδβ)0 - - - Asian Ithanet id: 
ithalD 1533 
Gγ(Aγδβ)0 Turkish 
(
Aγδβ)0 
NG_000007.3:g.4
5410_81665del36
256 
36.21 10-14 Turkish (Tuan et 
al., 1983, 
Henthorn 
et al., 
1990) 
Gγ(Aγδβ)0 German 
(
Aγδβ)0 
NG_000007.3:g.(4
5922_46319)_(98
640_99640)del 
52 9.9-12.5 German (Anagnou 
et al., 
1988) 
Gγ(Aγδβ)0 Malaysian-2 
(
Aγδβ)0 
NG_000007.3:g.(47376_
47553)_(89149_90149)d
el 
42 - Malay (George et 
al., 1986) 
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Phenotype Mutation HGVS 
nomenclature 
Size 
 (kb) 
%F   
hetero- 
zygote 
Ethnic Origin Reference 
Gγ(Aγδβ)0 Chinese 
(
Aγδβ)0 
NG_000007.3:g.4
8795_127698del7
8904 
78.85 9-20 Chinese (Jones et 
al., 1981b) 
Gγ(Aγδβ)0 Black (Aγδβ)0 NG_000007.3:g.490
40_84889del35850 
35.81 6-21 African (Henthorn 
et al., 
1985) 
Gγ(Aγδβ)0 Indian 
(
Aγδβ)0 inv 
- 0.834+7.46
0del15.5inv 
10-18 Indian, 
Bangladeshi, 
Kuwaiti, Iranian 
(Jones et 
al., 1981a) 
Gγ(Aγδβ)0 Cantonese 
(
Aγδβ)0 
- - 19-20 Cantonese (Zeng et 
al., 1985) 
Gγ(Aγδβ)0 Malyasian-1 
(
Aγδβ)0 
- - 25 Malay (Trent et 
al., 1984) 
Gγ(Aγδβ)0 Belgian 
(
Aγδβ)0 
- 50 14-15 Belgian (Losekoot 
et al., 
1991) 
Gγ(Aγδβ)0 Yunnanese 
(
Aγδβ)0 
- 88 9-17 Chinese (Zhang et 
al., 1993) 
*Adapted from ITHANET database (Lederer et al,. 2009). 
 
 
1.6.2.2 Increased HbF levels in hereditary persistence of fetal 
haemoglobin (HPFH) 
HPFH is the name given to a heterogenous group of disorders where there is a 
genetically determined persistence of fetal haemoglobin production into adult 
life, in the absence of any other haematological disorder (Bollekens and Forget, 
1991).  Two distinct types of HPFH have been classified, non-deletion and 
deletional.  These are discussed in greater detail in section 1.7 and 1.8.  The 
mechanisms by which deletions such as δβ-thalassaemia and HPFH lead to 
  21 
increased levels of HbF production has been the subject of much interest.  
Three mechanisms have been proposed:  
 
1. The deletion removes regulatory sequences within the β-globin gene cluster 
resulting in increased HbF levels due to the balance of the regulatory 
sequences which remain in the cluster.  The identification of a 3.5kb Aγ-δ-globin 
intergenic region which is a binding site for BCL11A has been shown to be an 
important site in haemoglobin silencing (Sankaran et al,. 2011).  Removal of this 
region, for example in the HPFH deletions, results in higher HbF levels than in 
deletions which leave this region intact. 
2. The deletion enables the 3 enhancer elements downstream of the β-globin 
gene to be in closer proximity with the γ-globin genes thereby increasing their 
expression. 
3.  Deletion of the β-globin gene region allows the β-LCR to continue interacting 
with the normally silenced adult γ-globin genes.   
 
The elevation in γ-chain production in deletional HPFH is sufficient to 
compensate for the loss of  β-chain production from the deleted β-globin gene; 
however this is not the case in δβ-thalassaemia.   It may be that there is no 
simple explanation for the persistent γ-gene expression in deletional HPFH.  
Although it seems likely that the mechanisms listed above play an important 
role in this process with the degree of importance varying depending on the 
deletion.  Given that there are a large number of elements around the β-globin 
gene cluster that affect regulation of the globin genes, it is entirely possible that 
other elements outside of the gene cluster are also involved in gene regulation.   
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1.7 Deletional HPFH 
 
Deletional HPFH is relatively rare and is caused by extensive deletions of the  
β-globin gene cluster (including the δ- and β-globin genes).  This form of HPFH 
demonstrates clear Mendelian inheritance and heterozygotes have higher HbF 
levels of 10-40% with normal red cell indices (Table 1.3).  Heterozygotes and 
homozygotes for these deletions are unaffected clinically.  
  
Table 1.3 Reported deletional HPFH mutations*. 
 
Mutation HGVS nomenclature Size (kb) %F  
heterozygote 
Ethnic Origin Reference 
HPFH-1; 
Black 
NG_000007.3:g.59478
_144395del84918 
84.92 20-30 African (Tuan et al., 1983, Kutlar 
et al., 1984) 
HPFH-2; 
Ghanaian 
NG_000007.3:g.54867
_139178del84312 
83.68 20-30 African (Tuan et al., 1983, Kutlar 
et al., 1984) 
HPFH-3; 
Indian 
NG_000007.3:g.50509
_83170del32662 
47.73 22-23 Indian (Kutlar et al., 1984, 
Schroeder et al., 1973) 
HPFH-4; 
Italian 1 
NG_000007.3:g. 40 14-30 Italian (Saglio et al., 1986) 
HPFH-5; 
Italian 2 
NG_000007.3:g. 12.91 16-20 Sicilian (Camaschella et al., 
1990) 
HPFH-6;  
SE Asian 
NG_000007.3:g.45595
_124872del79278 
79.28 18-27 Thai (Kosteas et al., 1997) 
HPFH-7; 
Vietnamese 
NG_000007.3:g. 30 14-27 Vietnamese, 
Cambodian, 
Chinese 
(Motum et al., 1993) 
Algerian 
HPFH  
NG_000007.3:g.48747
_72606del23860 
23.9 41 Algerian (Joly et al., 2009) 
French West-
Indies HPFH 
NG_000007.3:g.48762
_72489del23728 
23.7 36.5 French West-
Indies 
(Joly et al., 2009) 
French HPFH NG_000007.3:g.53013
_72746del19734 
19.7 35.7 French (Joly et al., 2009) 
*Adapted from ITHANET database (Lederer et al,. 2009). 
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1.8 Non-deletion HPFH  
 
This type of HPFH has normal β-globin gene expression and all the genes 
within the β-globin cluster remain intact. The increase in HbF production is 
extremely heterogeneous ranging from 1-30%. Non-deletion forms of HPFH can 
be due to  point mutations in either the Gγ- or Aγ-gene promoters, γ-globin gene 
rearrangements or ‘Swiss type of HPFH’ which does not follow Mendelian 
inheritance.   As in the deletion type of HPFH, individuals with non-deletion 
HPFH have normal red cell morphology and counts with no clinical 
abnormalities.   
1.8.1 γ-globin gene promoter mutations 
Over the last fifty years several different types of non-deletion HPFH due to  
γ-globin gene promoter mutations have been reported.  Sequencing of both the 
γ-genes revealed single nucleotide substitutions in the promoters of the  
γ-genes in a region that could affect their transcription.  Studies on transgenic 
mice comparing the expression of normal and mutated genes have shown that 
these nucleotide substitutions in the promoters of the γ-genes are responsible 
for the increased levels of HbF and were not simply associated polymorphisms 
(Peterson et al., 1995).  To date, 25 such mutations have been described with 
12 Gγ HPFHs and 13 Aγ HPFHs (Table 1.4).  HbF levels in heterozygotes range 
from modest elevations to increases similar to those observed in deletion HPFH 
conditions.  Homozygotes have been observed in both the British and Greek 
types of Aγ HPFH presenting with normal red cell indices and HbF levels twice 
the level seen in heterozygotes (Camaschella et al., 1989, Weatherall et al., 
1975) 
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Table 1.4 Reported non-deletion HPFH point mutations*. 
 
Gene Mutation HGVS 
nomenclature 
%F 
heterozygote   
Ethnic 
origin 
Reference 
Gγ -37 (A-T) HBG2:c.-90 A>T 2.3 Dutch (Bouva et al., 2006) 
Gγ -109 (G-T) HBG2:c.-162 A>C 4.1 Greek (Chassanidis et al., 2009) 
Gγ -110 (A-C) HBG2:c.-163 A>C 3.1 Czech (Indrak et al., 1991) 
Gγ -114 (C-T) HBG2:c.-167 C>T 11-14 Japanese (Fucharoen et al., 1990) 
Gγ -114 (C-A) HBG2:c.-167 C>A 0.6-3.5 Algerian (Zertal-Zidani et al., 1999) 
Gγ -114 (C-G) HBG2:c.-167 C>G 8.6 Australian (Motum et al., 1994) 
Gγ -161 (G-A) HBG2:c.-215 G>A 4 African (Leonova et al., 1996) 
Gγ -175 (T-C) HBG2:c.-228 T>C 17-30 African (Friedman and Schwartz, 
1976) 
Gγ -196 (C-T) HBG2:c.-249 C>T 8.6 Greek (Tasiopoulou et al., 2008) 
Gγ -200 (+C) HBG2:c.-253-254insC 18-28 Tunisian (Pissard et al., 1996) 
Gγ -202 (C-G) HBG2:c.-255 C>G 14-21 African (Collins et al., 1984) 
Gγ -567 (T-G) HBG2:c.-610 T>G 5.9-10.2 Iranian (Chen et al., 2008) 
Aγ -114(C-T) HBG1:c.-167 C>T 3-6.5 African (Oner et al., 1991) 
Aγ -114 to -102  HBG1:c.-167-155del 30-32 African (Gilman et al., 1988b) 
Aγ -117 (G-A) HBG1:c.-170 G>A 7.1-19 Greek, Italian, 
African 
(Collins et al., 1985, Gelinas 
et al., 1985, Ottolenghi et al., 
1988, Huang et al., 1987) 
Aγ -158 (C-T) HBG1:c.-211 C>T 2.9-5.1 Greek (Patrinos et al., 1998) 
Aγ -175 (T-C) HBG1:c.-228 T>C 36-41 African (Stoming et al., 1989, 
Coleman et al., 1993) 
Aγ -195 (C-G) HBG1:c.-248 C>G 4.5-7.0 Brazilian (Costa et al., 1990) 
Aγ -196 (C-T) HBG1:c.-249 C>T 14-21 Italian, 
Chinese 
(Giglioni et al., 1984, Gelinas 
et al., 1986) 
Aγ -198 (T-C) HBG1:c.-251 T>C 3.5-12 British (Tate et al., 1986) 
Aγ -201 (C-T) HBG1:c.-254 C>T 10.2 Greek (Tasiopoulou et al., 2008) 
Aγ -202 (C-T) HBG1:c.-255 C>T 1.6-3.4 African (Gilman et al., 1988a) 
Aγ -211 (C-T) HBG1:c.-264 C>T 2.7-6.3 African (Arends et al., 2004) 
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Gene 
 
Mutation HGVS 
nomenclature 
%F 
heterozygote 
Ethnic 
origin 
Reference 
Aγ -225 to -222 
(delAGCA) 
HBG1:c-279-276del 6.7 African (Gilman et al., 1988) 
Aγ -226 to -223 
(delAAGC) 
HBG1:c.-280-277del 3.2-5.4 Chinese (Huang et al., 2000) 
*Adapted from ITHANET databases (Lederer et al., 2009). 
 
Analysis of protein binding to the promoters of the γ-genes has demonstrated 
potential binding sites for ubiquitous and erythroid-specific trans-acting 
transcription factors (Wood, 1993).  Many of the nucleotide substitutions in non-
deletion HPFH lie within or are close to the binding sites for these transcription 
factors and it seems likely that they exert their effect by altering the pattern of 
protein binding (Figure 1.5).  However the precise mechanisms by which each 
mutation results in increased HbF production may differ.  (Forget, 1998).  
Mutations could result in increased affinity for transcription factors which 
activate the γ-genes in adult life, decreased affinity for repressor molecules or a 
combination of both mechanisms.  
1.8.2 γ-globin gene rearrangements  
Several gene rearrangements have been reported in the β-globin gene locus 
and some have been identified which are responsible for different Gγ- and  
Aγ-ratios.  The two most frequently reported are point mutations or gene 
conversions resulting in Gγ-Gγ- or Aγ- Aγ- which replaces the normal  
Gγ-Aγ- and the presence of multiple genes with three, four and even five  
γ-globin genes having been discovered (Huisman et al., 1991).   
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Figure 1.5 Transcription factor binding regions and positions of known mutations in the γ-globin gene promoters.   
Boxed areas show conserved sequences which are binding sites for the transcription factors indicated below the sequence.  
Arrows above the sequence show the positions of the known non-deletion HPFH point mutations with the sequence in red 
indicating the 13bp deletion (-114 to -102). 
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The first gene arrangement to be described in adults was the Gγ- Gγ- found in 
several African families.  This rearrangement in also known as the Atlanta type 
of non-deletion HPFH and is characterised by HbF levels ranging from 1.3-9.8% 
with Gγ- values of 98% (Huisman et al., 1985a).  Further studies went on to 
show that the C→T polymorphism at position -158 of the Gγ-globin gene occur 
on both genes in the Atlanta non-deletion HPFH and mRNA data implied that it 
is actually the -158 polymorphism in both Gγ-globin genes which exerts its 
effects on HbF (Efremov et al., 1994). Multiple Gγ-globin genes also result in 
increased adult HbF as in the case of the Gγ-globin triplication where HbF levels 
vary from 3.4-6.4% in heterozygotes but again only provided the C→T 
polymorphism at position -158 of the Gγ-globin gene occurs on the Gγ-globin 
genes (Efremov et al., 1986a).  Individuals with this triplication but without the 
C→T polymorphism at -158 were shown to have lower levels of HbF and also 
lower Gγ-values (Yang et al., 1986).  Yang et al (1986) also identified members 
of a Turkish family with γ-globin gene quadruplication and only slightly increased 
HbF levels of 0.7-3.8%. 
 
1.8.3 Swiss type of non-deletion HPFH 
This group of non-deletion HPFH disorders appear to have a genetically 
determined increase in HbF production in adult life but the inheritance is not 
well defined.  In most cases they are characterised by only a very small 
increase in HbF (rarely above 5%). However there is evidence that they may 
play an important role in modifying the phenotype of β-thalassaemia or sickle 
cell anaemia and therefore efforts have been made to target therapies which 
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activate HbF.  These conditions are referred to as ‘Swiss HPFH’ after the 
discovery in the 1960s of HbF persistence in Swiss army recruits (Marti and 
Buetler, 1961) or heterocellular HPFH since the distribution of HbF is uneven 
among the red cells (Boyer et al., 1975).  The study by Marti and Buetler (1961) 
showed heritability, Swiss HPFH is quite different from classical HPFH as the 
inheritance does not follow Mendelian patterns and the HbF elevation is 
modest.  Further studies showed that the amount of HbF varies considerably 
and that the distribution among the normal population is continuous and 
positively skewed (Thein and Craig, 1998).  Heterocellular HPFH is found in 
approximately 10% of the population with HbF levels between 0.8 and 5% 
(Thein et al., 2009).  Studies in twins went on to show that genetic factors in 
HbF levels account for 89% of the variability in F cell levels (Garner et al., 2000) 
with the remaining 11% of variance being accounted for by age and sex (2%) 
and unknown environmental factors.   
 
In the past 10 years, several trans-acting mutations (mutations that are not 
actually physically linked to the locus) have been identified that alter the pattern 
of globin gene expression (Higgs et al., 2012).  Insights into the regulation of 
globin genes that are obtained from these sporadic mutations have been greatly 
enhanced by extensive observations from family studies, twin studies, and 
genome-wide association studies (GWAS).  Findings from these GWAS studies 
have identified other trans-acting factors (BCL11A and HBS1L-MYB) that can 
normally regulate the patterns of globin gene expression.   
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1.8.3.1 XmnI-HBG2 polymorphism at the β-globin gene locus  
In 1985 a single nucleotide polymorphism (SNP) C→T at position -158 of the 
Gγ-globin gene, later termed the XmnI-HBG2 polymorphism was identified and 
shown to promote expression of the Gγ-globin gene (Gilman and Huisman, 
1985).  This polymorphism is common in all population groups with a frequency 
of about 0.35 (Garner et al., 2000) and has been shown to increase HbF levels 
under conditions of erythroid expansion such as sickle cell anaemia and  
β-thalassaemia major leading to a milder disease (Thein et al., 1987, Labie et 
al., 1985).  Certain haplotypes with this polymorphism have been shown to have 
higher HbF levels in sickle cell disease individuals from India, eastern Saudi 
Arabia and the Senegal (Labie and Elion, 1996) (Figure 1.6).  The C→T change 
at position -158 was also shown to be associated with the ‘Swiss-type’ of HPFH 
in non-anaemic Europeans (Efremov et al., 1987) and in individuals with high, 
normal or slightly raised HbF levels (Sampietro et al., 1992).  However this is 
not a consistent finding as this polymorphism is not present in all affected 
individuals and has been found in individuals with normal HbF levels.  In one 
large pedigree with normal individuals having HbF levels between 2-6% the 
high HbF levels segregated with a β-globin gene haplotype which lacked the  
-158 C→T polymorphism (Donald et al., 1988).  It seems likely that in order to 
produce a full high HbF phenotype the XmnI-HBG2 polymorphism must exist on 
a genetic background requiring the presence of additional factors (Thein and 
Menzel, 2009). 
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Figure 1.6 Genomic organisation of the β-globin gene cluster with the different polymorphic restriction enzyme sites.   
β-globin haplotypes are generated by linkage patterns of the RFLPs.  The haplotypes associated with the sickle gene from 
various regions are shown. The Senegal and Arab/Indian and Swiss Type HPFH haplotypes carry the Xmn variant. The 
Senegal and Arab/Indian haplotypes have the highest HbF levels and the mildest clinical course. The Bantu haplotype has the 
lowest HbF levels and the severest clinical course (adapted and modified from Steinberg & Nagel, 2009). 
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1.8.3.2 X-linked on chromosome Xp22.2  
Several studies in the 1980s showed that females had higher HbF levels than 
males.  Rutland et al (1983) showed that females had higher HbF levels 
throughout life, whilst Mason et al (1982) observed higher HbF levels in normal 
females aged between 1-6 years than in males.  They also noted that this 
finding was not evident in patients with sickle cell anaemia.  Another study 
undertaken in Japanese adults showed that the high HbF phenotype might be 
an X-linked trait with 11% of males and 21% of females being carriers for 
heterocellular HPFH (Miyoshi et al., 1988).  An extensive series of studies was 
then carried out by Dover et al (1992) looking at HbF levels in individuals with 
sickle cell anaemia.  They noticed that females had much higher levels of HbF 
than the males and undertook segregation analysis based on the phenotypes 
they had found, discovering a putative locus at Xp22.2 which he called the FC 
locus.  This group then went on to use multiple linear regression analysis to 
determine the importance of this locus along with other known variables which 
increase HbF such as age, sex, α-globin gene number and β-globin gene 
haplotype.  They concluded that all the variables in the study accounted for 50% 
of the variation in HbF levels with the FC locus being the most important factor 
accounting for 35-41% of the total HbF variation seen in homozygous sickle cell 
subjects (Chang et al., 1995).  When they removed this locus from their 
regression model they found that the second most important predictor of HbF 
levels were the genetic factors associated with the common β-globin gene 
haplotypes.  Therefore 50% of the variation in HbF levels in homozygous sickle 
cell disease patients remained unexplained. However others went on to 
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conclude that they could not replicate the same finding and that further trans-
acting factors must be involved in the increased HbF phenotype. 
 
1.8.3.3 HBS1L-MYB intergenic region on chromosome 6q23  
For over 20 years scientists at the Weatherall Institute of Molecular Medicine 
(WIMM) in Oxford have been studying a large Asian-Indian pedigree with  
β-thalassaemia and heterocellular HPFH in order to try and explain some of the 
genetic variance seen in HbF levels ( Wood et al., 1977, Thein et al., 1994, 
Craig et al., 1996).  These and other early studies suggested that the high HbF 
determinate segregates independently of the β-globin gene in some families 
with β-thalassaemia and sickle cell anaemia and families were discovered 
through probands with unexpectedly mild disease (Cappellini et al., 1981, Old et 
al., 1982). In the case of the Asian-Indian family individuals without  
β-thalassaemia had HbF levels ranging from 0-3%, while heterozygotes for  
β-thalassaemia having HbF levels from 0.8-24% (Thein et al., 1994).  Therefore 
the inheritance of the high HbF in this family was unclear.  Genome-wide 
linkage analysis using 210 microsatellite markers was undertaken and this led 
to the discovery of linkage to a small segment of chromosome 6, 6q22.3-q24 
(Craig et al., 1996).  Interestingly they found no evidence of any contribution 
from the FC locus on Xp22.2 and further fine mapping refined the area to a 1.5 
Mb region containing 5 known genes (ALDH8A1, HBS1L, MYB, AHI1 and 
PDE7B) none of which had a mutation and three (HBS1L, MYB and AHI1) that 
are expressed in erythroid cells (Garner et al., 1998, Close et al., 2004).  
Further high resolution association mapping was carried out on individuals of 
northern European ancestry and showed linkage to a set of 7 common SNPs 
  33
  
spanning a region of 79kb.  The SNPs were distributed into three linkage blocks 
referred to as HBS1L-MYB intergenic polymorphisms (HMIP) blocks 1, 2 and 3 
(Thein et al., 2007).  These three haplotype blocks completely account for the 
FC variance due to the 6q23 locus but the second block had the strongest effect 
and further studies in African individuals also found the same strong association 
with FC levels and HMIP-2 (Creary et al., 2009).  The HMIP-2 block has been 
shown to contain a regulatory locus as evidenced by several GATA-1 signals 
that coincided with DNase1 hypersensitive sites in erythroid precursor cells 
(Wahlberg et al., 2009).  It has been suggested that this regulatory locus 
controls MYB expression which in turn influences erythroid differentiation and 
indirectly the control of HbF levels (Thein et al., 2009). 
 
1.8.3.4 BCL11A (B-cell lymphoma/leukemia 11A) on chromosome 2p16  
By 2006 genome-wide association studies (GWAS) were being undertaken to 
look at common polymorphisms and relate them to phenotypes and variations 
at chosen loci.  GWAS studies when applied to the variation in HbF yielded 
interesting findings showing that the variation can be accounted for by just three 
loci (Menzel et al., 2007, Uda et al., 2008, Lettre et al., 2008, Sedgewick et al., 
2008, Galanello et al., 2009, Nuinoon et al., 2010).  These loci include the  
β-globin cluster itself, the intergenic region between HBS1L and MYB genes 
and also a new locus in intron 2 of the oncogene BCL11A on chromosome 
2p16.  BCL11A is a zinc-finger transcriptional repressor found to be active in B 
lymphoid cells and expressed in erythroid cells and had not been previously 
implicated in haemoglobin switching (Bauer and Orkin., 2011).  Several studies 
went on to show that BCL11A silences the γ-genes (Sankaran et al., 2008, 
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2009).  Sankaran’s studies showed that knockdown of BCL11A increases HbF 
synthesis in human erythroid progenitors and complete knock-out of the gene in 
mice causes profoundly delayed switching from embryonic to adult globins as 
well as silencing of the γ-globin genes. BCL11A has a binding site not in the  
γ-promoter but in the β-LCR as well as intergenic regions on the β-globin gene 
cluster which are associated with γ-globin gene repression (Xu et al., 2010, 
Jawaid et al., 2010).  BCL11A associates with other transcription factors such 
as GATA-1 and SOX-6 (Xu et al., 2010, Jawaid et al., 2010) and unlike 
BCL11A, SOX6 directly occupies the γ-globin promoter (Figure 1.7).  Xu et al 
(2010) showed that double knockdown of BCL11A and SOX6 has an additive 
effect on HbF derepression, suggesting that BCL11A may exert part of its  
γ-globin repression with SOX6. SNPs within the 14kb intron 2 of BCL11A 
correlate most strongly with HbF expression.  These findings are very exciting 
and put BCL11A in the running as a potential therapeutic target for the 
reactivation of HbF. 
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Figure 1.7 Model of BCL11A silencing of the γ-globin genes.  The diagram 
illustrates the physical interaction between BCL11A and the Mi-2/NuRD 
complexes, erythroid transcription factors GATA1 and FOG1, and the HMG-box 
protein SOX6. Rather than binding to the promoters of the γ-globin or β-globin 
genes as these latter factors do, BCL11A protein occupies the upstream LCR 
and γδ-intergenic regions of the β-globin cluster in adult human erythroid 
progenitors. Transcriptional silencing of the γ-globin expression by BCL11A 
involves long-range interaction within the β-globin cluster and local interactions 
with the chromatin associated SOX6 proteins at the proximal promoters of the  
γ-globin genes. (Adapted and modified from Xu et al., 2010) 
 
1.8.3.5 KLF1 (Erythroid Krüppel-like Factor 1) on chromosome 19p13.2  
Recently an additional potential locus was identified when point mutations in the 
KLF1 (also known as EKLF) gene were found to be associated with HPFH in a 
Maltese family (Borg et al., 2010) and in a family from Sardinia (Satta et al., 
2011). KLF1 is an essential erythroid transcription factor first identified in 1993 
that binds to an important DNA binding site, the CACCC motif in the β-globin 
gene (Miller and Bieker, 1993).  Mutations in the CACCC region of the β-globin 
gene have been shown to be a cause of β-thalassaemia as KLF1 binding is 
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prevented (Feng et al., 1994).  Experiments in mice showed that ablation of 
KLF1 caused profound β-thalassaemia and lethality (Nuez et al., 1995).  The 
gene found on chromosome 19 comprises of a proline rich N-terminal region 
containing a transactivation domain and a C-terminal region containing three 
zinc finger domains essential for DNA binding.   
 
KLF1 mutations have been associated with several erythroid phenotypes. In the 
two family studies exhibiting the HPFH phenotype, HbF levels ranged from 0.9-
30.9%.  Variability in HbF was found throughout both families with different 
KLF1 missense mutations.  In 2008 Singleton et al (2008) reported the first 
mutations in human KLF1.  They identified 9 different loss-of-function mutations 
being responsible for the blood group phenotype In(Lu).  However no clinical 
features or haematological parameters were reported. Arnaud et al (2010) 
found KLF1 mutations in 2 unrelated patients with congenital dyserythropoietic 
anaemia (CDA). Their patients had a heterozygous missense mutation 
(p.E325K) in the second zinc finger of the KLF1 gene which caused a dominant 
effect resulting in a severe haemolytic anaemia.  Very high levels of HbF were 
seen (31.6% and 44%) and they also had expression of embryonic 
haemoglobins ζ-and ε-globin. A further study in Sardinia went on to show that 
KLF1 mutations are linked to borderline HbA2 levels and normal to moderately 
increased HbF levels (Perseu et al., 2011).   
 
Studies started to link together KLF1 and BCL11A with the phenotype of HPFH 
(Borg et al., 2010)  In the Maltese family with HPFH it was found that samples 
from the affected individuals had KLF1 levels directly proportional to BCL11A 
  37
  
levels and inversely proportional to γ-globin levels (Bieker, 2010).  Importantly it 
was also shown that human KLF1 binds to the BCL11A gene.  Zhou et al (2010) 
then went on to confirm these findings showing that BCL11A levels were 
dramatically downregulated in KLF1 knockdown mice and in human cells and 
that a decrease in BCL11A levels is seen with an increase in γ-globin levels.  
This suggests that KLF1 plays a critical role in regulating the switch between 
fetal and adult haemoglobin expression both by direct activation of β-globin and 
indirect repression of γ-globin gene expression in adult erythroid progenitors via 
regulation of BCL11A (Fig 1.8) (Siatecka and Bieker, 2011).   
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[BCL11A]highi[β−globin]highl i i
[KLF1]low[ ]l
[BCL11A]low[ ]l
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KLF1 
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AdultEmbryonic, fetal or KLF1 
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Figure 1.8 KLF1 regulates globin switching.  During embryonic and fetal 
development or in KLF1-haploinsufficient adults (left), KLF1 levels are low, 
resulting in low levels of adult -globin and BCL11A and high levels of  
-globin. In adults with two functional copies of KLF1 (right), increased 
expression of KLF1 in definitive red blood cells promotes high levels of adult  
-globin and BCL11A expression, which in turn represses -globin expression 
(adapted from Bieker, 2010). 
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Although major trans-acting factors have been located the mechanisms through 
which they operate to increase HbF production are still not identified fully.  The 
molecular basis for persistent HbF expression in adults is extremely 
heterogenous.  It is possible to identify the deletional HPFH mutations both 
genotypically and phenotypically and it is indicated that the γ-globin genes can 
be reactivated to high levels of expression.  However there are still no answers 
as to what the mechanisms are for the increased HbF synthesis.  The trans-
acting factors are believed to be responsible for the inheritance of non-
deletional HPFH accounting for 20-50% of the HbF variability (Thein and 
Menzel, 2009).   Therefore much work is still to be done in order to obtain all the 
factors that contribute to HbF production and to define the molecular network 
through which these operate. 
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1.9 Therapeutics for HbF induction 
 
The ameliorating effect of HbF has led to the development of pharmacological 
agents that reactivate HbF synthesis; however current therapeutic agents do 
have toxic side effects (Perrine, 2005). Currently the only potentially curative 
therapies that are available for sickle cell disease and β-thalassaemia major are 
bone marrow transplantation and gene therapy but both have significant 
limitations for widespread use, particularly in the developing world (Sankaran 
and Orkin, 2013). Gene therapy remains largely experimental although 
advances in this approach are being made (Cavazzana-Calvo et al., 2010). The 
major treatment for these disorders involves symptomatic care and red blood 
cell transfusion as is clinically necessary, yet transfusions can lead to major 
clinical problems such as iron overload. The recent identification of transcription 
factors that play a role in globin gene regulation and in particular HbF 
expression has lead to the promise of potential therapeutic targets which could 
lead to better, less toxic and more effective strategies for HbF induction 
(Sankaran, 2011). Further work will be necessary before these molecular 
targets can be translated into therapeutic advances but the fact that so many 
targets have been recently identified lends promise in this field. A better 
understanding of the mechanisms involved in the silencing of HbF will 
undoubtedly yield additional insights into how this process can best be 
modulated. 
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1.10 Thesis aims 
 
The work presented in this thesis aims to identify the main genetic factors 
known to be involved in HbF expression in a cohort of patients with elevated 
HbF levels.  This objective will be achieved by: 
 
1) Identifying β-globin gene cluster deletion mutations in a high HbF cohort and 
determining the range and frequency of these deletions which is unknown.   
 
2) Fine mapping of any novel mutations with a view to understanding the 
molecular mechanisms involved. 
 
2) Ascertaining the frequency and range of γ-globin gene promoter mutations in 
the UK population. 
 
3) Determining whether polymorphisms in the three major loci (XmnI-HBG2, 
BCL11A and HBS1L-MYB) are associated with increased HbF in a high HbF 
cohort. 
 
4) Performing sequence analysis of the KLF1 gene to see whether mutations in 
this essential transcription factor play a significant role in increasing HbF levels 
in adults. 
 
5) Investigating the finding that Asian Indian newborns appear to have less HbF 
at birth than newborns from other ethnic groups.  Could they be switching 
earlier? 
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CHAPTER TWO: MATERIALS AND METHODS 
2.1 Introduction 
 
This chapter outlines the standard protocols used in this project.  Other 
methods used and developed are described in detail in the appropriate sections 
of the thesis (Chapters 3, 4, 5, 6, 7 and 8).  Unless otherwise stated, all 
chemicals were of analytical grade or higher and were obtained from Sigma-
Aldrich or BDH. 
2.2 Haematological analysis 
2.2.1 Full blood count (FBC) 
Venous blood was collected in VacutainerTM tubes using ethylenediamine 
tetraacetic acid (EDTA) as an anticoagulant.  Hb level, red blood cell (RBC) 
count, mean cell volume (MCV) and mean cell haemoglobin (MCH) were 
determined using a Sysmex XE2100 haematology analyser.   
2.2.2 High performance liquid chromatography (HPLC) 
The measurement of haemoglobins in blood samples can be determined by 
passing solutions of haemoglobin through a weak cation-exchange high 
performance liquid chromatography (HPLC) system.   Adult blood samples 
collected in EDTA were analysed using the Bio-Rad VariantTM II Hemoglobin 
Testing System (Bio-Rad Laboratories Inc) according to the manufacturer’s 
instructions.  Analysis of the haemoglobin fractions were provided by the  
Bio-RadTM CDM software package and all buffers and columns were provided in 
the β-thalassaemia shortTM kits supplied by Bio-RadTM.  Newborn blood spots 
were analysed on a Vnbs (variant newborn system) Bio-RadTM Sickle Cell 
Program with kits supplied by Bio-RadTM. 
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2.2.3 Isoelectric focusing (IEF) 
Isoelectric focusing is a technique used for separating haemoglobin molecules 
by differences in their isoelectric point (pI).  The pI is the pH at which a protein 
has no net charge and therefore does not migrate further in an electric field.  
The Multiphor II IEF tank was supplied by Amersham Biosciences linked to a 
Caron 2050W Circulating water bath and Thermo Electron Corporation 2060P 
power pack.  Reagents and pre-cast agarose gels were supplied in kit form 
(Resolve® Neonatal Hemoglobin Test Kit) by Perkin Elmer.   
 
2.3 Extraction of genomic DNA 
 
2.3.1 Manual phenol-chloroform DNA extraction from whole blood 
DNA from samples with less than 1ml of whole blood, as seen in paediatric 
samples, were manually extracted using phenol chloroform.  DNA was prepared 
from peripheral blood leukocytes.  Venous blood in VacutainerTM tubes 
containing EDTA were washed with 2 volumes of reticulocyte saline (0.13M 
NaCL, 5mM KCL, and 7.4mM MgCl2).   The sample was inverted several times 
to ensure mixing and then centrifuged at 3500rpm for 5 mins at 40C.  
Afterwards, the supernatant was discarded and the cell pellet resuspended in 
1ml of 2x lysis solution (0.77M NH4Cl, 0.046M KHCO3). The solution was mixed 
by invertion and rotated for 10 mins to lyse the red blood cells. The 
centrifugation step was repeated and after discarding the supernatant the buffy 
coat was resuspended in 150µl of lysing solution (100mM NaCl, 25mM EDTA) 
with 0.5ML 10% SDS and 20ml 20µg/ml Proteinase K (Roche).  The sample 
was then incubated overnight at 370C. Proteins were then removed by 
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extracting twice with an equal volume of phenol. This was followed by repeating 
the extraction with an equal volume of chloroform.  Following each extraction 
the sample was centrifuged at 3500rpm for 5 minutes at room temperature.  
The aqueous phase was then transferred to a clean tube and DNA precipitated 
by adding two volumes of 100% ethanol and 1/10 volume of 7.5M ammonium 
acetate.  The mixture was centrifuged again and then the pellet washed in 70% 
ethanol.  The DNA pellet was air-dried and then resuspended in DNase free 
water (Sigma). 
2.3.2 Automated chemagen DNA extraction from whole blood  
Samples with volumes of >1ml were placed on an automated DNA extractor.  
The extractor used was the Chemagen-Perkin Elmer Integrated Automated 
DNA Extractor.  It consists of two integrated systems: the Chemagen MSM I 
extraction robot and the Perkin Elmer MPII liquid handler.  Before placing onto 
the extractor, 1ml of EDTA whole blood had 10µl of protease and 1.5mls of lysis 
buffer1 added into a 50ml Falcon tube.  The sample was then incubated for 10 
mins and 120µl of paramagnetic bead solution was added to the lysed blood 
sample together with 4ml of binding buffer.  This buffer should enhance the 
binding of the DNA to the magnetic beads.  The Falcon tube was then loaded 
onto the automated DNA extraction platform.  The DNA released from the lysed 
white blood cells gets bound to the magnetic beads and then subsequently 
transferred from one washing buffer to another by way of the magnetic rods on 
the extractor.  Each washing step includes a homogenisation.  There were four 
serial washing buffers with different ethanol concentrations.  In the final step the 
DNA gets released from the beads in the elution buffer (DNase free water, 
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Sigma®) and transferred into a labeled tube.  All reagents and chemagen kits 
are supplied by Perkin Elmer. 
2.3.3 Extraction of DNA from hair follicles  
DNA was extracted from hair follicles using the following protocol: 200µl of 
Buffer X1 (10mM TrisCl pH 8.0, 10mM EDTA, 100mM NaCl, 40mM DTT,  
2% SDS and 250µg/ml proteinase K) was added to five hair follicles placed in a 
1.5ml microcentrifuge tube and incubated overnight at 550C until dissolved.  
Standard phenol cholorform extraction of the DNA was then performed on the 
lysate (as described in section 2.3.1). 
2.3.4 Extraction of DNA from dried blood spots 
Two 3mm dried blood spots were added to a 1.5ml Eppendorf tube. 1ml of 0.5% 
saponin in PBS was added and incubated overnight at 4oC.  The spots were 
transferred to a new 1.5ml Eppendorf containing 1ml of PBS and incubated for 
1hr at 4oC.  Then 75µl of 20% Chelex in distilled water was added to a 0.5ml 
Eppendorf tube.  The blood spots were transferred into this tube.  The tube was 
vortexed for 30 secs and incubated at 99 oC for 15 mins in a thermocycler with a 
heated lid.  Further vortexing for 10-15 seconds was performed and then the 
Eppendorf tube was spun in a centrifuge at 10,000rpm for 5 mins. The 
supernatant was transferred into a final 0.5ml Eppendorf tube for storage. 
 
2.4 Measurement of DNA concentration by nanodrop 
 
The quality and concentration of the DNA extracted using the above methods 
was determined using a Nanodrop 2000c UV-Vis spectrophotometer (Nanodrop 
Technologies).  The equipment utilises a sample retention technology which 
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allows direct measurement of 1µl of double-stranded DNA samples without 
dilution.  With the sampling arm open, 1.5µl of DNA was pipetted directly onto 
the lower measurement pedestal after blanking.  By closing the sampling arm, a 
column was automatically drawn between the upper and lower measurement 
pedestals through two corresponding optical fibers and a spectral measurement 
established.  After measurement the sampling arm was opened and the upper 
and lower pedestals wiped clean with distilled water.  The measurements were 
recorded and stored on a database and on the side of the DNA sample tube. 
 
2.5 Polymerase chain reaction (PCR) 
 
Many of the experiments mentioned throughout this thesis will employ the PCR 
technique.  The conditions of each PCR amplification were optimised for each 
specific set of primers, the thermostable polymerase used and the length of the 
target sequence.  Unless otherwise stated, a standard 25µl reaction contained 
100-250ng of genomic DNA, 2 units of Taq polymerase (Invitrogen), 10pmol of 
each primer, 0.2mM dNTPs (GE Healthcare Life Sciences), 1.5mM MgCl2 
(Abgene) and 1 X Buffer IV (Abgene).   All primers were designed and the 
melting temperatures calculated manually using the formula: Tm= [2(A+T) 
+4(C+G)] where A, T, C and G are the number of each of these nucleotides in 
the primer sequence.  PCRs were carried out in a thermocycler (T3 Biometra) in 
0.5ml PCR tubes with no heated lid and mineral oil in most cases.  When using 
AmpliTaq DNA polymerase, the initial melting cycle was for 5 minutes.   
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The standard cycling conditions were: 
 
1 cycle of:   950C for 3 min 
30-40 cycles of: 950C for 1 min 
   Tm0C for 1 min 
   720C for 1 min 
1 cycle of:  720C for 10 min 
 
When QIAGEN Multiplex PCR Master Mix (QIAGEN) was used instead of 
Buffer IV then the following conditions and reaction mix was used.  A 25µl 
reaction contained 1µl of 100-250ng of genomic DNA, 10pmol of each primer, 
12.5µl Multiplex PCR Master Mix (QIAGEN) and 9.5µl DNase-free water 
(Sigma).  The conditions were as per the standard PCR cycling above except 
an initial activation of the HotStart Taq polymerase is required: 
 
1 cycle of:   950C for 15 min 
30-40 cycles of: 940C for 1 min 
   Tm 0C for 1 min 
   720C for 1 min 
1 cycle of:  720C for 10 min 
 
2.5.1 Long range PCR 
SeqTarget LongRange PCR kit from QIAGEN was used.  This kit has a blend of 
enzyme and thermostable DNA polymerases with enhanced proofreading 
ability.  This kit can amplify long-range PCR fragments 2kb to 20kb, G-C rich 
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regions and other difficult templates. The kit also includes Q-solution which 
facilitates amplification of difficult templates by modifying the melting behavior of 
DNA and a control primer pair which allows checking of the suitability of the 
human genomic DNA for use as a template. The reaction mix was prepared as 
per the kit instructions and the cycling protocol chosen depending on whether 
the amplification product would be 2-8kb or greater. 
2.5.2 Gap-PCR for the common β-globin gene cluster deletion mutations 
The technique of Gap-PCR is used routinely to detect many common deletion 
mutations.  The technique is based upon the inability of PCR primers that are 
far apart to direct amplification unless a deletion brings them closer together.  
PCR primer pairs are designed to flank a known deletion, generating a unique 
amplicon that will be smaller in the mutant sequence compared with the wild 
type.  Seven common β-globin gene deletion mutations were screened for by 
Gap-PCR. These consisted of HPFH-1, HPFH-2, HPFH-3, Sicilian 
(δβ)0 thalassaemia, Chinese Gγ(Αγδβ)0 thalassaemia and two complex 
rearrangements: the Asian-Indian inversion-deletion Gγ(Αγδβ)0 thalassaemia and 
the Turkish form of inversion-deletion (δβ)0 thalassaemia. The Gap-PCR 
primers and amplification conditions used for all these deletions were as 
previously described (Craig et al., 1994). 
 
2.6 Agarose gel electrophoresis of DNA 
 
DNA fragments were separated by horizontal agarose gel electrophoresis.  1.5 
to 3% (w/v) agarose gels were prepared in 1X TBE with the gel concentration 
depending on the size of the DNA fragments to be resolved.  The sample was 
mixed with 1/10 volume of 10X TBE gel loading buffer and ran with appropriate 
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DNA markers.  A potential difference of 2-5V/cm was applied across the gel 
until a satisfactory resolution was achieved.  The gels were stained in 0.5µg/ml 
ethidium bromide solution and then destained in distilled water for 10 mins.  The 
gels were placed on a UV transilluminator (Bio-Rad Gel-DocTM) to illuminate the 
DNA under ultraviolet light and a permanent record captured onto thermal print 
paper. 
 
2.7 DNA sequence analysis 
 
Sequencing was based on Sanger’s chain termination method (Sanger et al., 
1977).  Sequencing was carried out using an ABI PRISM® 3100 or a Beckman 
Coulter CEQ 8000 genetic analyser.  The initial PCR amplification was 
performed as per the conditions in section 2.5 above.  
2.7.1 PCR product purification 
After PCR amplification 10µl of the PCR product was mixed with 10µl of Micro 
Clean (Microzone Ltd).  The plate wells were pipette mixed and left for 5 
minutes at room temperature.  The plate was spun at 4700rpm for 40 minutes, 
turned upside down and spun for 10 seconds at very low speed (10rpm) then air 
dried. The pellet was resuspended in 12µls of DNase-free water (Sigma) and 
left for 10 minutes to rehydrate. 
2.7.2 Cycle sequencing 
 
2.7.2.1 Beckman coulter CEQ 8000 
For each reaction 4µl of QuickStart Mix (GenomeLabTM), 0.4µl of sequencing 
primers, 4.6µl of distilled water and 1.5µl of purified PCR products were added 
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to the well of a PCR plate, mixed thoroughly and sealed.  The plate was placed 
into a thermal cycler (T3 Biometra) with the following conditions: 30 cycles of 
960C for 20secs, 500C for 20secs and 600C for 4 mins and pause at 150C. Each 
sample was then purified by ethanol precipitation. 
 
2.7.2.2 ABI PRISM® 3100 
Sequencing reactions contained 1µl of PCR product and 9µl of reaction mix 
containing 2pmol of sequencing primer, 2µl ready reaction premix (ABI PRISM® 
Big DyeTM Primer Cycle Sequencing Kit, Invitrogen), 1µl Big Dye sequencing 
buffer and 3µl DNase-free water.  Cycling conditions were an initial activation of 
960C for 3 minutes followed by 25 cycles of:  960C for 15 secs, 500C for 10 
secs, 600C for 2 mins and a final extension of 150C for 5 mins.  Each sample 
was then purified by ethanol precipitation. 
 
2.7.3 Ethanol precipitation 
For each reaction 15µl of stop solution (2µl of 100mM EDTA, 2µl CH3COONa 
(3M, pH 5.2), 1µl of glycogen and 10µl of distilled water) was added to the PCR 
products.  60µl of ice cold 100% ethanol was added to each well and the plate 
mixed and sealed.  The plate was centrifuged at 4700rpm for 30mins at 40C.  
The plate was turned upside down to remove the supernatant and a further 
200µl of ice cold 70% ethanol added to the wells. Further centrifugation at 
4700rpm for 5mins at 40C and the supernatant removed.  The PCR product was 
washed with 70% ethanol again by repeating the last step.  Products were left 
to air dry for 30mins before 40µl of sample loading solution (SLS, Beckman 
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Coulter) or 8.5µl HiDi (ABI PRISM®) was added followed by a drop of mineral 
oil. 
 
2.7.3 Analysis of sequence data by mutation surveyor 
Mutation surveyor® (SoftGenetics, USA) was used to analyse the data obtained 
from the sequencers.  This software is designed to find mutations and SNPs 
using a patented technology that allows base-to-base comparison of single and 
bi-directional DNA sequence traces generated by a standard automated 
sequencer.  The software has a capacity to perform mutational analysis on up 
to 400 lanes of data simultaneously.  The manufacturer claims that the software 
is capable of detecting >99% of mutations and can process up to 1 billion base 
pairs of sequence data per day under fully unattended operation (see 
http://www.softgenetics.com for further details). 
 
2.8 Pyrosequencing assays for the SNPs in BCL11A and 
HBS1L-MYB 
 
Pyrosequencing is a sequencing-by-synthesis method that enables rapid 
real-time sequencing of short DNA sequences, which can be used for the 
analysis of single nucleotide polymorphisms (Timbs et al., 2012).   
This method was adopted to identify the two most common SNPs found in 
northern European and African populations in the gene BCL11A  
(rs 11886868) and the intergenic region HBS1L-MYB (rs 9399137).  Using the 
Pyromark Assay Design Software 2.0 (QIAGEN) several sets of primers were 
designed and the following pairs worked optimally: rs 11886868 forward 
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TGCCCCTTTGCTGTCAAT, reverse ACCATGGATGAATCCCAGAAT 
(biotinylated) and sequencing primer CGTCTTTTGTGTTTAATTC.  
 
Rs 9399137 forward CAACATCACCTTAAAAGGCGGTAT (biotinylated), 
reverse GCAGGGTTGCTTGTGAAAAAA and sequencing primer 
TGCTTGTGAAAAAACTGT.  The standard QIAGEN PCR Multiplex Master Mix 
method was used (see section 2.5 above) with the following conditions: 950C for 
10 mins followed by 30 cycles of 950C for 1 min, 630C for 1 min, 720C for 1.5 
mins with a final extension of 720C for 10 mins.  The pyrosequencing assays 
were carried out on a Pyromark Q24 as per the manufactures instructions and 
all reagents were supplied by QIAGEN.  See Appendix 3 and 4 for examples of 
pyrosequencing traces and assay design. 
 
2.9 Multiplex ligation-dependent probe amplification (MLPA) 
The MLPA technique was used to detect deletions and copy number variations 
in the β-globin gene cluster.  DNA probe sets are designed to span the area of 
interest and after hybridisation are amplified using only one pair of PCR primers 
(Appendix 1). The quantity of amplification product from each probe will be 
proportional to the copy number of the target sequence. The amplification 
products are then separated by capillary electrophoresis. A deletion on one 
chromosome can be detected by reduced relative peak heights in comparison 
to controls.  The extent and position of the deletion were determined by 
mapping the positions of the probes with reduced peak height. Several different 
β-globin gene cluster probe sets were adopted but all developed and designed 
around the probe sets by Harteveld et al (2005).  The method used was as per 
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the manufacturers’ instructions and the β-globin gene cluster probe sets and 
reagent kits were supplied by ServiceXS (Leiden, Netherlands) and MRC-
Holland (Amsterdam, Netherlands). The ServiceXS kit comprised of a total of 
three probe sets consisting of 50 probe pairs spanning a region of ~500kb and 
an average distance of ~10kb (β-globinxs MLPA Kit, ServiceXS).  The MRC-
Holland P102-B2 HBB MLPA probemix contained 28 probes within the β-globin 
gene cluster region, including several probes for the upstream regulatory 
sequences and one probe that was specific for the haemoglobin S mutation 
(rs334) which is frequently found in Africans and African-Americans.  All patient 
samples were tested with known controls and run at least twice.  Deletions were 
detected visually by reduced probe signal strength of one or more probes.   
 
2.10 Genome-wide SNP array 
 
Since 2005, whole-genome SNP arrays have become an important tool for 
discovering variants that contribute to human diseases and phenotypes.  
Dr Ruth Clifford (The Oxford Biomedical Research Centre, Oxford) performed 
whole-genome SNP array analysis on the novel/rare deletions discovered in 
chapter three. Analysis was carried out on an iScan (Illumina®) and 
hybridisation to illumina SNP chips (HumanOmni1-Quad) was performed 
according to the manufacturer’s protocols (www.illumina.com/products). The 
HumanOmni1-Quad featured over one million strategically selected markers 
that deliver dense genome-wide coverage and include data from the 1000 
genomes project. The data was processed using GenomeStudioV2009.2 
(Illumina, Inc., San Diego, California, USA) and then analysed using Nexus 6.1 
Discovery Edition (BioDiscovery, Inc., El Segundo, California, USA). 
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2.11 Next-generation whole exome sequencing 
 
Dr Lorna Gregory at The Wellcome Trust Centre for Human Genetics, Oxford 
performed next-generation whole exome sequencing on case 12 from chapter 
seven.  Analysis was performed on a HiSeq 2500 system run in rapid-run mode 
(Illumina®) according to the manufacturer’s protocols 
(http://www.illumina.com/products).  The library was a Truseq exome library 
(62Mb capture kit) with 2x100bp paired-end reads. The analysis was run 
through Platypus (Rimmer et al, 2012) and STAMPY (Lunter and Goodson, 
2011) software and aligned to the Genome Reference Consortium, GRCh37 
sequence (www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/human/). The 
remaining data was annotated in ANNOVAR and the gene list checked visually 
for mutations (Wang et al., 2010).   
 
 
 
 
 
 
 


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CHAPTER THREE: BETA GLOBIN GENE CLUSTER DELETIONS 
ASSOCIATED WITH INCREASED HBF LEVELS IN ADULTS 
3.1 Introduction 
 
As discussed in chapter 1, the human β-like globin genes are arranged in a 
single cluster on the short arm of chromosome 11 in their order of expression 
during development; 5 ε−Gγ−Aγ−δ−β 3 (Weatherall et al., 1985).  Deletions and 
rearrangements in the β-globin gene cluster can produce 4 distinct phenotypes. 
The phenotypes are classified according to the particular genes which are 
deleted and consist of the clinically significant phenotypes of β-thalassaemia, 
δβ-thalassaemia, εγδβ-thalassaemia and the less clinically significant phenotype 
of HPFH.  At least 40 different deletions larger than 1kb involving the β-globin 
gene cluster have been described to date in the HbVar database (Giardine et 
al., 2007, Patrinos et al., 2004). 
It is well known that large deletions of the β-globin gene cluster are a significant 
cause of elevated HbF levels in adults.  What is not well known however is the 
frequency and range of these mutations in the UK as they have traditionally 
been problematic to diagnose.  The work described in this chapter aimed to 
evaluate the efficacy of the recently available technique of multiplex ligation-
dependent probe amplification (MLPA) to determine the frequency and range of 
these mutations in the UK population and therefore aid in the identification of 
these deletions within a diagnostic setting. 
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3.2 Detecting β-globin gene deletions 
 
Deletion mutations in the β-globin gene cluster have traditionally been detected 
by Southern blot analysis or Gap-PCR. However the technique of Southern 
blotting is not best suited to a routine diagnostic laboratory as it requires large 
amounts of DNA and is time consuming and technically demanding. Gap-PCR 
analysis is a simple and quick technique but can only be used to detect 
deletions that have previously characterised breakpoint sequences. 
Consequently Gap-PCR assays have been designed for the 9 
deletions/rearrangements which are known to occur frequently (Craig et al., 
1994).  Due to these technical difficulties at the time of carrying out this study 
the frequency and range of β-globin gene cluster deletion mutations was 
unknown in most populations. 
The technique of MLPA first described by Schouten et al (2002) has been 
shown to be relatively simple and able to detect copy number variations and 
large deletions of target DNA sequences. This method has been applied 
successfully to a number of genes in which deletions and duplications are 
common.  In 2005 Harteveld et al designed MLPA probe sets for the β-globin 
gene and -globin gene clusters and reported the technique to be robust, 
simple and specific for the detection and characterisation of deletions and 
duplications.  The β-globin gene cluster probe set consisted of three probe sets 
containing 50 probe pairs spanning a region of 500kb and an average distance 
of 10kb (Appendix 2).  Probes within each set were designed to produce PCR 
products differing by 2bp in length which allowed separation in the size range 
80-125bp. 
 56 
3.3 Study subjects 
 
Over a 3 year period (December 2005-December 2008) 4,041 patient blood 
samples were referred to the National Haemoglobinopathy Reference 
Laboratory in Oxford for haematological and DNA analysis.  During this time 
316 samples were identified as potentially having a -globin gene cluster 
deletion. They had a raised HbF or thalassaemic red cell indices or a 
combination of both. Point mutations responsible for -thalassaemia and  
-thalassaemia (both deletion and non-deletion mutations) had been excluded 
in all samples. Individuals with an elevated HbF level due to the hybrid 
haemoglobins Lepore and Kenya were diagnosed by haematological methods 
and confirmed by Gap-PCR, and therefore not included in this study. 
3.4 Laboratory procedures 
 
Peripheral blood counts and erythrocyte indices were determined using an 
automated cell counter.  Haemoglobin quantifications were carried out using a 
cation exchange high performance liquid chromatography (HPLC) system 
(VARIANTTM, Bio-Rad Laboratories, Hercules, CA USA).  DNA was extracted 
from peripheral blood leukocytes by conventional phenol chloroform extraction 
or on an automated DNA extractor (Chemagen). Deletions of the β-globin gene 
cluster were determined using the MLPA method described previously 
(Harteveld et al., 2005). The β-globin gene cluster probe sets and reagent kits 
were supplied (β-globinxs MLPA Kit; ServiceXS, Leiden, The Netherlands).  
Deletions were detected by reduced signal strength of one or more probes. 
Deletions with a position and size suggestive of one of the common deletion 
mutations were confirmed by Gap-PCR (Figure 3.1).  
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3.5 Results 
 
A total of 316 selected samples were analysed by MLPA and where appropriate 
Gap-PCR for a β-globin gene cluster deletion performed.  Seventy five (24%) 
were found to have a mutation (Figure 3.2).  Of these, 52 samples (16.5%) were 
confirmed by Gap-PCR to have one of the 7 common HPFH or δβ-thalassaemia 
mutations (Table 3.1).  In all cases the genotype matched the phenotype in that 
patients with a HPFH deletion had the higher levels of HbF (up to 35%) and 
normal red cell indices.  Patients with δβ-thalassaemia had more modest 
elevations in HbF (4-14%) with hypochromic, microcytic red cell indices.  
Patients with HPFH and therefore the highest HbF levels were found to have 
deletions which removed the 3.5kb intergenic region between the Aγ- and  
δ- globin genes known to be an important region for HbF silencing (Figure 3.2).  
The lowest HbF levels were seen in deletions which did not remove the 3.5kb 
intergenic region as in the Turkish and Sicilian (δβ)0-thalassaemia.  
 
The remaining 23 samples (7.3%) had one of 10 different deletions (Figure 3.2). 
Analysis of the location and size of 6 of these deletions and their associated 
haematological parameters, together with the ethnicity of the patient, suggested 
they may be previously reported rare deletions (Table 3.2). However, MLPA on 
its own does not identify the precise breakpoints of a deletion so without further 
characterisation it is not possible to be certain as to their identification. The 
other 4 deletions identified do not match any previously reported deletions and 
appear to be novel (Table 3.2). These mutations consisted of a 2-8kb  
β0-thalassaemia deletion identified in an Afro-Caribbean family,  a 0.2-1kb  
β0-thalassaemia deletion in an Afghanistan family, a 30-40kb (δβ)0-thalassaemia 
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deletion in an African patient, and a >160kb (εGγAγδβ)0 thalassaemia deletion 
found in an Asian Indian family.  
 
In summary a total of 17 different -globin gene cluster deletions were 
identified, comprising 13 previously reported mutations and four new mutations 
illustrating the heterogeneity of the molecular basis of the β-thalassaemia 
disorders in the UK. Mutations were found in all major UK population ethnic 
groups (Asian Indian, African, Mediterranean, Southeast Asian and white 
British). 
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Figure 3.1 HPFH-2 deletion mutation by MLPA and Gap-PCR.  
a) MLPA peak patterns for the β-globin gene green probe set (β-globinxs MLPA 
Kit; ServiceXS.  This set comprises of 17 probes and two control probes 
(marked as C).  The upper window shows a normal control and the lower 
window a patient heterozygous for the HPFH-2 deletion. The HPFH-2 deletion 
is shown by the reduced peak heights of probes 19-28 b) Gap-PCR for the 
HPFH-2 deletion mutation.  M= 1kb marker. Lane 1= normal control, Lane 2= 
heterozygous control, Lane 5= patient with the HPFH-2 deletion by MLPA.
a) 
b) 
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Table 3.1 Haematological indices and MLPA results of common β- globin cluster deletions confirmed by Gap-PCR. 
 
 
 
 
 
 
 
Deleted 
Genes 
(MLPA) 
Size 
kb 
n HbA2 
% 
HbF 
% 
RBC 
1012/l 
Hb 
g/dl 
MCV 
fl 
MCH 
pg 
Ethnicity Confirmed Deletion 
δβ 106 2 1.6-2 31-32.6 4.2-5.0 8.5-12.2 71-73.2 20.2-20.8 Black HPFH-1 (Black) 
(Collins et al., 1987) 
δβ 105 25 2.2-3.1 18-36.1 4.03-5.8 9.2-37.2 73.1-91.4 22.3-31.2 Black/Mixed HPFH-2  (Ghanaian) 
(Collins et al., 1987) 
δβ 48.5 1 2.1 28.6 5.10 13.6 81.7 26.7 Mediterranean HPFH-3 (Indian) 
(Kutlar et al., 1984) 
δβ 20.6 1 2.5 8.3 5.77 12.0 70.0 20.9 Not given 
 
Turkish (δβ)0 thal 
(Kulozik et al., 1992) 
δβ 13.4 11 2.4-3.6 4.2-14.1 4.79-5.8 9.4-13.3 62.9-74.2 19.6-24.8 Mixed/Caucasian Sicilian (δβ)0 thal 
(Ottolenghi et al., 1982) 
Aγδβ 100 5 2.4-3.1 13.2-17.8 5.96-6.4 12-16.3 73.1-77.3 22.6-25.2 Asian/Chinese Chinese (δβ)0 thal 
(Jones et al., 1981b) 
Aγδβ 23.4 7 2.1-3.2 14.1-17.8 5.1-6.5 10-14.5 66-70.2 20.8-22.9 Indian Indian  Gγ(Aγδβ)0 thal 
(Jones et al., 1981a) 
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Table 3.2 Haematological indices and MLPA results of rare/novel β− globin cluster deletions. 
 
 
 
 
* all members of the same family 
 
 
Deleted 
Genes 
(MLPA) 
Size kb n HbA2  
% 
HbF 
% 
RBC 
10
12
/l 
Hb 
g/dl 
MCV 
fl 
MCH 
pg 
Ethnicity Previously reported candidate 
deletion 
εGγAγδβ >200 1 3.7 0.9 6.7 13.1 63.0 19.0 White British Scottish-Irish (εGγAγδβ)0 thal 
(Trent et al., 1990) 
εGγAγδβ >160 4* 3.0-3.7 0.0-0.7 5.6-6.8 11-13.7 58-69 17.3-20.3 Asian Indian None - Novel 
 
δβ 25-45 3 3.1-3.3 12-25 4.9-5.7 11-13.7 67.4-71.3 22-24.1 Indian Indian GγAγ(δβ)0 thal 
(Mishima et al., 1989) 
δβ 8-12 1 2.9 11.5 5.9 13.6 69.1 23 White British East European GγAγ(δβ)0 thal 
(Palena et al., 1994) 
δβ 10-12 1 2.3 21.9 5.24 12.7 73.6 24.3 Thai Vietnamese GγAγ(δβ)0 thal 
(Craig et al., 1994) 
δβ 30-40 1 2.8 16.4 6.1 16.3 77.7 25.2 African None - Novel 
 
β >45 6 7.3-8.0 1.6-4.0 4.4-6.6 9.4-13.9 62-66.7 18.7-21.6 Filipino Filipino β0 thal 
(Waye et al., 1994) 
β 10-12 1 8.3 3.1 4.6 9.7 61.9 21.3 Not given Australian β0 thal 
(Motum et al., 1992) 
β 0.2-1 3* 8.6-9.0 1.7-3.9 5.6-6.2 9.7-10.5 61-61.9 18.6-21.3 Afghanistan None - Novel 
 
β 2-8 2* 7.3 8.4 4.54 11.2 72 24.7 Afro-Caribbean None - Novel 
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Novel GγΑγ(δβ)0 thal (1)
Filipino (β)0 thal (6)
Australian (β)0 thal (1)
Novel (β)0 thal (3)
Novel (β)0 thal (2) 
 
Figure 3.2 The human β-globin gene cluster on chromosome 11p. 
The ε,Gγ, Αγ, δ and β genes are indicated by grey boxes.  The  vertical arrows indicate the positions of the MLPA probe sets on the cluster and the colour 
of the arrow corresponds to the fluorescent dye label (green, blue or red) used in the MLPA reaction. The grey vertical arrows represent the 
hypersensitivity sites 1 and 4 for which two of the MLPA probes target.  The positions of the 17 different deletions are shown below the β−globin cluster.  
The orange horizontal bars represent the common deletions which were confirmed by Gap-PCR.  The blue horizontal bars show the rare deletions 
which have a possible candidate.  The burgundy horizontal bars show the deletions which are possibly novel.  The white boxes represent the positions 
between the probes with which further characterisation is needed in order to confirm the precise break points.  The green hatched box represents the 
location of the 3.5kb 
Aγ-δ globin intergenic region important in γ-globin gene silencing.  Deletions removing this region had the highest levels of HbF.
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3.6 Discussion 
 
This study showed the efficacy of MLPA at identifying -globin gene cluster 
deletions in a routine diagnostic laboratory setting. Fifty two of the deletion 
mutations detected were subsequently confirmed by Gap-PCR which validated 
the accuracy and sensitivity of the method. The technique only required the use 
of standard DNA laboratory equipment (thermal cyclers and capillary 
electrophoresis) and was found to be robust in routine use. It was also much 
quicker than conventional Southern blot analysis in that results could be 
obtained within two days. The main limitation of the method was that it could 
only detect deletions/duplications that alter overall copy number; other 
rearrangements such as simple inversions will be missed. Also, the MLPA 
technique on its own cannot define the exact breakpoints of a deletion; however 
this is not usually required in a diagnostic setting. If full characterisation of a 
particular deletion is required, a simple approach is to design sets of PCR 
primers which flank the deleted region indicated by the MLPA results. The 
primer pairs are then used to amplify across the deletion as Gap-PCR primers. 
The resulting PCR product can then be sequenced and the breakpoints 
determined by comparison with the normal β-globin gene cluster sequence in 
this region. 
 
These results showed that -globin gene cluster deletions were present at 
significant frequencies in the UK population. Over the 3 year period of the study 
the 75 patients identified with a deletion comprised 11% of the total number of 
patients/families referred for investigation of -thalassaemia. All 7 of the 
common -globin gene deletion/rearrangement mutations described by Craig et 
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al (1994) were observed and comprised 69% of the total mutations found. The 
most common deletions were HPFH-2, the Sicilian δβ-thalassaemia deletion, 
the Indian inversion δβ-thalassaemia mutation and the Chinese δβ-
thalassaemia deletion (Table 3.I).  Much rarer were the HPFH-1, HPFH-3 and 
the Turkish δβ-thalassaemia deletions which were each found only once or 
twice.  The remaining 31% (23) of patients had one of 10 different rare or novel 
deletion mutations (Table 3.2). These would have been missed by a 
conventional Gap-PCR screen for the 7 common mutations. These results 
showed that rare/novel mutations comprise a significant proportion of the  
-globin gene cluster deletion mutations in the UK population and indicate that 
the use of MLPA to detect them is warranted.  
 
Two of the rare/novel mutations identified were particularly interesting as they 
had a deletion of the ε,γ,δ and β-globin genes, and thus the patients exhibited 
the rare phenotype of (εGγAγδβ)0- thalassaemia trait.  At the time of performing 
this analysis only 16 different (εGγAγδβ)0- thalassaemia mutations had previously 
been reported in the literature (Rooks et al., 2005, Furuya et al., 2008). Of these 
16 large deletions, 11 remove all or a greater part of the β-globin gene cluster 
but 5 leave the β-globin gene intact but inactivated.  The two deletion mutations 
described here were of the category with the β-globin gene deleted. The first 
matched the previously described Scottish-Irish mutation. The second was 
found in an Asian Indian family and is most likely novel. 
 
Two hundred and forty one of the 316 samples studied did not have a large 
deletion of the β-globin gene cluster. Beta-thalassaemia point mutations and  
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-thalassaemia mutations (both deletion and non-deletion mutations) had 
previously been excluded in all samples.  Therefore the reasons for the raised 
HbF and/or thalassaemic red cell indices in these 241 patients remained 
unclear. It was difficult to ascertain whether comprehensive iron studies had 
been carried out on all these patients and was therefore likely that at least some 
will simply have iron deficiency anaemia. It was also possible that some will 
have a -globin gene cluster rearrangement that cannot be detected by MLPA; 
these include small deletions that lie between the MLPA probes and gene 
rearrangements such as a simple inversion which effectively silences the genes 
but does not alter gene copy number. Other patients may have thalassaemia or 
high HbF levels due to as yet unidentified genetic determinates.  
 
A significant proportion of the samples in which a mutation was not identified 
had normal red cell indices and a modest increase in HbF consistent with  
non-deletion HPFH.  Sequence analysis of the γ-globin genes in these patients 
would be necessary in order to eliminate any variants or point mutations such 
as the XmnI-Gγ mutation which has been shown to be a major locus responsible 
for increasing HbF (Gilman and Huisman, 1985).  It has been suggested that 
>50% of the variance seen in HbF levels is unlinked to the β-globin gene locus 
and two other major loci have been identified and are unlinked to chromosome 
11p15 (Garner et al., 2000).  These are the HBS1L-MYB intergenic region on 
chromosome 6q23 and BCL11A on chromosome 2p15 (Thein et al., 2007, 
Menzel et al., 2007).  The most significant of these is the BCL11A gene on 
chromosome 2 which was identified as a critical factor in the down regulation of 
HbF expression in adult erythrocytes (Sankaran et al., 2008).  Therefore it was 
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also highly probable that some of the samples in this group may be linked to 
one of the above loci unlinked to the β-globin gene locus. 
   
Although it is important to detect  β-globin gene cluster deletion mutations for 
clinical reasons it is also useful for research purposes.  By mapping novel 
mutations and studying the genotype-phenotype relationship of these deletions 
our understanding of the mechanisms involved in the control of the fetal and 
adult globin gene expression may be enhanced. This study alone has identified 
4 possible novel deletions within the UK population, the simplicity of the MLPA 
technique makes it likely that many more will be detected.  
 
In summary the results of this study have demonstrated the wide spectrum of  
β-globin gene cluster deletion mutations in the UK population, in which 13 
known deletion mutations have been identified (22% of the published spectrum 
of 60 for all ethnic groups) plus four novel deletions. The MLPA method is 
simple and reliable and is recommended as the first choice method for 
screening for these clinically significant large deletion mutations.  
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CHAPTER FOUR: MAPPING OF PRECISE BREAKPOINTS IN NOVEL 
DELETIONS 
4.1 Introduction 
 
The results from the work described in chapter 3 demonstrated that the 
technique of MLPA was able to identify deletions in the β-globin gene clusters of 
patients referred to our laboratory for haemoglobinopathy investigations.  As 
discussed this had importance for clinical reasons and was also useful for 
research purposes. The mapping of novel deletions may aid in the 
understanding of the genotype-phenotype relationships and also shed some 
light on the mechanisms involved in the fetal to adult haemoglobin switching 
process.  The work described in chapter 3 led to the identification of four 
possible novel deletions in the β-globin gene clusters of patients from the UK 
population.  However, the technique of MLPA was not able to define the exact 
breakpoints and therefore mapping using Gap-PCR methodology would need to 
be undertaken to characterise the deletions.  The work described in this chapter 
aimed to fully characterise the breakpoints of the four novel deletions (deletion 
1-4). 
4.2 Deletion 1 
 
This was the first reported case of a β-globin gene deletion mutation in a family 
of Afghan ancestry.  The proband was a 10 year old Afghan female who had 
been referred for β-thalassaemia genotyping.  She was transfusion dependent 
and had the phenotype of β-thalassaemia major with a complete absence of 
HbA (Table 4.1). Her parents are consanguineous (first cousins) and both had 
reduced red cell indices and elevated HbA2 levels consistent with  
-thalassaemia trait.  
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Table 4.1 Haematological parameters for deletion 1. 
 
 Hb 
g/dl 
RBC  
x1012/l 
MCV 
fl 
MCH 
pg 
HbA2 
% 
HbF 
% 
Mother 10.5 5.66 61.0 18.6 9.0 1.7 
Father 13.2 6.01 65.0 17.9 8.6 3.9 
Proband* 5.6 2.21 64.2 19.0 3.3 95.9 
*Pre-transfusion sample 
 
 
Initial molecular investigations by ARMS-PCR and β-globin gene sequence 
analysis (from the promoter to the polyadenylation signal region) failed to 
identify a -thalassaemia point mutation. Further investigations using the 
technique of MLPA revealed a reduction in the height of a single probe for both 
parents and a complete absence of the same probe in the proband (Figure 4.1). 
The deleted probe was located in the β-globin gene promoter region.  All other 
surrounding probes were normal.  Cases of a reduction in the height of a single 
probe must be interpreted with caution as the reduced peak height could be due 
the presence of a rare sequence variant under the ligation site.  However in this 
case the proband’s β-globin gene promoter region had been sequenced 
previously and confirmed to be normal.  Therefore the results indicated that the 
parents are carriers of a small deletion at the 5 end of the β-globin gene, and 
the proband was homozygous for this deletion mutation.  The MLPA results 
were not consistent with any previously reported β-globin gene deletion.   
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Figure 4.1 MLPA results for deletion 1 (β-globinxs MLPA Kit; ServiceXS). 
 
a) Normal control (arrow indicates normal probe height for probe 23) 
b) Mother/father (arrow indicates reduced height for probe 23) 
c) Proband (arrow indicates complete absence of probe 23) 
 
 
 
a) 
 
c) 
b) 
23 
23 
23 
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Figure 4.2 Gap-PCR amplification products in deletion 1. 
Lane 1 & 2= mother, lane 3 & 4= father, lane 5 & 6= proband, lane 7= blank 
lane M= 100bp DNA ladder (New England BioLabs). 
 
 
PCR primers were designed (forward TAATCTGAGCCAAGTAGAAG and 
reverse CACTGATGCAATCATTCGTC) to flank the deleted region indicated by 
the MLPA results.  The primer pair was then used to amplify across the deletion 
as Gap-PCR primers (Figure 4.2).  Amplifications were performed in 25µl tubes 
with the standard PCR reagents (see section 2.5).  The PCR conditions 
involved an initial denaturation of 3 minutes at 950C, then 30 cycles of 950C for 
1 minute, 560C for 2 minutes, 720C for 2 minutes and ending with a final 
extension of 720C for 10 minutes.  Some of the resulting product (10µl) was 
electrophoresed through a 1.5% agarose, 1 x TBE gel at 100 Volts for one hour 
(Figure 4.2).  The remaining product (15µl) was sequenced using a Beckman 
Coulter DNA sequencer and the breakpoints determined by comparison with the 
normal β-globin gene cluster sequence (Figure 4.3).   
    1         2         3        4       5          6        7        M 
Mutant 
600bp 
Wild type 
1500bp 
 71 
 
Figure 4.3 Sequence analysis results (β-globin gene) for deletion 1. 
a) Diagram to illustrate the structure of the β-globin gene cluster and the 
positions of all the MLPA probes (black vertical arrows) used in the analysis.  
Below the cluster is a diagram showing the size and location of the deletion in 
relation to the β-globin gene. 
b) Sequence chromatogram for the proband, where * denotes the deletion 
breakpoint. 
c) The sequence of the junction fragment showing the 5 normal, mutant and 3 
normal sequences.  The vertical bars illustrate the positions at which the 
sequences are identical. 
* 
a) 
c) 
b) 
 72 
The proband was found to be homozygous for a novel 909 bp deletion (-478 
through to + 432) removing the β-globin gene promoter, exon I and IVS-I 
entirely and most of exon II of the β-globin gene (Figure 4a).  The 5 breakpoint 
was demonstrated to lie at position 5,205,311 and the 3 breakpoint at 
5,204,404 according to the UCSC human chromosome 11 genome browser.  
Examination of the nucleotide sequences upstream and downstream of the 
junction breakpoints did not reveal any significant sequence homology 
suggesting that the deletion was caused by a non homologous recombination 
event (Figure 4.3b, 4.3c).  However, there were AT-rich stretches of sequences 
around the 5 breakpoint which have been previously postulated as significant in 
the generation of β-globin gene deletions (Thein et al., 1989, Huang et al., 
2008). 
 
Very little is known regarding the frequency and range of thalassaemia 
mutations in Afghanistan.  The frequency of β-thalassaemia carriers had been 
estimated at 3% but there was no published data on the percentage of affected 
individuals (Galanello et al., 2003).  Several unusual or novel β0-thalassaemia 
mutations had been previously reported in immigrant Afghan families (Giordano 
et al., 1999, Krugluger and Hopmeier, 2002, Kornblit et al., 2005) but there were 
no published studies of the spectrum of thalassaemia mutations in this 
population (Henderson et al., 2009).  This novel mutation was the first reported 
case of a β-globin gene deletion mutation in the Afghan population and 
indicated that the Afghani population had a complex heterogeneous array of 
haemoglobin disorders due to invasions of different ethnic groups during 
various periods in history. The impact of racially heterogeneous immigrant 
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populations in European countries was responsible for a large increase in the 
number and variety of mutations encountered, creating challenging problems in 
carrier diagnosis, genetic counselling and prenatal diagnosis. 
4.3 Deletion 2 
 
An Afro-Caribbean antenatal lady was referred for prenatal diagnosis for a 
possible risk to her fetus of HbSickle/β-thalassaemia.  Her partner was a sickle 
cell carrier and she had been identified on antenatal screening as having 
reduced red cell indices and an elevated HbA2 level consistent with  
-thalassaemia trait.  A sample was referred from the mother and an amniotic 
fluid sample from the fetus but the father refused any further testing. 
 
Table 4.2 Haematological parameters on the mother in deletion 2. 
 
 Hb 
g/dl 
RBC  
x1012/l 
MCV 
fl 
MCH 
pg 
HbA2 
% 
HbF 
% 
Mother 11.2 4.5 72.0 24.7 7.3 8.4 
 
 
Initial molecular investigations by ARMS-PCR and β-globin gene sequence 
analysis failed to identify a -thalassaemia point mutation in both the mother 
and the fetus.  The fetus also tested negative for the sickle mutation by ARMS-
PCR confirming that the fetus had not inherited the father’s mutation.  Further 
investigations using β-globin gene cluster MLPA probe sets (β-globinxs MLPA 
Kit; ServiceXS and the P102-B2 HBB; MRC-HOLLAND) revealed a reduction in 
height of the probes shown in Figure 4.4 for both the mother and the fetus.  
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Figure 4.4 β-globin gene cluster MLPA results for deletion 2.  
Numbered peaks represent individual probes along the β-globin gene cluster.  
Peaks denoted by the letter c= control peaks. a) Normal control patient sample 
analysed with the ServiceXS MLPA kit b) Mother’s sample analysed with the 
ServiceXS MLPA kit c) Normal control patient sample analysed with the MRC-
Holland MLPA kit d) Mother’s sample analysed with the MRC-Holland MLPA kit.  
Red arrows indicate probes reduced in height when compared to the normal 
control and control peaks within each analysis. 
a) 
b) 
c) 
d) 
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Figure 4.5 Schematic representations of the MLPA probes deleted in 
deletion 2. a) ServiceXS MLPA probe set and b) MRC-Holland P102-B2 MLPA 
probe set.  The genes are shown as light blue boxes; arrows denote the probe 
position with the numbered red probes having reduced height. The deletion is 
illustrated below the genes as a red bar and the hatched blue areas show the 
possible breakpoint regions. 
 
 
The deleted probes show that the whole of the β-globin gene is removed by the 
deletion.  All other surrounding probes were normal.  The MLPA results were 
not consistent with any previously reported β-globin gene deletion.   
 
a) 
b) 
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PCR primers were designed to flank the deleted region indicated by 
the MLPA results (forward TAATCTGAGCCAAGTAGAAG and reverse 
CCTCTACTTGAATCCTTTTC) with the maximum size of the deletion being 
2,676bp and the minimum deletion size of 1,692bp (Figure 4.5).  The primer 
pair was then amplified across the deletion as Gap-PCR primers using the 
QIAGEN Mastermix protocol (section 2.5) with an annealing temperature of 
600C. The resulting fragment was sequenced using an ABI-PRISM 3100 
automated DNA sequencer (Applied Biosystems) and the breakpoints were 
determined by comparison with the normal β-globin gene cluster sequence 
(Figure 4.6). 
Figure 4.6 Analysed sequence data (Mutation Surveyor®) on the mother 
showing the deletion breakpoint.  The top electropherogram is the reference 
trace, the middle the test sample trace and the bottom is the mutation 
electropherogram which highlights any differences between the reference and 
test sample traces as spikes.  * denotes the possible deletion breakpoint.
*
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The sequence analysis results showed a deletion of 1,393bp (HGVS: 
NG_000007.3:g.70060_71452del1393) (Figure 4.7) which fitted exactly with a 
previously reported deletion found in African-American and British patients 
(Anand et al., 1988, Thein et al., 1989).  The deletion extends from 485bp  
5 to the mRNA CAP site to the middle of the second intervening sequence.   
 
 
3’5’ +51 +274 +496 +1364
EX-IIIVS-I
CAP POLY A
-400 -200
1,393bp (-485 to 908)
IVS-II EX-IIIEX-I
 
 
Figure 4.7 Diagram showing the size and location of the 1,393bp deletion 
in relation to the β-globin gene. The hatched red bar represents the size of 
the deletion. 
 
Both the ServiceXS and MRC-Holland MLPA probe sets sized the deletion at a 
minimum size of 1,692bp, which was greater than its actual size of 1,393bp.  
This difference was most likely due to a common polymorphism in the target 
sequence which resides where probe 25 (ServiceXS) and 26 (MRC-Holland) 
anneal.  It has been well documented than one of the limitations of the MLPA 
technique is that probes will be deleted in the presence of a polymorphism 
(Stuppia et al., 2012).  This can lead to deletions appearing larger than they 
actually are and highlights why only having one probe reduced in height is not 
always a reliable indicator of a deletion. 
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4.4 Deletion 3 
 
An African man was referred from his GP as he had an unexplained raised HbF 
level and a persistently low MCV (Table 4.3).   
 
Table 4.3 Haematological parameters on deletion 3. 
 
Hb 
g/dl 
RBC  
x1012/l 
MCV 
fl 
MCH 
pg 
HbA2 
% 
HbF 
% 
16.3 6.1 77.7 25.2 2.8 16.4 
 
 
His phenotype was consistent with a diagnosis of δβ−thalassaemia trait.  MLPA 
results (Figure 4.8) revealed heterozygosity for a large deletion in the β-globin 
gene cluster which as predicted removed the δ and β-globin genes and possibly 
the Aγ-gene.  Both the ServiceXS and MRC-Holland probe sets showed the 
same deleted region.  All three ServiceXS probe sets (green, red and blue) 
were analysed with only the green and blue sets showing probes with reduced 
height. From the results the size of the deletion was calculated to be between 
32,275bp and 44,303bp (Figure 4.9).   
 
Thirty different primer pairs were designed spanning the breakpoint regions and 
long range PCR (section 2.5.1) was performed in an attempt to produce an 
amplification product for sequence analysis.  None of the primer pairs amplified 
which might be explained by the deletion size being incorrect. If there was a 
polymorphism in the target sequence of one of the probes, like in deletion 2, the 
size may actually be smaller.   
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Figure 4.8 ServiceXS MLPA results for deletion 3. Numbered peaks 
represent individual probes along the β-globin gene cluster.  Peaks denoted by 
the letter c= control peaks. a) Normal control patient sample analysed with the 
ServiceXS green probe set b) Patient sample analysed with the ServiceXS 
green probe set c) Normal control patient sample analysed with the ServiceXS 
blue probe set d) Patient sample analysed with the ServiceXS blue probe set.  
Red arrows indicate probes reduced in height compared to the normal control 
and control peaks within each analysis. 
 
a) 
d) 
c) 
b) 
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Figure 4.9 Schematic representation of the probes reduced in height in 
deletion 3 (ServiceXS MLPA set). The genes are shown as light blue boxes 
and the arrows denote the probe position with the probes numbered red having 
reduced height. The deletion is illustrated below the genes as a red bar and the 
hatched blue areas show the breakpoint regions. 
 
 
As precise characterisation of the breakpoints in deletion 3 was proving difficult 
it was decided to try another approach. The development of microarray 
technology over the last few years has proven to be an essential tool in looking 
for copy number variation (Phylipsen et al., 2012). It was decided to analyse this 
sample on an iScan microarray (Illumina®) using the HumanOmni1- 
Quad chip with the analysis performed by Dr Ruth Clifford 
(http://www.illumina.com/products). This chip had over one million strategically 
selected markers therefore offering dense genome-wide coverage and also 
included data from the 1000 genomes project. The data was processed using 
GenomeStudioV2009.2 (Illumina, Inc., San Diego, California, USA) and then 
analysed using Nexus 6.1 Discovery Edition (BioDiscovery, Inc., El Segundo, 
California, USA). 
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Figure 4.10 Microarray (iScan) results for deletion 3.  The top panel shows 
the position of the deletion represented by a red bar with the genes affected 
below.  The middle panel is the Log2 Ratio track and the lower panel the B allele 
frequency plot.  Both plots show heterozygosity for a large deletion. Single 
nucleotide polymorphism (SNP) probes are represented by grey dots. 
 
The results of the microarray confirmed the presence of a heterozygous 
deletion removing part of the Aγ-gene and all of the δ- and β-globin genes 
(Figure 4.10).  Forty three probes covered the deleted region and the size of the 
deletion ranged from 49,247bp to 51,322bp.  The microarray results suggested 
that the MLPA results had underestimated the size of the deletion.  The 5 end 
of the deletion seemed comparable with both techniques, removing part of the 
Aγ-gene however the 3 end appeared on the microarray to be larger than the 
MLPA results.  Probe 43 with the ServiceXS MLPA probe set (Figure 4.9 and 
4.11) was not reduced in height yet would appear to be deleted on the 
microarray.   
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Figure 4.11 Schematic representation of the probes reduced in height in 
deletion 3 (ServiceXS) with the size of the deletion from the microarray. 
The genes are shown as light blue boxes and the arrows denote the probe 
positions with the probes numbered red having reduced height. The SNP array 
deletion size is illustrated below the genes as a red bar and the hatched blue 
areas show the breakpoint regions. 
 
In order to explain why probe 43 failed to show any reduction in height,  
5 known positive control samples with HPFH-2 (which would be expected to 
remove probe 43) were analysed using the same ServiceXS MLPA kit.  The 
results showed that probe 43 failed to be reduced in height in all 5 control 
samples and therefore was unreliable.  One possible explanation for this finding 
was that probe 43 was annealing to an alternative site in the genome. 
 
In the literature 14 Aγδβ-thalassaemias had been reported and found in most 
ethnic groups (Table 1.2).  Only one Aγδβ-thalassaemia had been reported in 
Africans with a deletion size of 35.81kb (Henthorn et al., 1985) which was 
smaller in size than deletion 3.  However there was one Aγδβ-thalassaemia with 
a deletion size of 50kb which was similar to the size of deletion 3.  This deletion 
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had been found previously in Belgians (Losekoot et al., 1991).  Therefore 
deletion 3 could be a novel African Aγδβ-thalassaemia or the Belgian  
Aγδβ-thalassaemia found for the first time in an individual of African origin.  The 
design of primers flanking the deletion breakpoints determined from the 
microarray data should enable confirmation of its precise size. 
4.5 Deletion 4 
 
Four Asian Indian family members were referred for investigation as their 2 
month old son (case 19) had unexplained persistent anaemia in the newborn 
period. The child’s grandmother (case 2) was under the care of the same 
clinician and had been prescribed oral iron for 10 years without a response in 
her red cell indices. The β-globin gene cluster MLPA results revealed 
heterozygosity for a large deletion consistent with the rare genotype of  
(εγδβ)0-thalassaemia (Figure 4.13). The deletion removed most of the  
β-globin gene cluster including the β-LCR, ε, γ, δ, and β-globin genes.  
 
Adult heterozygotes for the rare condition of εγδβ-thalassaemia have a typical  
β-thalassaemia trait blood picture but with normal HbA2 and HbF levels.  
However in the neonatal period heterozygotes for this disorder are anaemic and 
can be so severely affected that they require blood transfusions (Rooks et al., 
2005, Driscoll et al., 1989).  The condition improves as they get older (3-6 
months after birth) and the anaemia becomes less severe.  The homozygous 
state for this disorder has not been encountered, presumably because it is not 
compatible with fetal survival.  It is difficult to understand why this condition is 
more severe in fetal life, particularly as infants have two out of the four γ-globin 
 84 
genes intact.  The exact mechanisms involved are still not clear but the 
condition has clinical variability, even within the same family (Trent et al., 1990). 
 
In view of the clinical significance of this deletion the referring clinician then 
referred a further 20 family members. MLPA results revealed that a total of 12 
family members had inherited the same (εγδβ)0-thalassaemia deletion  
(Figure 4.12).  The haematological parameters for all 12 patients which proved 
to be heterozygote for the deletion are shown in Table 4.4. 
 
Table 4.4 Haematological parameters for the pedigree with deletion 4. 
 
Case Age 
(years) 
Hb 
g/dl 
RBC  
x1012/l 
MCV 
fl 
MCH 
pg 
HbA2 
% 
HbF 
% 
2 55 9.4 4.87 59.0 19.3 3.0 0.4 
4 34 13.7 6.75 64.0 20.3 3.0 <1.0 
6 32 12.9 6.54 60.0 19.7 3.2 0.7 
9 24 11.6 6.06 59.0 19.1 2.8 0.2 
12 24 10.3 5.16 62.0 20.2 3.3 0.3 
13 21 10.2 5.16 61.0 19.8 3.4 1.0 
14 19 11.6 5.75 61.0 20.1 3.1 1.2 
15 16 12.5 6.10 62.0 20.5 3.2 0.5 
17 10 10.2 5.81 58.0 17.6 3.7 0.5 
19 2months 5.5 2.77 71.0 20.0 0 55.2 
20 8 11.0 6.00 55.0 18.3 2.9 0.3 
21 5 9.7 5.62 68.7 17.3 3.2 0.7 
 
8
5
 
 
  
Figure 4.12 Diagram showing the pedigree of the Asian Indian family with (εγδβ)0-thalassaemia (deletion).
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Figure 4.13 ServiceXS MLPA results for deletion 4. Numbered peaks represent 
probes along the β-globin gene cluster.  C= control peaks. a) Normal control analysed 
with the green probe set b) Patient sample analysed with the green probe set 
c) Normal control analysed with the red probe set d) Patient sample analysed with the
red probe set e) Normal control analysed with the blue probe set 
f) Patient sample analysed with the blue probe set. Red arrows indicate probes
reduced in height compared to the normal control and control peaks within each 
analysis. 
a) 
b) 
c) 
d) 
e) 
f)
 87 
0kb
ε
G
γ
Aγ ψβ δ β
250kb-250kb
5’ 3’
HS-4 HS-1
21-25
43 7 9 11 13 16 19 26 28 32 33
1 2
50
27 29 30
44
45 4635 36 37 38
O
R
5
2
D
1
O
R
5
1
M
1
O
R
5
1
V
1
O
R
5
2
Z
1
P
O
R
5
1
A
1
P
? 289,188bp 11076bp
 
Figure 4.14 Schematic representation of the probes reduced in height in 
deletion 4 (ServiceXS). The genes are shown as light blue boxes and the 
arrows denote the probe position with the numbered red probes having reduced 
height. The SNP array deletion size is illustrated below the genes as a red bar 
and the hatched blue areas show the breakpoint regions. 
 
Both the ServiceXS and MRC-Holland probe sets showed the same deleted 
region.  All three ServiceXS probe sets (green, red and blue) were analysed 
with probes 1 to 44 showing reduced height and the entire set of probes in the 
MRC-Holland kit being reduced (1-29). Probes 28, 29 and 30 which were 
located 5 to probe 44 were not reduced in height.  It was possible that probe 44 
was showing reduced height due to a polymorphism in the target sequence and 
therefore probe 27 was taken as the last probe.  From the MLPA results the 
smallest deletion size was calculated as 289,188bp with the largest size 
unknown as the last 5 probe was deleted (Figure 4.14). Without the presence 
of an intact probe at the 5 end of the β-globin gene cluster it was not possible to 
characterise the 5 breakpoint. Therefore, further characterisation of this 
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deletion was attempted using microarray technology. DNA from case 2 was 
analysed using the iScan (Illumina®) microarray with the HumanOmni1-Quad 
chip. The results of the microarray confirmed the presence of a heterozygous 
deletion which removed all the globin genes on the cluster (Figure 4.15).  The 
deleted region was covered by 604 probes and the size of the deletion from the 
results was calculated to be between 502,051bp and 507,634bp.   
 
 
Figure 4.15 SNP microarray (iScan) results for deletion 4.  The top panel 
shows the position of the deletion represented by a red bar with the genes 
affected below.  The middle panel is the Log2 Ratio track and the lower panel 
the B allele frequency plot.  Both plots show heterozygosity for a large deletion.  
SNP probes are represented by grey dots. 
 
The microarray results suggested that the actual size of the deletion was twice 
as large as expected from the MLPA results. The 3 end does remove the 
olfactory gene OR51V1 as expected and probe 44 should not have been 
reduced on the MLPA results.  The 5 end removes two more olfactory genes 
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(OR52H1 and OR52B6) and three TRIM genes (TRIM6, TRIM5 and TRIM22) 
which code for a family of proteins whose function is to mediate interferon.   
 
As stated in chapter 3, at the time of performing this analysis (2008) only 16 
different (εGγAγδβ)0- thalassaemia mutations had been reported in the literature.  
This deletion was the largest (εγδβ)0-thalassaemia mutation reported at that 
time and the first found in the Asian Indian population.   Since then however 30 
different (εGγAγδβ)0- thalassaemia deletion mutations have been reported with 
one deleting a large region of 1.7Mb (Shalev et al., 2013).  Yet only 13 of the 
reported 29 different (εGγAγδβ)0- thalassaemia deletion mutations have been  
fully characterised due to the difficulties in mapping breakpoints in large 
deletions.  Recently a 506kb (εGγAγδβ)0- thalassaemia deletion mutation (termed 
Pakistani I) found in a Pakistani family was fully characterised having taken the 
researchers over 20 years to define the exact breakpoints (Rooks et al., 2012).  
Eventually the breakpoints were defined using array comparative genome 
hybridization (aCGH) experiments, a similar approach as was carried out with 
deletion 4.  In the Pakistani I deletion there was no sequence homology 
between the 5 and 3 breakpoint region.  This type of non-homologous 
recombination has been observed in other deletions of the β-globin gene 
cluster.  However the break point region was found in a palindrome region, a 
finding which has been associated with other deletion breakpoints and 
demonstrates that palindromes may play a large role in the formation of 
deletions.  The exact breakpoints of the Pakistani I deletion match the deleted 
region from the microarray results in deletion 4. It is therefore possible that 
deletion 4 is in fact the Pakistani I deletion.   
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4.6 Discussion 
 
Fully characterising deletions is important for comprehensive prenatal genetic 
diagnosis (as seen in deletion 2) and because it can lead to defining novel 
regulatory regions.  By examining the breakpoints regions and comparing them 
between different deletions we improve our understanding of the biological 
processes that created them.  The work described in this chapter illustrates the 
technical challenges in mapping large deletions.  It demonstrates that there is a 
need for a single methodology similar to next generation sequencing techniques 
that can fully characterise deletions and rearrangements in a single analytical 
process.  Since carrying out this work others have used fine-tiling aCGH 
technology to detect small and large rearrangements in both the α- and β-globin 
gene clusters with high resolution (Phylipsen et al., 2012).  The recent advance 
of microarray based technology brings hope that methods of detecting deletions 
and rearrangements of the β-globin gene cluster will be improved.  Further 
design of primers flanking the microarray deletion breakpoints in deletion 3 and 
4 should enable confirmation of their precise size. 
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CHAPTER FIVE: GAMMA GLOBIN GENE PROMOTER MUTATIONS 
ASSOCIATED WITH INCREASED HBF LEVELS IN ADULTS 
5.1 Introduction 
 
Among the factors known to influence increases in HbF production are a 
number of point mutations in the promoter region of the γ-globin genes. The 
work described in this chapter investigated whether γ-globin gene promoter 
mutations were a significant cause of the increased HbF levels observed in the 
patient samples referred to our laboratory for haemoglobinopathy investigations.  
A number of γ-globin gene promoter mutations had been discovered in 
individuals in other countries (Table 1.4) but this cause of HPFH had not been 
widely investigated in the UK.  There was also little evidence to show whether 
these mutations were responsible for the high HbF levels observed in patients 
with a haemoglobinopathy as well as in patients with a non-deletion HPFH 
phenotype only.  Therefore samples from patients with an unexplained raised 
HbF and a haemoglobinopathy were included in this study along with patients 
with a high HbF phenotype only (collected from the study in chapter 3).  This 
work aimed to provide data regarding the spectrum of γ-globin gene promoter 
mutations in the UK and increase our knowledge of these genetic conditions.    
5.2 Study subjects 
 
A total of 131 patient samples were selected for this study.  Forty one samples 
had increased HbF levels only (ranging from 1.5-25%) and came from the 
cohort of 316 patient samples analysed for a β-globin gene cluster deletion in 
chapter 3.  The other 90 samples were referred for investigations into an 
unexplained elevated HbF level with a co-existing haemoglobinopathy.  All 
samples had been analysed by β-globin gene cluster MLPA and there was no 
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evidence of a deletion mutation.  Patient ages in this group ranged from aged 
1-81 years and they were from all the major UK population ethnic groups with 
36 being African, 36 white British, 28 Indian, 14 South-East Asian, 7 white 
European, 7 Mediterranean and 3 from the Middle East.  Haemoglobinopathy 
phenotypes consisted of 55 samples with co-existing α-thalassaemia trait, 6 
carriers for sickle cell trait, 28 β-thalassaemia carriers, 1 case with HbE disease 
and 41 samples with no evidence of any other haemoglobinopathy apart from 
the elevated HbF level. 
5.3 Laboratory procedures 
Haematological parameters were ascertained and DNA extraction performed as 
previously described (sections 2.2 and 2.3).  DNA samples underwent PCR 
amplification and Sanger sequence analysis for both the Gγ- and 
Aγ-promoter regions using published primers and PCR conditions (Huang et al., 
2000). 
5.4 Results 
A total of 131 selected samples were analysed by Sanger sequencing for a 
non-deletion HPFH point mutation in the promoter of either of the γ-globin 
genes.  Twenty eight (21%) were found to be heterozygous for a mutation 
(Table 5.1 and 5.2).  Of these, 22 had one of the previously reported mutations 
with 6 different point mutations being identified, 2 were in the Gγ- and 4 in the 
Aγ-promoter.  In the majority of cases the mutation was found in the same ethnic 
group and the HbF levels were similar to those which had been previously 
reported. The remaining 6 samples had unreported mutations.  Three different 
novel mutations were identified; one in the Gγ- promoter and two in the 
9
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Table 5.1 Haematological parameters and genotypes in patients with mutations detected in the Gγ globin gene 
promoter region.  One of the mutations detected is previously unreported (marked with an *). 
Case Gene Ethnic 
Origin 
Hb 
(g/dl) 
RBC 
(10
6
/mm
3
)
MCV 
(fl) 
MCH 
(pg) 
HbA2 
(%) 
HbF 
(%) 
β-globin 
phenotype 
α-globin 
genotype 
Gγ globin genotype 
1 Gγ African 16.2 6.52 74.5 24.2 2.4 14.1 HPFH -α3.7/−α3.7 -202 C>G Heterozygous 
2 Gγ African 12.6 5.7 71.1 22.4 1.9 12.7 HPFH -α3.7/−α3.7 -202 C>G Heterozygous 
3 Gγ African 13.4 4.7 88.0 28.8 1.8 17.9 HPFH -α3.7/αα -202 C>G Heterozygous 
4 Gγ African 13.5 6.2 69.9 22.0 1.6 8.8 HPFH -α3.7/−α4.2 -200 +C Heterozygous 
5 Gγ African 11.3 5.1 73 22.1 2.3 6.0 HPFH -α3.7/−α3.7 -194 C>T *Heterozygous
6 Gγ African 11.8 4.1 94.2 28.6 3.5 6.3 HPFH αα/αα -194 C>T *Heterozygous 
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Table 5.2 Haematological parameters and genotypes in patients with mutations detected in the Aγ globin gene 
promoter region.  Two of the mutations detected are previously unreported (marked with an *). 
 
Case Gene Ethnic Origin Hb 
(g/dl) 
RBC 
(10
6
/mm3) 
MCV 
(fl) 
MCH 
(pg) 
Hb A2 
(%) 
Hb F 
(%) 
β-globin phenotype α-globin genotype Aγ globin genotype 
7 Aγ White British 12.8 4.2 91.2 30.4 2.5 8.2 HPFH αα/αα -198 T>C 
8 Aγ White British 11.4 4.1 95.0 28.0 2.1 6.8 HPFH αα/αα -198 T>C 
9 Aγ White British 12.7 4.17 96.0 30.5 2.4 7.2 HPFH αα/αα -198 T>C 
10 Aγ White British 12.9 4.8 92.0 26.7 2.3 6.3 HPFH αα/αα -198 T>C 
11 Aγ White British 12.4 4.5 95.1 27.4 3.1 6.7 HPFH αα/αα -198 T>C 
12 Aγ White British 11.0 3.4 93.8 32.0 2.6 9.5 HPFH αα/αα -198 T>C 
13 Aγ White British 14.4 4.8 91.0 30.0 2.4 8.0 HPFH αα/αα -198 T>C 
14 Aγ White British 12.6 4.2 83.9 29.6 3.0 6.0 HPFH αα/αα -198 T>C 
15 Aγ White British 11.7 3.9 89.6 30.4 2.5 8.5 HPFH αα/αα -198 T>C 
16 Aγ White British 11.1 3.8 85.7 29.4 2.4 10.4 HPFH αα/αα -198 T>C 
17 Aγ White British 12.8 4.2 95.5 30.3 2.8 11.3 HPFH αα/αα -198 T>C 
18 Aγ White British 13.0 4.2 89.7 30.9 2.8 10.1 HPFH αα/αα -198 T>C 
19 Aγ Chinese 8.2 5.2 58.0 15.7 2.4 15.1 HPFH αα/αα -196 C>T 
20 Aγ Spanish 13.1 4.3 93.1 30.2 2.7 7.9 HPFH αα/αα -195 C>G 
21 Aγ White Italian 11.1 5.0 70.0 22.4 4 20.5 β-thalassaemia trait αα/αα -158 C>T 
22 Aγ White British 13.0 4.1 90.1 31.4 3 7.4 HPFH αα/αα -158 C>T 
23 Aγ White British 12.8 4.4 89.5 29.2 2.8 5.8 HPFH αα/αα -158 C>T 
24 Aγ African 9.1 4.7 64.7 19.4 1.8 10.0 HPFH -α3.7/−α3.7 -158 C>T 
25 Aγ Asian-Indian 16.2 5.4 88.8 29.8 2.6 3.2 HPFH αα/αα -130 C>G * 
26 Aγ Asian-Indian 12.2 4.7 78.3 25.9 2.5 9.7 HPFH αα/αα -130 C>G * 
27 Aγ Asian-Indian 12.1 4.3 86.0 28.1 2.5 5.6 HPFH αα/αα -130 C>G * 
28 Aγ South-East Asian 12.8 4.0 93.7 32.2 2 9.8 HPFH αα/αα -117 G>C * 
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TCTTGGGGGCCCCTTCCCCACACTATCTCAATGCAAATATCTGT  CACCC  TTGCCTTGACCAATAGCCTTGACAAGGCAAACTTGACCAATAGTCTT
Sp1
CACCC 
binding factor
CDPCP1
CDPCP1OCT-1
GATA-1
GATA-1GATA-1
NF-E3
Region I Region II Region III
-567
-202 
-109
-110
-114 C-T
-114 C-A
-114 C-G
-175-196
-200(+C)
-37
-194 C-T
Figure 5.1 Positions of point mutations in the Gγ-globin gene promoters.   
Boxed areas show conserved sequences which are binding sites for the transcription factors indicated below the sequence. 
Key:  - previously reported mutations not found in this study
  - previously reported mutations found in this study
   - mutations identified in this study which are novel
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TCTTGGGGGCCCCTTCCCCACACTATCTCAATGCAAATATCTGT   CACCC   TTGCCTTGACCAATAGCCTTGACAAGGCAAACTTGACCAATAGTCTT
Sp1
CACCC 
binding factor
CDPCP1
CDPCP1OCT-1
GATA-1
GATA-1GATA-1
NF-E3
Region I Region II Region III
-211
-202 
-158
-114 C-T
-201
-195
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-198
-117 G-A
-117 G-C
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Figure 5.2 Positions of point mutations in the Aγ-globin gene promoters.   
Boxed areas show conserved sequences which are binding sites for the transcription factors indicated below the sequence. 
Key:  - previously reported mutations not found in this study
  - previously reported mutations found in this study
   - mutations identified in this study which are novel
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Aγ (Figure 5.1 and 5.2).  Twenty one of the 28 patients with a mutation were 
from the cohort of 41 samples with no evidence of any other 
haemoglobinopathy apart from an elevated HbF level.  The remaining 7 patients 
with a mutation consisted of 1 patient with β-thalassaemia trait, 5 patients 
homozygous for α+-thalassaemia and one patient heterozygous for 
α+-thalassaemia.  All six of the patients with a γ-globin gene promoter mutation 
and α-thalassaemia were of African ancestry.  The ethnic group where the most 
mutations were identified was the cohort of 36 white British individuals.  A total 
of 14 (39%) of these patients were identified as having a γ-promoter mutation. 
5.5 Discussion 
The range and frequency of non-deletion HPFH point mutations in the UK 
population was unknown.  The results of this study show that mutations in the 
γ-globin gene promoters are likely to be present at significant frequencies in the 
UK population.  Twenty eight patients were identified with a point mutation 
which comprised 21% of the total number of patients referred for investigation of 
a high HbF level in which a large deletion had been excluded.  Six of the 25 
previously reported mutations were identified.  Two of the six mutations were in 
the Gγ-promoter and 4 in the Aγ-promoter.   
The most common mutation identified was the -198 (T-C) Aγ-promoter mutation 
found in twelve unrelated patients of white British decent with HbF levels 
ranging from 6-11.3%.  This is the only mutation reported in the literature to 
have been identified in patients of British origin and importantly this mutation 
has not been reported in any other ethnic groups.  In 1986 Tate et al identified a 
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patient who was homozygous for the -198 (T-C) Aγ-promoter mutation and who 
had an elevated HbF level of 21%.   However, since this time there has been no 
reported data on the frequency of this mutation in the British population.  This 
study identified that 33% of our British cohort with elevated HbF levels have the 
-198 (T-C) Aγ-promoter mutation indicating that this mutation was likely to be a 
common cause of non-deletion HPFH in the British population.  As this mutation 
had not been identified in other ethnic groups it was expected that it has arisen 
independently (therefore not through racial admixture) and was an example of 
the founder effect.   Another interesting finding was that 6 of the 12 patients with 
this mutation came from the north of England with the other 6 being scattered 
across the midlands (Figure 5.3).  In 1989 Higgs et al discovered that several 
individuals with the exclusively British determinant of α0-thalassaemia (--BRIT) 
resided in the north west of England and that the mutation had become 
established through the UK through genetic drift (Higgs et al., 1985, Bhavnani et 
al., 1989).It is likely that the -198 (T-C) Aγ-promoter mutation has arisen in the 
same way. 
Four patients were identified as having the previously described -158 (C-T)
Aγ mutation, one patient being white Italian, one African and two were of white 
British decent.  This mutation had previously been reported to be found in 
Greeks at a range of 2.9-5.1%.  Therefore this study identified a second 
γ-globin gene mutation that was also found in the British population. 
As this mutation had been identified in the Mediterranean it was possible that 
the African and two white British patients have some Mediterranean ancestry. 
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The other 2 previously reported Aγ-mutations (-196 C-T and -195 C-G) were 
identified in single patients with the HbF levels being in the same range as 
previously identified and in the same ethnic groups.  The two Gγ-mutations 
identified (-202 C-G and -200+C) were both found in patients of African decent 
and with HbF levels matching with the reported phenotypes in the literature. 
Figure 5.3 Map of the UK showing where the 12 patients with the British 
-198 Gγ point mutation originate. Adapted from www.map-of-UK.com
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Of the three novel mutations identified, one lies in the Gγ-promoter at position  
-194 C-T and was identified in two unrelated African patients with modest HbF 
levels ranging from 6-6.3%.  This mutation resides in region 1 (Figure 5.1 and 
5.2) of the Gγ-globin gene promoter and mutations close to this mutation such 
as the -196 (C-T) have been shown to affect the binding of the ubiquitous factor 
Sp1 (Gumucio et al., 1991).  One theory on how this mutation increases HbF is 
that it creates a higher affinity or new binding sites for Sp1 and the stage 
selector protein (SSP).  The higher affinity Sp1 binding site is associated with 
an increase in promoter activity and one explanation for the increase in HbF is 
that these new binding sites can overcome the suppression of the γ-globin gene 
promoter in the adult stage (Ronchi et al., 1989).  A second theory is that 
mutations in region 1 alter the DNA conformation of a specific region of the 
promoter (-206 to -217).  This location is thought to be a binding site for a 
repressor complex but this complex gets displaced by the transcription factors 
that bind to the new sequence created by the γ-globin gene promoter mutation 
(Ulrich et al., 1992).  Therefore it is possible that the novel -194 C-T mutation 
has the same mechanism in increasing HbF levels as described above for the  
-196 C-T point mutation. 
 
The second novel mutation was identified in the promoter of the Aγ-globin gene 
at position -130 (C-G).  Three unrelated patients all of Asian Indian ancestry 
had this novel mutation with modest HbF levels ranging from  
3.2-9.7% (Table 5.3).  Between positions -160 and -130 lies the CACCC box 
motif which is highly conserved in all globin gene promoters.  This element has 
been widely studied and shown to be functionally important as it stabilises the 
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interaction between the γ-globin gene promoter and the β-LCR (Li et al., 2001).  
Normally, in the adult, the CACCC box may become inactivated contributing to 
the down-regulation of γ-globin gene expression but mutations in this motif can 
produce an alternative CACCC box that allows the interaction of the γ-promoter 
with the β-LCR, resulting in the phenotype of HPFH (Li et al., 2001).  Therefore 
it is possible that the -130 (C-G) mutation interferes with the CACCC box motif 
via a similar mechanism to cause a HPFH phenotype or as with other γ-globin 
gene promoter mutations it alters a binding site for a particular transcription 
factor. 
 
The third novel mutation was also found in the promoter of the Aγ-globin gene at 
position -117 (G-C) in a Southeast Asian patient with an HbF level of 9.8%.  A  
γ-globin gene promoter point mutation has been reported extensively in the 
literature at this -117 position of the Aγ-globin gene but the nucleotide 
substitution was G-A not G-C.  The -117 (G-A) mutation has been reported in 
Greeks, Italians and Africans before but not in Southeast Asians.  It is likely that 
this nucleotide substitution will have a similar effect as has been shown with the 
reported -117 (G-A) point mutation as the -114 Gγ-globin gene also has been 
found to cause the HPFH phenotype with different nucleotide substitutions 
(Table 5.1).  The -117 G-A mutation affects the distal CCAAT box of the  
Aγ-globin gene and has been the subject of large numbers of studies (Li et al., 
2001).  The mechanism proposed to explain the HPFH phenotype is that the 
mutation increases transcription by increasing promoter strength.  Several 
binding proteins (e.g. CPI and CDP) bind to the CCAAT box while sites for 
GATA-1 lie nearby and another erythroid specific protein NFE-3. The -117 
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mutation increases both CPI and CDP binding together with a decrease in 
GATA-1 and NFE-3 binding (Mantovani et al., 1988, Gumucio et al., 1988). 
This study also showed that the γ-globin gene promoter mutations are inherited 
with both α- and β-thalassaemia.  Of the 131 patients with high HbF levels, 55 
had α-thalassaemia with the majority of these patients being of African 
ancestry.  It was not surprising therefore that the six African patients with a 
γ-globin gene promoter mutation were also identified as having 
co-existing α-thalassaemia trait.  α+-thalassaemia trait is common in Africa with 
one third of the population being a carrier.   One β-thalassaemia patient out of 
the 28 carriers in the cohort was also identified as having a γ-globin gene 
promoter mutation. Mutations were not seen in patients with sickle 
haemoglobin.  However further studies would have to be carried out to 
determine the frequency in this group as only 6 sickle cell trait patients were 
included in this study. 
In summary, the results show that mutations in the promoter regions of the 
γ-globin genes are a significant cause of HPFH in the UK population (21% of 
cases) where deletional HPFH has been excluded. 
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CHAPTER SIX: DNA POLYMORPHISMS ASSOCIATED WITH 
INCREASED HBF LEVELS IN ADULTS 
6.1 Introduction 
 
The work described in this chapter investigated the three major polymorphisms 
identified as being associated with the variation in HbF levels in adults.  These 
are polymorphisms in XmnI-HBG2, HBS1L-MYB intergenic region on 
chromosome 6q23 and in the BCL11A gene on chromosome 2p16.  These 
three loci have been shown previously to account for 20-50% of the variation in 
HbF levels in patients (Thein et al., 2009). Several SNPs in the BCL11A gene 
and HBS1L-MYB intergenic region have previously been identified as being 
linked to increases in HbF.  Two have been shown to have a strong association 
in healthy Europeans, African sickle cell patients and β-thalassaemia patients; 
rs11886868 in exon 2 of BCL11A gene and rs9399137 in the HBS1L-MYB 
intergenic region (Thein et al., 2009). 
6.2 Study subjects 
 
One hundred and thirty one patient samples collected from the study described 
in chapter 5 had increases in HbF levels (ranging from 1.5-25%) but did not 
have a large deletion mutation.  Patient ages in this group ranged from 1-81 
years and they were from all the major UK population ethnic groups with 36 
being African, 36 white British, 28 Indian, 14 South-East Asian, 7 white 
European, 7 Mediterranean and 3 from the Middle East.  Haemoglobinopathy 
phenotypes consisted of 55 samples with α-thalassaemia carriers, 6 carriers for 
sickle cell trait, 28 β-thalassaemia carriers, 1 case with HbE disease and 41 
samples with no evidence of any other haemoglobinopathy apart from the 
elevated HbF level.   
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6.3 Laboratory procedures 
 
PCR amplification and Sanger sequence analysis of the Gγ-promoter region 
using published primers (Huang et al., 2000) was carried out to identify the SNP 
rs7482144 also known as the XmnI-HBG2 polymorphism. PCR products were 
sequenced using the ABI-PRISM 3100 automated DNA sequencer (Applied 
Biosystems). Sequencing of this region also detected whether the rare 
polymorphism G→A at -161 of the Gγ-gene was present in any of the samples 
which is also known to increase HbF levels.   Pyrosequencing assays were 
designed for both rs11886868 and rs9399137 SNPs and all 131 samples were 
analysed by this method (section 2.8).  Statistical analysis was undertaken 
using Analyse-it Microsoft Excel software version 2.20 (Analyse-it Software 
Ltd, Leeds, UK) and significant associations between the different 
polymorphisms and HbF was tested using a one-way ANOVA test.  Groups 
showing an overall significance by the ANOVA test were then analysed using 
the Dunnett’s test (Appendix 4). 
6.4 Results 
 
All 131 selected samples were analysed by Sanger sequencing and 
pyrosequencing for the three major SNPs (rs7482144 XmnI-HBG2, rs9399137 
HBS1L-MYB, and rs11886868 BCL11A) associated with slight increases in HbF 
levels in adults.  The samples were divided into the following genotype groups: 
β-thalassaemia trait (29 samples), α-thalassaemia trait (55 samples), sickle cell 
trait (6 samples) and no significant haemoglobinopathy but increased HbF (41 
samples).  Statistical analysis of HbF levels was carried out with the above 
groups for each SNP genotype (wild type, heterozygous and homozygous).   
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6.4.1 rs7482144 XmnI-HBG2  
The whisker box plots in figure 6.1 show that the rs7482144 polymorphism is 
associated with increased HbF levels in both the β- and α-thalassaemia 
genotype groups with homozygotes having a higher HbF percentage.  This 
polymorphism was not demonstrated in the sickle cell trait group so statistical 
analysis could not be performed.  Unlike the thalassaemia genotype groups, the 
isolated high HbF group did not see an associated increased HbF with either 
heterozygosity or homozygosity for the rs7482144 polymorphism.  Table 6.1 
shows the mean value of HbF for each group with the different SNP genotypes.  
Statistical differences between the group means was given by the ANOVA p 
value.  The β-thalassaemia group showed the most significant association with 
the rs7482144 polymorphism and HbF levels, with a p value of 0.0169.  The 
Dunnett’s test results showed borderline significance for both the heterozygous 
and homozygous groups and given the small sample numbers it is reasonable 
to expect that more data could yield more significant results. The other groups 
did not show a significant increase in HbF levels with this polymorphism and 
when the total HbF levels for each group were analysed for each SNP genotype 
the p value was 0.059.    
6.4.2 rs9399137 HBS1L-MYB   
The whisker box plots in figure 6.2 show that there is an association with higher 
HbF levels and the rs9399137 polymorphism in the β-thalassaemia group, with 
homozygotes having the greatest HbF level.  Table 6.2 shows that the statistical 
significance for this difference in HbF levels was not shown with a p value of 
0.3067.  This was probably due to the small sample size in the homozygous 
group (n=4).  The isolated high F group saw a significant difference in the 
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means (p = 0.0098) but with only heterozygotes having higher HbF levels.  The 
homozygote group had a lower mean HbF level than the wild type group.  The 
Dunnett’s test results showed that there was a statistical significance in HbF 
levels between the heterozygous and wild type group (p = 0.0201).  The  
α-thalassaemia and sickle cell trait groups did not show an association with 
higher HbF levels and the rs9399137 polymorphism. 
6.4.3 rs11886868 BCL11A  
The whisker box plots in figure 6.3 and the statistical analysis in table 6.3 show 
that the β-thalassaemia group is the only group to have a significant difference 
between the three SNP genotypes (p=0.0364),  with heterozygotes having 
higher HbF levels but homozygotes have less HbF than the wild type.  The 
Dunnett’s test results show that the difference was between the heterozygous 
and wild type group, however the difference was not significant (p=0.111).  
Unlike the other two SNPs (rs7482144 and rs9399137) the C allele or minor 
allele for the rs11886868 polymorphism seems to be more prevalent than the T 
allele or major allele.  Heterozygotes (TC) and homozygotes (CC) were more 
frequent through all genotype groups than the wild type allele (TT).  
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Figure 6.1 Association between rs7482144 genotypes and the proportion 
of HbF.  a) β-thalassaemia trait  b) α-thalassaemia trait c) sickle cell trait and  
d) isolated high HbF subjects.  Boxes have lines at the lower quartile, median 
and upper quartile.  The plot whiskers extend up and down from the median 
distance 1.5 times the interquartile range of the boxes.   
Key:         mean,     +    outliers   
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Table 6.1 Mean value of HbF % associated with the rs7482144 (XmnI) polymorphism for each SNP genotype.  Values in 
red indicate results showing a significant statistical difference. 
 
rs7482144 (XmnI polymorphism) 
 Mean value of HbF % for genotype ANOVA results Dunnett’s results 
 CC (n) 
(wild type) 
CT (n) 
(heterozygous) 
TT (n) 
(homozygous) 
p value p adjusted 
(0.05 significance) 
β-thalassaemia trait 8.6 (14) 15.3 (9) 17.1 (6) 0.0169 0.0501 – CC vs CT 
  0.0582 – CC vs TT 
α-thalassaemia trait 8.2 (32) 9.9 (19) 11.7 (4) 0.2924 - 
Sickle cell trait 12.9 (6) - - - - 
High HbF 8.1 (24) 7.7 (12) 6.0 (5) 0.5346 - 
Total 8.6 (76) 10.5 (40) 12.0 (15) 0.0591 - 
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Figure 6.2 Association between rs9399137 genotypes and the proportion 
of HbF.  a) β-thalassaemia trait  b) α-thalassaemia trait c) sickle cell trait and  
d) isolated high HbF subjects. Boxes have lines at the lower quartile, median 
and upper quartile.  The plot whiskers extend up and down from the median 
distance 1.5 times the interquartile range of the boxes.  
Key:            mean,   +  outliers  
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Table 6.2 Mean value of HbF % associated with the rs9399137 (intergenic region of HBS1L-MYB) polymorphism with 
each SNP genotype.  Values in red indicate results showing a significant statistical difference. 
 
rs9399137 (intergenic region of HBS1L-MYB) 
 Mean value of HbF % for genotype ANOVA  Dunnett’s Test 
 TT (n) 
(wild type) 
TC (n) 
(heterozygous) 
CC (n) 
(homozygous) 
p value p adjusted 
(0.05 significance) 
β-thalassaemia trait 11.2 (16) 13.2 (9) 17.3 (4) 0.3067 - 
α-thalassaemia trait 10.1 (41) 7.6 (12) 10.5 (2) 0.4772 - 
Sickle cell trait 11.4 (5) 20 (1) - 0.4120 - 
High HbF 7.2 (25) 10.9 (9) 5.9 (7) 0.0098 0.0201 – TT vs TC 
Total 9.6 (87) 10.6 (31) 10.1 (13) 0.7371 - 
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Figure 6.3 Association between rs11886868 genotypes and the proportion 
of HbF.  a) β-thalassaemia trait  b) α-thalassaemia trait c) sickle cell trait and  
d) isolated high HbF subjects. Boxes have lines at the lower quartile, median 
and upper quartile.  The plot whiskers extend up and down from the median 
distance 1.5 times the interquartile range of the boxes.  
Key:            mean,  +   outliers  
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Table 6.3 Mean value of HbF % associated with the rs11886868 (on the BCL11A gene) polymorphism with each SNP 
genotype. Values in red indicate results showing a significant statistical difference. 
 
rs11886868 (on the BCL11A gene) 
 Mean value of HbF % for genotype ANOVA  Dunnett’s Test 
 TT (n) 
(wild type) 
TC (n) 
(heterozygous) 
CC (n) 
(homozygous) 
p value p adjusted 
(0.05 significance) 
β-thalassaemia trait 11.1 (9) 16.8 (11) 9.2 (9) 0.0364 0.111 – TT vs TC 
α-thalassaemia trait 9.4 (10) 9.9 (26) 9 (19) 0.8974 - 
Sickle cell trait 22.6 (2) 7.3 (3) 1 (1) - - 
High HbF 8.2 (9) 7.9 (15) 7.4 (17) 0.8590 - 
Total 10.4 (30) 10.6 (55) 8.5 (46) 0.1900 - 
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6.5 Discussion 
 
Three major loci (XmnI-HBG2, HBS1L-MYB and BCL11A) have been identified 
and shown to effect HbF expression in adults.  The results of this study were 
aimed at identifying whether the three polymorphisms associated with the 
above loci were found to have increased HbF levels in the 131 study samples. 
 
Of the 131 samples, the rs7482144 (XmnI-HBG2) polymorphism was found in 
42% with 40 patients being heterozygous and 15 patients homozygous.  
Homozygotes were seen in all groups apart from the subjects with sickle cell 
trait where the polymorphism was not present in any of the 6 samples.  The 
percentage of heterozygotes and homozygotes across all genotype groups was 
comparable.  In the β-thalassaemia trait cohort a significant statistical 
association (Table 6.1) was identified between the heterozygous and 
homozygous groups compared to the wild type.  Previous studies have shown 
that the rs7482144 (XmnI-HBG2) polymorphism plays an important role in 
ameliorating the clinical severity in sickle cell anaemia and  
β-thalassaemia major patients by increasing HbF levels (Gilman and Huisman, 
1985, Labie et al., 1985).  Several studies have concluded that this 
polymorphism only exerts its effects of increasing HbF under conditions of 
erythropoietic stress and that no conclusive evidence was demonstrated for its 
influence on HbF levels in heterozygous β-thalassaemia and in normal 
individuals (Thein et al., 1987, Efremov et al., 1987).  However this study has 
shown HbF levels to be higher in β-thalassaemia trait individuals with this 
polymorphism. The results also showed a modest effect in HbF levels in  
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α-thalassaemia cohort although no significant statistical association could be 
demonstrated.  In order to fully elucidate this finding, larger sample groups 
would need to be collected and analysed.  In the group with only a high HbF 
phenotype, associations between the rs7482144 polymorphism and increased 
HbF expression was not demonstrated and homozygotes had lower HbF levels 
than individuals without the polymorphism (-/-).  Results did confirm that this is a 
common polymorphism found extensively in different population groups.  
However only modest increases in HbF were seen in the thalassaemia trait 
cohorts and this polymorphism was unable to explain the variance in HbF levels 
seen in the sickle cell trait and high HbF only groups.  Only 6 samples had 
sickle cell trait and it might be that none of these patients had the Senegal or 
Arab-Indian sickle cell haplotype that are known to contain the XmnI-HBG2 
variant.  
 
The rs9399137 polymorphism found in the intergenic region between HBS1L 
and MYB have been previously shown to be associated with HbF expression in 
Chinese, Europeans and Africans (Farrell et al., 2011, Menzel et al., 2007, 
Lettre et al., 2008, Creary et al., 2009).  Several other SNPs in this region have 
also been associated with HbF expression, however the rs9399137 
polymorphism was prevalent in a wider spread of populations and the 131 
samples varied greatly in ethnicity so this polymorphism became the most likely 
candidate for this study.  Results from figure 6.2 showed that homozygotes 
were seen in all groups apart from the subjects with sickle cell trait where the 
polymorphism was only found once in the heterozygous form.  The percentage 
of heterozygotes and homozygotes across all genotype groups was 
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comparable.  In the β-thalassaemia trait group the polymorphism was 
associated with increased HbF levels with homozygotes having the highest 
levels although no statistical significance could be shown.  In the  
α-thalassaemia group heterozygotes had lower HbF levels than the wild type. In 
the high HbF group heterozygotes had higher HbF levels than both the 
homozygotes and the wild type group.  Statistical association was shown 
between the heterozygous group and samples without the polymorphism but 
further larger studies with more homozygotes would need to be carried out to 
confirm whether this finding is significant.   
 
The polymorphism rs11886868 in intron 2 of the BCL11A gene has been shown 
to be in association with HbF expression in Europeans, Africans and Sardinians 
(Uda et al., 2008).   Results described in this chapter showed that homozygotes 
and heterozygotes were found in each genotype group however the frequencies 
were not as expected.  Of  the 131 samples analysed, 71% had the rs11886868 
polymorphism with 35% being homozygous.  Uda et al (2008) found the same 
finding when they directly genotyped 1,412 samples for this SNP.  They found 
in the 134 HPFH samples genotyped, a 2 fold enrichment in the C allele in 
heterozygotes and a 5 fold enrichment in the C/C genotype when compared to 
individuals with normal HbF levels.  No significant association was seen in any 
of the groups with this polymorphism and increases in HbF expression.  In all 
groups homozygotes had lower HbF levels than individuals without the 
polymorphism.   
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Therefore the strongest association with the three polymorphisms and HbF 
expression was seen in β-thalassaemia trait subjects with the rs7482144  
XmnI-HBG2 polymorphism.  Several studies involving different genotype 
groups, for example sickle cell anaemia and β-thalassaemia intermedia patients 
have been undertaken studying the polymorphisms in these three loci.  One 
such study in Mediterraneans with β-thalassaemia intermedia also failed to 
show statistical correlations with HbF with SNPs in BCL11A and HBS1L-MYB 
(Nguyen et al., 2010).  The results of their study suggested that BCL11A and 
HBS1L-MYB have a minor effect on HbF levels compared to the  
XmnI-HBG2 polymorphism in β-thalassaemia intermedia patients. 
 
Further studies would need to be carried out with larger sample sizes in order to 
accurately determine whether BCL11A and HBS1L-MYB are involved in 
increased HbF expression in our individuals with an HPFH phenotype.  The 
interest in these loci has led researchers to primarily study disease phenotypes 
rather than milder conditions such as HPFH.  Two large studies, one using 
meta-analysis data from 2,040 sickle cell anaemia patients and the other using 
two large sickle cell disease cohorts from America have both shown statistical 
association with HbF levels and the three major loci in African Americans with 
sickle cell disease (Lettre et al., 2008, Bae et al., 2012).  It appears from this 
and other studies that associations between the loci and HbF can be revealed 
by large GWAS studies but often the exact polymorphisms involved will vary 
between cohorts.  Recent studies now use these genetic modifiers to predict the 
type of thalassaemia (Galanello et al., 2009, Badens et al., 2011).  Clinicians 
are now looking at scoring β-thalassaemia major and intermedia dependent on 
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whether ameliorating alleles such as the XmnI-HBG2, BCL11A and HBS1L-
MYB polymorphisms are present in order to act as an early predictor of the type 
of thalassaemia the patient will develop.  When further validated, this prediction 
tool of severity may have implications for genetic counselling and also 
therapeutic decisions such as stem cell transplantation (Badens et al., 2011). 
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CHAPTER SEVEN:  KLF1 GENE ASSOCIATED WITH INCREASED 
HBF LEVELS IN ADULTS 
7.1 Introduction 
 
The work described in chapter 6 introduced single nucleotide polymorphisms 
(SNPs) as being associated with increased HbF expression in adults.  The three 
major loci (XmnI-HBG2 on chromosome 11p15.5, HBS1L-MYB inter-genic 
region on chromosome 6q23 and BCL11A on chromosome 2p16.1) being 
reported in the literature as accounting for 50% of the variance seen in HbF 
levels thus indicating that additional loci must be involved (Thein et al., 2009).  
 
Recent studies have shown that the erythroid transcription factor KLF1 could 
play a critical role in regulating the switch between fetal and adult haemoglobin 
gene expression.  In a Maltese study, 10 out of 27 family members exhibited 
HPFH due to a single point mutation in the KLF1 gene.  This mutation was 
found to remove the DNA binding domain which resulted in haploinsufficiency of 
the KLF1 gene (Borg et al., 2010).  Carriers of the mutation (p.K288X) had high 
HbF levels although variability was shown throughout the family with a range of 
3.3%-19.5%.  In a similar study from Sardinia, three heterozygous carriers of 
KLF1 mutations (p.S270X or p.K332Q) had HbF levels ranging from  
0.9%-1.2%.  However two family members were compound heterozygous for 
both of the KLF1 mutations and had very high HbF levels of 22.1% and 30.9% 
(Satta et al., 2011).  The individuals with compound heterozygosity for the KLF1 
mutations also had very high levels of zinc protoporphyrin in their circulation 
which they suggest confirms the relevance of KLF1 in the control of the 
erythropoietic pathway leading to haem biosynthesis (Satta et al., 2011).  They 
conclude that their results do not confirm that the HPFH phenotype is caused by 
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mutations giving rise to KLF1 haploinsufficiency.  Results of only these two 
studies link the HPFH phenotype to mutations in the KLF1 gene and therefore 
further studies need to be carried out with a large cohort of patients with the 
HPFH phenotype in order to confirm these findings. 
 
The aim of the work described in this chapter is to investigate whether KLF1 
mutations are associated with the elevated HbF levels observed in the 131 
samples studied in the work in chapters 5 and 6. 
7.2 Study subjects 
7.2.1 Elevated HbF level and matched control group 
131 blood samples analysed in the work described in chapter 5 and six (subject 
age 1-81 years) with an elevated HbF level (range 1.5 – 25%) were tested for 
KLF1 mutations and compared against a matched control group of 121 samples 
that had also been referred for haemoglobinopathy investigation but had normal 
HbF levels (<1%). Haemoglobinopathy phenotypes in the study group with an 
elevated HbF level consisted of 55 samples with co-existing α-thalassaemia 
trait, 6 carriers for sickle cell trait, 28 β-thalassaemia carriers, 1 case of HbE 
disease and 41 samples with no evidence of any other haemoglobinopathy 
apart from the elevated HbF level. Haemoglobinopathy phenotypes in the 
control group with normal HbF levels consisted of 41 α-thalassaemia carriers, 9 
sickle cell carriers, 29 carriers for a haemoglobin variant, 20 β-thalassaemia 
carriers and 22 samples with no evidence of any haemoglobinopathy.   
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7.2.2 Sickle cell disease 
A cohort of 55 patient samples with sickle cell disease (all homozygous for the 
sickle cell mutation) were studied to investigate whether KLF1 mutations could 
be involved in HbF level variation in this group. Twenty patients had HbF levels 
below 10% and 35 had HbF levels >10%.   
7.3 Laboratory procedures 
 
Peripheral blood erythrocyte indices were determined using an automated cell 
counter (Sysmex XE 2100™). Haemoglobin identification and quantifications 
were carried out using a high performance liquid chromatography system 
(VARIANT™, Bio-Rad Laboratories, USA) and isoelectric focusing gel 
electrophoresis (RESOLVE®, PerkinElmer, USA).  DNA was extracted from 
peripheral blood leukocytes by conventional phenol chloroform extraction or on 
an automated DNA extractor (Chemagen, Baesweiler, Germany).  Genomic 
DNA samples underwent PCR to amplify the human KLF1 gene (NT_086897.1: 
4090501-4093981) using previously published primers (Singleton et al., 2008).  
PCR products were sequenced using the ABI-PRISM 3100 automated DNA 
sequencer (Applied Biosystems).  Samples containing a mutation in the KLF1 
gene had the promoter regions of both the Aγ- and Gγ-genes amplified using 
previously published primers (Huang et al., 2000) and the PCR products 
sequenced as above. The common 3.7 and 4.2 Kb single α+ thalassaemia 
globin gene deletion mutations were identified by Gap-PCR (Liu et al., 2000) 
and β-globin gene cluster deletions excluded by MLPA in all samples.  
PolyPhen-2 and SIFT were used to predict the effects of any mutations on 
protein structure and function (Ramensky et al., 2002, Ng and Henikoff, 2003). 
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7.4 Results  
7.4.1 Elevated HbF subjects 
KLF1 mutations which are predicted to effect gene function (PolyPhen-2 and 
SIFT) were identified in 11 out of 131 (8.4%) subjects with increased HbF levels 
(Table 7.1). Ten had a single heterozygous mutation and one individual was 
compound heterozygous for two mutations. In total, eleven different KLF1 
mutations were identified (Table 7.1). Deletion mutation in the β-globin gene 
cluster and mutations in the γ-globin gene promoter sequences were excluded 
as a cause of the increased HbF level in all 11 subjects.  Functionally effective 
KLF1 mutations were not identified in the matched cohort of 121 samples with 
normal HbF levels. Nine of the 11 mutations identified were previously  
unreported (Figure 7.1). 
 
Eight were mis-sense mutations, one in exon 1 (L51R) and seven in the zinc 
finger domains (R301C, R301H, W313C, R328H, R328L, T334K and T334R) 
which would be expected to disrupt DNA binding (Figure 7.1). Two were frame 
shift mutations in exon 2, an 11bp deletion (K54PfsX9) producing a new stop 
codon 8 nucleotides downstream and a 7bp insertion (G176AfsX179) producing 
a stop codon 178 nucleotides downstream.  The latter mutation was identified in 
two patients, singly and compound heterozygous with the L51R mis-sense 
mutation. The final mutation identified in this group was a 1bp nucleotide 
substitution (c.913+1G>A) at the 3 end of exon 2 which would be predicted to 
disrupt splicing. 
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7.4.2 Sickle cell anaemia subjects 
Out of the 55 sickle cell disease patients studied one further unreported 
functionally effective KLF1 mutation was identified (c.914-4_914-1 del CTAG) in 
a sickle cell disease patient with an elevated HbF level of 20.3%. Mutations in 
the γ-globin gene promoter sequences and the XmnI-HBG2 polymorphism were 
excluded as the cause of the increased HbF in this patient. This KLF1 mutation 
is a 4bp deletion and is located close to the start of the second zinc finger 
domain in exon 3 and is likely to result in aberrant splicing.  
 
7.4.3 Tolerated SNPs 
Two patients in the HPFH cohort and one patient in the sickle cell disease 
cohort were found to have SNPs in the coding regions of the KLF1 gene  
(G5K, G160K, and G250A).  PolyPhen-2 and SIFT analyses suggest that they 
are neutral substitutions which are tolerated and therefore not pathogenic.  In 
support of this G5K and G160K were also found in 2 samples in the normal HbF 
level control group.  
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Table 7.1 Haematological parameters and genotypes in subjects with mutations detected in the KLF1 gene. 
Cases 1-11 are subjects from the elevated HbF cohort and case 12 was from the sickle cell anaemia cohort. Only 2 of the 13 
mutations detected had been reported previously (marked with an *). The presence of a wild type allele in the KLF1 genotype 
is indicated by [=]. 
 
Case Ethnic group Hb 
(g/dl) 
RBC 
(10
6
/mm
3
) 
MCV  
(fl) 
MCH 
(pg) 
HbA2 
(%) 
HbF 
(%) 
β-globin 
phenotype/ 
genotype 
α globin 
genotype 
KLF1 genotype KLF1 protein 
change 
1 White British 14.3 6.18 69.4 23.1 3.3 3.0 HPFH aa/aa c.[159_169 del GAAGTCTGAGG]+ [=] K54PfsX9 
2 Pakistani 12.7 4.72 79.4 26.9 2.4 14.6 HPFH aa/aa c.[901C>T]+ [=] R301C 
3 Black African 10.6 5.43 61 19 2.4 6.6 HPFH -a3.7/aa c.[902G>A]+ [=] R301H 
4 Black African 12.1 4.74 81.0 25.5 2.8 7.3 HPFH -a3.7/aa c. [939G>T]+ [=] W313C 
5 Thai 12.6 5.51 75.2 22.8 2.4 5.9 HPFH -a3.7/aa c.[983G>A]+[=] R328H* 
6 Slovakian 13.0 4.29 91.7 30.3 3.2 8.7 HPFH aa/aa c.[983G>T]+[=] R328L* 
7 Black African 10.7 4.24 80.4 25.2 3.3 6.8 HPFH -a3.7/aa c. [1001C>A]+ [=] T334K 
8 Black African 8.9 - 73.0 23.0 3.8 6.7 HPFH -a3.7/aa c.[913+1G>A]+[=] - 
9 Vietnamese 13.7 5.38 77.6 25.4 2.8 9.5 HPFH -a3.7/aa c. [526_527Ins CGGCGCC]+ 
[152T>G] 
G176AfsX179 
L51R 
10 Korean 13.8 5.34 78 24.5 4.0 1.7 HPFH -a3.7/aa c.[526_527Ins CGGCGCC ]+[=] G176AfsX179 
11 Thai 11.8 5.80 62.1 20.4 - 11.0 EE aa/aa c.[1001C>G]+[=] T334R 
12 Nigerian 12.7 6.0 67.0 21.0 - 20.3 SS -a3.7/ -a3.7 c.[914-4_914-1 del CTAG]+ [=] - 
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Figure 7.1 Diagram showing the position of the mutations identified in the KLF1 gene. 
a) Schematic representation of the KLF1 gene with numbered circles corresponding to the case number in table 7.1 
(untranslated regions= black, coding regions= green, zinc finger domains= orange and introns= blue). b) Amino acid sequence 
of the three zinc fingers (Zn) in KLF1 (NCBI’s Homologene) in Homosapiens (Sayers et al., 2011).  Arrows show the positions 
of mis-sense mutations within the zinc finger domains. 
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7.5 Discussion 
 
Recent reports have identified mutations in the KLF1 gene which are associated 
with a variety of phenotypes in humans. These include the Lutheran blood 
group (Singleton et al., 2008), congenital dyserythropoietic anaemia (Arnaud et 
al., 2010), hereditary spherocytosis (Heruth et al., 2010), high levels of zinc 
protoporphyrin (Satta et al., 2011), HPFH in two families (Borg et al., 2010,  
Satta et al., 2011) and more recently borderline increases in HbA2 levels 
(Perseu et al., 2011). The UK population is ethnically diverse and our laboratory 
receives requests for haemoglobinopathy investigations for individuals who 
originate from all the malarial regions of the world. This study identified KLF1 
mutations in a significant proportion of these referrals with increased HbF 
levels. KLF1 mutations predicted to have an effect were found in 11 out of 131 
referrals with increased HbF levels but KLF1 mutations were not identified in 
121 haemoglobinopathy referrals with normal HbF levels. This strongly 
suggests that the KLF1 mutations are associated with the observed increased 
HbF levels in these patients.  All the mutations identified were heterozygous 
indicating that a single altered KLF1 allele can elevate HbF.  
 
The increased HbF levels observed in our KLF1 mutation positive subjects 
ranged from 1.7% to 14.4%. Well established factors known to cause HPFH 
(deletions in the β-globin cluster or mutations in the γ-globin gene promoters) 
were excluded in all cases. An interesting finding was that 4 out of our 11 cases 
also had borderline increased HbA2 levels (3.3 – 4.0%). All of these samples 
had normal β-globin gene sequences, most likely excluding β-thalassaemia as 
the cause of the elevated HbA2 level. This finding concurs with a recent report 
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that shows that mutations in the KLF1 gene are associated with elevated  
δ-globin gene expression which gives rise to borderline increased HbA2 levels 
(Perseu et al., 2011). Significantly, a proportion of the cohort in that study had 
increased HbF levels as well as increased HbA2 levels. The proposed 
mechanism for KLF1 mutations increasing HbF levels is reduced activation of 
BCL11A by KLF1 which in turn results in inefficient repression of γ-globin 
synthesis. The δ-globin gene has no KLF1 binding sites therefore the increase 
in δ-globin gene expression is most likely to be due to indirect effects. Probably 
impaired looping of the β-LCR with the β-globin gene that results in increased 
expression of the competing δ-globin gene (Perseu et al., 2011). Whether a 
KLF1 mutation produces a HPFH phenotype or an increased HbA2 level (or a 
combination of both phenotypes) will possibly depend on the balance between 
these two effects, which in turn will most likely depend on factors specific to a 
particular KLF1 mutation and other interacting factors. 
 
The majority of our subjects with a KLF1 mutation had hypochromic red cells 
(MCH <27pg), however this could mostly be explained by the co-existing 
presence of the extremely common 3.7kb single α-globin gene deletion (Table 
7.1). Exceptions to this were cases 1, 3 and 5. Cases 3 and 5 had an MCH 
lower than normally observed with a single α-globin gene deletion. Case 1 was 
of white British descent and had markedly thalassaemic indices but had tested 
negative for all types of α- and β-thalassaemia mutations. The KLF1 mutation 
(K54PfsX9) identified in this individual would be predicted to be more severe 
than the other mutations in that it results in the loss of all three zinc finger 
domains and most of exon 2. It is possible that this could result in severe 
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impairment of the β-globin gene’s association with the β-LCR resulting in a 
marked reduction in β-globin expression producing a β-thalassaemia type 
phenotype. Only one mutation was found more than once (G176AfsX179), in 
case 10 it was associated with a HbF level of 1.7% whilst in case 9  where it 
was found in combination with the L51R mis-sense mutation the HbF level was 
9.5% suggesting that the effects of these mutations may be additive. 
 
A previously unreported KLF1 mutation (c.914-4_914-1 del CTAG) was 
identified in one of the 55 patients investigated who were homozygous for the 
sickle cell mutation, which suggests KLF1 mutations are not particularly 
common in sickle disease. However interestingly, the Nigerian sickle cell 
disease patient identified with this mutation was completely asymptomatic and 
maintained a haemoglobin level of 12.7g/dl with a HbF level of 20.3%.  It is 
possible the KLF1 mutation is ameliorating the phenotype by increasing the 
HbF level via reduced γ-globin gene suppression.  However the patient also has 
homozygous α+-thalassaemia, α-thalassaemia is known to have a complex 
interaction with sickle cell disease but does increase the overall haemoglobin 
level slightly (Ballas, 2001). It is therefore likely that complex mechanisms 
including multiple gene interactions are involved in the maintenance of this 
patient’s robust haemoglobin level and asymptomatic phenotype.  
 
In summary KLF1 mutations were found in 8.4% of our elevated HbF cohort, 
predominantly in individuals of African, Indian and Southeast Asian descent.  
This indicates KLF1 mutations could be a widespread cause of HPFH in 
malarial regions where haemoglobinopathies are common, possibly making a 
 
 128 
significant contribution to HbF variance in these populations. Also, the 
identification of KLF1 mutations in individuals with a thalassaemia carrier 
phenotype and a particularly mild form of sickle cell disease indicates the 
effects of these mutations are likely to be heterogeneous and complex.  
7.6 Case 12 – KLF1 mutation in a sickle cell disease patient 
 
A particularly noteworthy case was the occurrence of a previously unreported 
KLF1 mutation (c.914-4_914-1 del CTAG) in a 36 year old Nigerian male with a 
sickle cell disease genotype. Further investigations highlighted that this man 
had no family history of sickle cell disease and that his relatives were all 
clinically well and based in Nigeria.   He had no clinical history of sickling and 
had never had a blood transfusion.  Analysis of his HPLC and IEF results 
showed a complete absence of HbA (Figure 7.2).  MLPA analysis and  
β-globin gene sequencing had confirmed the genotype of HbSS and Gap-PCR 
homozygosity for the 3.7 kb single α+-globin gene deletion mutation.   
Co-existing α-thalassaemia in sickle cell disease has been shown to modify the 
phenotype (Steinberg and Sebastiani, 2012) and although this offers some 
explanation as to why his Hb level was normal it does not explain why he had 
an asymptomatic phenotype. If the KLF1 mutation is responsible for the 
dramatic phenotype amelioration observed in this case, it would be highly 
significant as it would provide in-vivo evidence that controlled reduction of KLF1 
expression could be an effective treatment for sickle cell disease. 
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Figure 7.2 HPLC and IEF results for case 12.  a) HPLC chromatogram 
showing the major haemoglobin peaks S (70.8%) and F (20.3%).  The small 
peak at the retention time consistent with HbA (3.7%) was a product of 
degradation and not HbA.  This was confirmed by the IEF result below   
b) IEF gel showing clearly that case 12 (lanes 2 and 4) had no visible HbA and 
only major bands in the positions of HbS, HbF and HbA2. 
 
 
KLF1 is considered an important player in the regulation of haemoglobin 
switching but many other genes are now also thought to play a part (e.g. SOX6, 
MYB, GATA-1, NuRD, BCL11A and HDAC1/2) (Sankaran, 2011). Moreover, 
there are likely to be other as yet unidentified genes involved. Therefore in order 
to establish whether mutations in other genes are contributing to this patient’s 
a) 
b) Lane 1 – HbSS control 
Lane 2 – case 12 
Lane 3 – HbA control 
Lane 4 – case 12 
Lane 5 – HbAFDC control 
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mild phenotype, analysis of his DNA by next generation sequencing techniques 
that employ whole exome sequencing would be required 
 
The referring clinician was contacted and the gentleman who resides in 
Aberdeen, Scotland consented to donating more blood and hair follicles.  All the 
above analysis was repeated on DNA extracted from both samples (section 
2.3.3) and confirmed the results of the original findings with the presence of the 
(c.914-4_914-1 del CTAG) KLF1 mutation.  DNA was also analysed on a whole 
genome SNP array (illumina iScan) by Dr Ruth Clifford. Analysis revealed that 
part of chromosome 11p showed an area with copy neutral loss of 
heterozygosity (cnLOH) or uniparental disomy (UPD) (Figure 7.3).  UPD occurs 
when a person receives two copies of a chromosome, or part of a chromosome, 
from one parent and no copies from the other parent (an error in meiosis).  It 
can be the result of 1) heterodisomy, in which a pair of non-identical 
chromosomes are inherited from one parent (meiosis I error) essentially benign 
or 2) isodisomy, in which a single chromosome from one parent is duplicated 
(meiosis II error).  It can lead to the duplication of harmful recessive genes, 
therefore being potentially dangerous (Figure 7.4). Cases of UPD have been 
reported to be found in sickle cell disease and β-thalassaemia major (Swensen 
et al., 2010, Harteveld et al., 2013). 
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B allele frequency plot 
Log2 Ratio Plot
Chromosome 11p15
 
Lack of probes sitting on the 0.5 line of B allele frequency plot = no AB phenotype 
(either all AA (0 line) or BB (1.0 line)). As there is no deletion in the Log2 Ratio 
plot above then this means there is cnLOH or UPD
Log2 Ratio Plot
B allele frequency plot 
β-globin gene
No deletion in Log2 Ratio plot
 
 
 
 
 
Figure 7.3 SNP array B allele frequency plots for case 12.   
a) the blue oval highlights a large area on the plot showing a complete lack of 
probes sitting on the 0.5 B allele frequency plot b) Expanding the plot from  
a) above shows that there is no deletion and that the cnLOH region affects the 
whole of the β-globin gene cluster at a size of approximately 0.84Mb at location 
p15.4. 
a) 
b) 
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Normal Heterodisomy Isodisomy
 
Figure 7.4 Diagram showing the inheritance of uniparental disomy. 
 
These results explain why there was no family history of sickle cell disease as 
he had inherited two copies of the sickle gene from one parent (isodisomy).  
However this does not offer any explanation as to why he was asymptomatic.  
 
In order to identify any other mutations in other genes associated with 
haemoglobin switching, DNA was analysed by Dr Lorna Gregory at The 
Wellcome Trust Centre for Human Genetics, Oxford by whole exome 
sequencing using a HiSeq® 2500 sequencing system (Illumina, Inc., San Diego, 
California, USA).  The analysis showed a run yield of 37Gb of mapped data with 
85.52% of reads being mapped to exonic regions and 98% coverage of the 
whole exome. After filtering and annotation using ANNOVAR, 348 predicted 
variants were left (specifically, insertions or deletions predicted to alter the 
reading frame, non-synonymous amino acid changes or loss or gain of a stop 
codon).   
 
 
1
3
3
 
 
 
 
Table 7.2 HiSeq 2500 whole exome sequence analysis results for case 12. 
 
 
 
 
    
No 
     
Function 
Gene Amino Acid Change dbSNP135 SIFT SIFT 
Pred 
Poly 
Phen2 
Poly 
Phen2 
Pred 
Chr Start End Reference Observed 
1 exonic CCND3 NM_001136125:c.T559G:p.S187A rs1051130 0.5 T 0 B chr6 41903782 41903782 A C 
2 exonic CDAN1 NM_138477:c.C2735T:p.A912V rs143086237 0.61 T 0.267 P chr15 43020919 43020919 G A 
3 exonic CDAN1 NM_138477:c.C2671T:p.R891C rs8023524 0.96 D 0.914 P chr15 43020983 43020983 G A 
4 exonic CDAN1 NM_138477:c.G1969A:p.G657S rs61747153 0.25 T 0.003 B chr15 43023161 43023161 C T 
5 exonic CDAN1 NM_138477:c.A1787G:p.Q596R rs12917189 0.55 T 0 B chr15 43023482 43023482 T C 
6 exonic HBB NM_000518:c.A20T:p.E7V rs77121243 0.97 D 0.001 P chr11 5248232 5248232 T A 
7 exonic FBXO7 NM_001033024:c.T35G:p.L12R rs8137714 0 T 0 B chr22 32871383 32871383 T G 
8 splicing KLF1 - - - - - - chr19 12995875 12995878 CTAG - 
9 exonic NT5C3B NM_052935:c.C638G:p.S213C rs1046404 0.98 D 0.725 P chr17 39983808 39983808 G C 
10 exonic NT5C3B NM_052935:c.C626T:p.A209V rs1046403 0 T 0 B chr17 39983820 39983820 G A 
11 exonic RPS24 NM_001142282:c.C391A:p.Q131K rs7899453     chr10 79799959 79799959 C A 
12 exonic TMPRSS6 NM_153609:c.T2207C:p.V736A rs855791 0.97 D 0 B chr22 37462936 37462936 A G 
13 exonic TMPRSS6 NM_153609:c.A757G:p.K253E rs2235324 0 T 0 B chr22 37485724 37485724 T C 
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Visual inspection of the 348 variant sequence calls revealed 13 to be valid, the 
others being invalid due to low coverage or resulting from misalignment.  Table 
7.2 shows the 13 possible sequence variants.  Further filtering removed 11 
sequence variants as these proved to all be tolerated benign SNPs, leaving 2 
possible pathogenic variants. Of these 2 variants, 1 confirmed the homozygosity 
for the sickle mutation (number 6) and 1 heterozygosity for the KLF1 splice site 
mutation (number 8).   
 
In summary, as no further mutations have been found to explain this 
gentleman’s asymptomatic phenotype, further family studies are now required 
to try and ascertain the phenotype of the KLF1 mutation on its own and with the 
sickle cell gene.  This patient has contacted his relations in Nigeria as he has 4 
siblings and both of his parents are still alive and well.  They have agreed to go 
to a local clinic in Nigeria and donate blood.  As well as family studies, 
functional analysis and gene expression of KLF1 with and without the mutation 
would confirm whether the KLF1 splice site mutation in case 12 is responsible 
for the increased HbF level seen. 
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CHAPTER EIGHT: HAEMOGLOBIN SWITCHING OCCURS EARLIER 
IN ASIAN-INDIAN NEWBORNS THAN NEWBORNS FROM OTHER 
ETHNIC GROUPS 
8.1 Introduction 
 
Newborns in the UK are screened for sickle cell disease and β-thalassaemia 
major at 5-8 days of age as part of the national dried blood spot screening 
programme (Streetly et al., 2009).  In the Thames Valley region of the UK we 
currently screen approximately 30,000 newborn blood spots a year.  Screening 
is carried out using a combination of high-performance liquid chromatography 
(HPLC) and isoelectric focusing (IEF).  The predominant haemoglobin at birth is 
HbF with HbA levels in normal term infants being in the range of 5-40%.  Whilst 
performing newborn screening for sickle cell and thalassaemia in the Thames 
Valley region I observed that the ratio of HbA to HbF appeared to show some 
variation with ethnic origin. Asian Indian (Indian, Pakistani and Bangladeshi) 
newborns had higher HbA levels than newborns from other ethnic groups.   
β- and α-thalassaemia are prevalent within this ethnic group, however, neither 
explains this finding.  The reason for the increased HbA level observed in Asian 
Indian newborns was unclear. 
8.2 Differences in haemoglobin switching in newborns 
 
HbA levels lower than normal (slowing of the switching process) have been 
shown in many pathological conditions.  These include premature newborns, 
maternal anoxia, placental insufficiency, intrauterine growth retardation, some 
chromosomal abnormalities, hyperinsulinaemia secondary to maternal diabetes 
mellitus and sudden infant death syndrome (Galacteros et al., 1991). 
Heterozygosity for β-thalassaemia also decreases HbA concentrations at birth 
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(Galanello et al., 1981).  A previous small study in 1987 had shown that 
newborns from the Far East (Japan and China) had slightly lower HbA levels at 
birth than infants from other ethnic groups (Kutlar et al., 1987).  However this 
study did not include Asian Indian newborns.   
 
Higher than normal HbA levels (accelerated Hb switching) can be an indication 
of a possible red blood cell transfusion, gestations >40 weeks or with larger 
than average birth weights (Galacteros et al., 1991, Smith and Cauchi, 1982).  It 
has also been reported to occur in some chromosomal abnormalities,  
γ-thalassaemia traits and in the Aγ-Aγ-globin gene rearrangement (Wilson et al., 
1968, Weller et al., 1966, Huisman et al., 1983).  In the Aγ-Aγ-globin gene 
rearrangement instead of having Gγ -Aγ-globin genes there is a nucleotide 
substitution at codon 136 and both Aγ-globin genes are inherited.   
8.3 Accurate HPLC quantitation of haemoglobins in newborns  
 
Newborn screening HPLC analysers for haemoglobinopathy identification are 
able to accurately identify the presence of clinically significant haemoglobin 
variants important in newborn screening such as sickle haemoglobin.  The 
major objective of all newborn haemoglobinopathy screening programmes is Hb 
identification rather than accurate quantitation.  The HPLC used in this study 
was a Bio-Rad Vnbs which adopts a set of integration rules to quantitate the 
percentage of haemoglobin present in a sample.  These integration rules were 
derived from those generated by the Genetic Disease Laboratory, California, 
USA after they analysed 2.5 million newborns by HPLC and are known to give 
slight variations in the quantitation of major haemoglobins within a given sample 
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run on separate occasions (Eastman et al., 1996).  Therefore in order to 
determine whether Asian Indians have increased HbA% when compared with 
other ethnic groups, accurate quantitation of HbA would be required. 
Discussions with the HPLC manufacturer, Bio-Rad about this problem led to the 
trial of some new improved integration software in development for the Vnbs 
analyser, termed Valley-to-Valley integration. This method provided consistent 
peak integration for each analysis.  The new Valley-to-Valley software was run 
in parallel with the old integration method for all newborn blood spots analysed 
during the work described in this chapter.  
 
8.4 Study subjects and laboratory procedures 
 
The ratio of HbA to HbF was studied in 2,286 term newborns (38-40 weeks 
gestation) from a variety of ethnic groups; all had a normal haemoglobin pattern 
(i.e. absence of any variant haemoglobin) and none of the newborns had 
received a blood transfusion.  The blood was collected from the heel of the baby 
between 5-8 days after birth and placed on a dried blood spot screening card by 
the midwife. Of the 2,286 samples, 1686 were of Caucasian origin, 496 were 
Asian Indian and 104 were of black African origin.  Along with the ethnic groups 
the birth weight, gestation and HPLC results were collected on all samples.  The 
blood spots for each newborn were run twice and in parallel with both software 
packages in order to ascertain which integration method gave the most reliable 
result.  Results were statistically analysed by means of an independent t-test 
using the software package Analyse -It®. 
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8.5 HbA levels in Caucasian, Asian Indian and black African 
newborns born at 38-40 weeks gestation 
 
The results showed that the Valley-to-Valley software integration gave HbA% 
approximately 0.2% higher for all samples than the existing software.  The 
results were reproducible and so the Valley-to-Valley software results were 
used to test the hypothesis.  Newborns born at gestation between 38-40 weeks 
were selected for analysis so as to eliminate premature newborns in the 
Caucasian or black African groups being responsible for the differences in HbA 
levels observed. The results revealed an average level of HbA in Asian Indian 
newborns of 20.0%, which was significantly higher (p=<0.001) than the average 
level of 17.4% observed in Caucasian babies, and 18.6% observed in babies of 
African origin (Table 8.1).  The standard deviation of the HbA levels in Asian 
Indian newborns (SD 7.2) was significantly greater than in Caucasian newborns 
(SD 6.0). This finding indicated that the increased average HbA level was due 
to a sub-group of infants with higher HbA levels (Fig 8.1). 
 
 
 
Table 8.1 HbA % in newborns from Caucasian, Asian Indian and black 
African origins 
 
 
Ethnicity n Average HbA%* Significance p value 
Caucasian 1686 17.4 ± 6.01 
(4.2 - 42.5) 
- - 
Asian Indian 496 20. 0 ± 7.16 
(5.5 - 43.3) 
Indian/Caucasian <0.001 
Black African 104 18.6 ± 7.05 
(5.9 - 37.9) 
Black/Caucasian <0.05 
 *Average Hb A % ± SD and range between parentheses 
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Figure 8.1 Histogram and boxplot showing HbA levels in each ethnic 
group.  
a) Caucasian b) Asian Indian c) black African 
 
Key:      Normal fit distribution              +       Outliers   
               
                       95% CI Outlier boxplot        95% CI mean  
 
 
HbA % 
HbA % 
HbA % 
    HbA % 
HbA % 
HbA % 
a) 
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8.6 Birth weight  
 
Differences in birth weight could be responsible for the increased HbA% seen in 
the Asian Indian newborns.  The birth weights of newborns born at gestation  
38-40 weeks were analysed. Results showed a statistical significance 
(p=<0.001) between the birth weights in the Asian Indian group compared to the 
Caucasian group (Table 8.2).  However the difference shown was that the Asian 
Indian newborns had the lowest birth weights (mean 3.1kg) with the Caucasian 
newborns being the heaviest (3.4 kg) (Table 8.2 and Figure 8.2).  A recent large 
study in the UK confirmed the same findings and found that newborns born from 
Asian Indian parents had considerably smaller birth weight babies than those 
born from European parents (Wells et al., 2013). 
 
 
 
Table 8.2 Average birth weight at term (38-40 wks gestation) from 
Caucasian, Asian Indian and black African newborns 
 
 
 
Ethnicity n Average Birth 
weight (kg)* 
Significance p value 
Caucasian 1686 3.4 ± 0.45 
(1.8 – 5.0) 
- - 
Asian Indian 496 3.1 ± 0.47 
(1.4 – 5.0) 
Indian/Caucasian <0.001 
Black African 104 3.3 ± 0.45 
(2.5-4.2) 
Black/Caucasian 0.309 
(not sig) 
* Average birth weight (kg) ± SD and range between parentheses 
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Figure 8.2 Histogram and boxplot showing the birth weight (g) at 38-40 
weeks gestation in each ethnic group.  
a) Caucasian b) Asian Indian c) black African 
 
Key:      Normal fit distribution              +       Outliers   
               
                        95% CI Outlier boxplot         95% CI mean 
 
a) 
b) 
c) 
Birth weight (g) Birth weight (g) 
Birth weight (g) Birth weight (g) 
Birth weight (g) Birth weight (g) 
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8.7 γ-thalassaemia 
 
Increased birth weight and gestation have been ruled out as the reason for the 
increased HbA levels observed in Asian Indian newborns but could this finding 
be explained by a cohort of Indian infants who have increased HbA levels at 
birth because they are carriers for γ-thalassaemia?  Cases of γ-thalassaemia 
have been described in most populations (Chinese, Indian, European, 
Japanese and African).  Huisman et al (1983) showed it occurred at very low 
frequencies in India; however they only looked at 208 newborns from Bombay.  
A further small study looked at 200 Indians from the Gond tribe of central India 
and failed to observe γ-thalassaemia among the tribe although other 
haemoglobinopathies such as sickle haemoglobin and α-thalassaemia were 
evident (Gupta et al., 1991).  
 
Only one type of γ-thalassaemia has been described (Figure 8.3) and it arises 
from a deletion of approximately 5kb which is the result of an unequal crossover 
between the Gγ- and Aγ-globin genes forming a GAγ-hybrid gene (Sukumaran et 
al., 1983). Deletion of a γ-gene removes competition for the upstream β-LCR 
leading to increased interaction of the β-LCR with the β-gene in cis, thus 
enhancing its expression.  This hybrid produces a protein product identical to 
the Aγ-gene but at a level normally seen for the Gγ-gene which explains why this 
deletion is not symptomatic even in the homozygous condition. Cases of  
γ-thalassaemia are also rarely detected because they would only be observed 
for a short period of time after birth when the unusually high HbA% is evident. 
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Figure 8.3 Schematic representation of deletional γ-thalassaemia.  
Sequencing the junction fragment reveals the presence of a hybrid gene 
identical to Gγ-gene before the polymorphic TG repeat in IVS2 and identical to 
the Aγ-gene after this repeat. The size of the deletion corresponds exactly to the 
size of DNA which separates the γ-genes. 
 
8.7.1 Identification of γ-thalassaemia by MLPA  
As already discussed in chapter 3, the MLPA technique detects large deletions 
and rearrangements in the β-globin gene cluster.  There are three probes 
spanning the γ-globin genes in the ServiceXS β-globin gene cluster probe set, 
with one probe (probe 16) targeting the intergenic region between the Gγ- and 
Aγ-gene.  Therefore it was possible to detect heterozygosity and homozygosity 
for γ-thalassaemia using the ServiceXS β-globin gene cluster MLPA probe set.  
MLPA is best suited to good quality DNA but only small amounts of dried blood 
spot samples were left with the majority being over a month old.  DNA was 
extracted from 10 newborn dried blood spots analysed from the 496 Asian 
Indian cohort who had HbA% ranging from 35-45%.  Results for the MLPA  
β-globin gene cluster probe set (β-globinxs MLPA Kit; ServiceXS) showed that 6 
out of the 10 samples had normal peak heights for all probes and therefore no 
evidence of the deletional  γ-thalassaemia already described.  The remaining 4 
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samples failed to achieve good quality MLPA results and had low signal 
strength.  This was most likely due to the age of the dried blood spot and the 
small sample size. 
8.7.2 Case of γ-thalassaemia in an Asian Indian family 
Whilst undertaking this study a family were referred to the laboratory from a 
hospital in Leeds, UK for investigations into a newborn Pakistani presenting at 
birth (40 weeks gestation) with a HbA level of 70% (Table 8.3).  No other 
abnormalities were evident and the proband was clinically well. The pregnancy 
and birth were uncomplicated and the proband had two normal siblings.  The 
proband had not received a red blood cell transfusion and had a healthy birth 
weight (3.21kg). The mother and father had no evidence of a 
haemoglobinopathy on antenatal screening.  EDTA whole blood samples were 
received from the mother, father and proband.  Haematological parameters 
were ascertained and DNA extraction performed as previously described 
(section 2.2 and 2.3).   
 
Table 8.3 Haematological data in family with γ-thalassaemia. 
 
 Hb 
g/dl 
RBC 
106/mm3 
MCV 
fl 
MCH 
pg 
HbA 
% 
HbF 
% 
HbA2 % 
Mother 12 4.5 93 27 87 0.2 2.8 
Father 15 5.4 93 28 86 0.2 2.6 
Proband 10 3.7 92 27 71.2 15 1.2 
 
Sequence analysis of the α- and β-globin genes was performed on all three 
samples and revealed no mutations.  The very high HbA% in the proband with 
no apparent haemoglobinopathy in the parents could be explained by the 
inheritance of γ-thalassaemia.   This is because γ-thalassaemia would only be 
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detected in adults by DNA analysis as the haematological parameters would be 
normal.  MLPA analysis using the ServiceXS β-globin gene cluster probe set 
was carried out on the family and the results showed a heterozygous deletion in 
probe 16 in both the proband and the father (Figure 8.4).  The mother showed 
no evidence of any deletions or rearrangements in the β-globin gene cluster.  
Probe 16 sits between the Gγ- and Aγ-gene and could indicate inheritance of the 
only deletional γ-thalassaemia described to date.   
 
 
 
Gγ Aγ ε
5 3
δ
21 24 26 28 32   33
Normal Control Proband
16
16
16
15 17
 
 
 
 
 
 
Figure 8.4 β-globin gene cluster MLPA results (ServiceXS) on the Asian 
Indian family.  a) Schematic diagram of the position of the sequence where 
probe 16 anneals on the β-globin gene cluster (green arrows represent the 
positions of some of the probes) b) MLPA results of a normal control and the 
proband.  Probe 16 is reduced by half height in the proband when compared to 
the control indicating the presence of a heterozygous deletion. 
 
a) 
b) 
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The MLPA results showed the presence of a heterozygous deletion however 
the proband had what would appear to be almost homozygous levels of HbA 
(70%).  Reports of patients with heterozygous γ-thalassaemia have shown HbA 
levels of 45% so further studies on this family need to be carried out to see 
whether they also have a γ-globin gene rearrangement or γ-globin variant as 
well as γ-thalassaemia.   
8.7.3 Identification of γ-thalassaemia by Gap-PCR 
No further DNA was available from the Asian Indian newborn dried blood spots 
as all the blood spots had been utilised.  Therefore in order to determine if the 
cohort of Indian infants who have increased HbA levels at birth are carriers for 
γ-thalassaemia, alternative samples were required to determine the frequency 
of γ-thalassaemia in the Asian Indian population.  Whole blood samples from 
300 adult Asian Indian (Pakistani, Bangladeshi and Indian) patients referred to 
the laboratory for either routine antenatal screening or partner testing were 
collected and the DNA extracted.  A full blood count and haemoglobinopathy 
screen by HPLC had been carried out.  Two hundred and forty three samples 
showed no evidence of a haemoglobinopathy, 48 had possible α+-thalassaemia, 
7 β-thalassaemia trait and 2 HbE trait. 
 
A Gap-PCR was designed to flank the deleted region of the γ-thalassaemia 
deletion mutation already described.  Primers were designed to flank the  
Gγ- and Aγ-gene: forward 5 TGTTGCTTTATAGGATTTTTCACT 3 and reverse 
5 TGATGAGCAAATAAAAGCAGTAAA 3, giving a mutant band of 2,526bp.   
A set of control primers were also added which targeted a sequence in the β-
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globin gene and therefore acted as non γ-gene specific primers: forward 5 
TAATCTGAGCCAAGTAGAAG 3 and reverse 5 CACTGATGCAATCATTCGTC 
3 and gave a control band size of 1,500bp.  The father and proband of the 
Asian Indian family with the deletional γ-thalassaemia were used as a positive 
control (Figure 8.5). The PCR reaction was performed in 25µl reaction volume 
containing 100-250ng of genomic DNA, 2 units of Taq polymerase, 10pmol of 
the γ-gene primer, 0.5pmol of the control primers, 0.2mM dNTPs, 2.0mM 
MgCl2,1 X Buffer IV (Abgene).  The cycling conditions were 95
0C for 5 min, 30 
cycles at 950C for 1 min, 620C for 2 min, 720C for 2 min and a final extension 
720C for 10 mins.   
 
 
 
 
 
Figure 8.5 Gap-PCR showing the 4.9kb γ-thalassaemia deletion mutation. 
Lane 1: Negative control 
Lane 2: Proband 
Lane 3: Father  
Lane 4: Blank 
Lane 5: 100bp marker 
 
Of the 300 adult Asian Indians analysed by Gap-PCR all were negative for the 
4.9kb γ-thalassaemia deletion mutation. This confirmed the low frequency of the 
4.9kb γ-thalassaemia deletion mutation in the Asian Indian population. 
 1        2        3       4       5 
Control 
1,500bp 
 Mutant 
2,526bp 
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8.7.4 Chromosomal abnormalities 
Chromosomal abnormalities have been associated with the differences in the 
timing of haemoglobin switching in newborns.  In 1966 there was a report on a 
child with a severe chromosomal abnormality (C/D translocation) who had 
started to switch from fetal to adult haemoglobin long before birth (Weller et al., 
1966).  His HbF% at 24 days was 9%.  Two years later in 1968 the 
haemoglobin levels of 12 infants with Down’s syndrome were compared against 
48 normal term newborns (Wilson et al., 1968). The infants with Down’s 
syndrome were found to have low HbF levels of 60%.  Discussions with the 
newborn screening midwive in Oxford confirmed that chromosomal 
abnormalities were not the reason for the increased HbA levels seen in the 
Asian Indian newborns in this study.  There was no evidence that any of the 
Asian Indian babies with elevated HbA levels had been referred to a paediatric 
clinic or had further tests for a possible chromosomal abnormality.   
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8.8 Discussion 
 
Whilst performing newborn screening in Oxford I observed that Asian Indian 
newborns had higher HbA% when analysed by HPLC than other ethnic groups.  
Several studies in the 1980s showed that there were differences in the timing of 
haemoglobin switching amongst newborns.  Many of these studies focused on 
the ratios of Gγ- and Aγ-chains at birth rather than HbF and HbA. They confirmed 
that some newborns had higher or lower Gγ- and Aγ-chain ratios than others.  
Only one report looked at the differences in the mean HbA values at birth in 
newborns from different countries but did not include Asian Indians (Kutlar et 
al., 1987).  They did however show that Far East Asian newborns (Chinese  
and Japanese) had lower HbA% when compared to Mediterranean and black 
African newborns. Other studies went on to report that γ-thalassaemia was 
present in these ethnic groups which would be expected to increase HbA levels.   
Therefore it was unclear why the 496 Asian Indian newborns analysed had had 
higher mean HbA levels (20.0%) at birth compared with the Caucasian (17.4%) 
and Black (18.6%) groups.  Statistical analysis using the independent t-test 
showed that the standard deviation in the Asian Indian newborns was high (SD 
7.16) and from the results it could be seen that there was a sub-group of Asian 
newborns with high HbA levels at birth.   
 
Birth weight and gestational age are known factors that can increase HbA levels 
in newborns.  Gestational differences were excluded by selecting newborns 
born at term (38 to 40 weeks).  The birth weights of the 2,286 newborns were 
collated and statistical analysis of the mean birth weights within each ethnic 
group showed that the Asian Indians newborns were lighter at birth.  A previous 
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large study of 6,123 newborns in France showed that babies with an increased 
birth weight have a higher HbA level at birth (Galacteros et al., 1991). 
Therefore it would not be expected that smaller birth weight newborns would 
have higher HbA% as evident in the Asian Indian group. 
Increased birth weight, gestational age and chromosomal abnormalities were 
not able to explain the finding of higher HbA levels in Asian Indian newborns but 
maybe it could be explained by a cohort of Asian Indian newborns with 
γ-thalassaemia.  Although γ-thalassaemia had been reported to be rare in most 
populations, accurate frequency data within many populations did not exist and 
only small sample numbers from Asian Indians from one particular region or 
tribe had been studied (Huisman et al., 1983, Huisman et al., 1991, Huisman et 
al., 1985b).  Only 6 of the 10 samples chosen with high HbA levels in the Asian 
Indian cohort had sufficient amounts of good quality DNA for MLPA analysis of 
the β-globin gene cluster. Results showed no evidence of deletional 
γ-thalassaemia or a γ-globin gene rearrangement.  Further studies on the 
differences in newborn haemoglobin levels between the ethnic groups would 
ideally require consent at birth for another dried blood spot or a cord blood 
sample to be taken from the newborn. DNA analysis of the 
γ-globin genes by MLPA would then be possible and the frequency of 
γ-thalassaemia and γ-globin gene rearrangements in each ethnic group 
determined. Obtaining further blood samples and undertaking family studies on 
specific cases with high HbA levels such as in the Asian Indian family referred 
from Leeds with γ-thalassaemia would be valuable in trying to determine the 
cause of the differences seen in HbA levels in newborns. 
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γ-thalassaemia is analogous to the 3.7kb α+-globin gene deletion mutation and 
like the α-globin genes the γ-globin genes have highly homologous flanking 
sequences which represent a potential target area for genetic rearrangements.  
The 3.7kb α+-thalassaemia deletion is very frequent in Asian Indians and 
therefore it would be thought that γ-thalassaemia is too.  DNA was extracted 
from 300 adult Asian Indians and a Gap-PCR designed to detect the 4.9kb 
deletional γ-thalassaemia in order determine what the frequency of this mutation 
was in the Asian Indian population.  The referral of the Asian Indian family with 
the 4.9kb γ-thalassaemia deletion mutation also indicated that these mutations 
exist within this population.   All 300 adult samples gave negative results by 
Gap-PCR for the deletional 4.9kb γ-thalassaemia mutation.  Results showed 
that the frequency of this mutation is low within Asian Indians but it might be 
that other novel types of γ-thalassaemia are prevalent.  It is unlikely that there is 
only one type of γ-thalassaemia mutation and with the emergence of DNA 
techniques like MLPA, which is in routine use in most laboratories now, gene 
deletions and rearrangements can be more easily detected allowing for the 
detection of novel mutations.  Therefore the hypothesis that γ-thalassaemia 
might be responsible for the increased HbA levels seen in several Asian Indian 
newborns can only be answered by further large scale studies.  
 
Further DNA analysis by γ-globin gene sequencing would also be to identify the 
presence of the Aγ -Aγ-globin gene rearrangement.  Although reported to be 
relatively rare it has been found in black African, Chinese, Japanese and 
Mediterranean newborns (Huisman et al., 1983).  This rearrangement is also 
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responsible for lowering HbF levels and therefore increasing HbA levels in 
newborns.   
 
In summary, this is the first study to identify a cohort of Asian Indian newborns 
that undergo haemoglobin switching earlier than other ethnic groups.  It was not 
possible to identify the precise mechanisms involved and large scale DNA 
studies would need to be carried out to determine whether γ-globin gene 
deletions or rearrangements are responsible for this finding.  As well as looking 
at the γ-globin genes it would be interesting to study the other known factors 
involved in haemoglobin switching such as the transcription factors KLF1 and 
BCL11A.   
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CHAPTER NINE: DISCUSSION 
9.1 Summary of findings 
 
The work described in this thesis aimed to increase our knowledge and 
understanding of what the genetic reasons are for the variations in HbF levels 
seen in the UK population with a view to further understanding some of the 
molecular mechanisms involved.   
 
One well documented cause of HPFH is the inheritance of deletions in the  
-globin gene cluster.  Yet the frequency and range of deletional -globin gene 
cluster mutations in the UK population was unknown.  The work described in 
chapter 3 used samples taken from a large diverse ethnic population with an 
HPFH phenotype to determine that -globin gene cluster deletions are present 
at significant frequencies in the UK population.  24% of the selected samples 
were found to have a deletion. A wide spectrum of mutations were identified 
and found in all major UK population ethnic groups.  This study also evaluated 
the efficacy of the recently available technique of MLPA and concluded that the 
technique should be the recommended as the first choice method for screening 
for these clinically significant large deletion mutations in a routine diagnostic 
laboratory setting.   
 
The work described in chapter 3 identified 4 possible novel deletions in the  
β-globin gene clusters of patients from the UK population.  The work described 
in chapter 4 used several DNA techniques to try and determine the exact 
breakpoints in each deletion in order to gain an understanding of the molecular 
mechanisms involved.  Two of the 4 deletions were characterised fully.  
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Deletion 1, a novel 909 bp β-globin gene mutation was the first reported case of 
a β-globin gene deletion in the Afghan population. The deletion was caused by 
a non homologous recombination event; however there were AT-rich stretches 
of sequences around the 5 breakpoint thought to be significant in the 
generation of β-globin gene deletions.  Deletion 2 was the previously reported 
1,393bp β-globin gene deletion, highlighting the fact that the MLPA technique 
cannot size deletions accurately when polymorphisms in the target sequence 
are present.  A similar problem arose with deletion 3 as repeated efforts to map 
the breakpoints failed possibly due to incorrect sizing of the deletion by the 
MLPA probes.  Microarray analysis showed the presence of a heterozygous 
Aγδβ-thalassaemia deletion.  Further primer walking with the new array deletion 
breakpoints should enable confirmation of its precise size. Deletion 4 was a rare 
(εγδβ)0-thalassaemia deletion found in 12 family members of a large Asian 
Indian pedigree.  All MLPA probe sets were reduced making identifying the 
exact breakpoints difficult. Microarray analysis confirmed a large  
(εγδβ)0-thalassaemia mutation which could be the Pakistani I deletion mutation.   
 
Among the factors known to influence increases in HbF production are a 
number of point mutations in the promoter region of the γ-globin genes.  The 
range and frequency of non-deletion HPFH γ-globin gene point mutations in the 
UK population was unknown.  The work described in chapter 5 demonstrated 
that these mutations are a frequent cause of non-deletion HPFH in the UK and 
were found in 28 (21%) patients.  Six of the mutations identified were previously 
reported point mutations and three were novel mutations.  Interestingly most 
mutations were found in white British individuals and is a likely cause of  
 
 155 
non-deletion HPFH in the British population.  It is expected that this mutation 
has arisen independently and has been established through genetic drift.  The 
frequency of γ-globin gene promoter mutations in patients with an unexplained 
increased HbF and a haemoglobinopathy were low.  The three novel mutations 
were found in important regions for transcription factor binding.  This suggested 
that the molecular mechanism responsible for the upregulation of HbF involved 
altering the binding site for a particular transcription factor. 
 
The work described in chapter 6 looked at three polymorphisms in the major loci 
(XmnI-HBG2, HBS1L-MYB and BCL11A) that have been identified and shown 
previously to account for 20-50% of the variation in HbF levels in patients.  The 
strongest statistical association with the three polymorphisms and HbF 
expression was seen in β-thalassaemia trait subjects with the XmnI-HBG2 
polymorphism. The SNPs in BCL11A and HBS1L-MYB failed to show statistical 
correlations with HbF.  These results confirm the findings of previous studies 
that have suggested that BCL11A and HBS1L-MYB have a minor effect on HbF 
levels compared to the XmnI polymorphism in β-thalassaemia patients.  Further 
large scale studies would need to be performed in order to accurately determine 
whether BCL11A and HBS1L-MYB are involved in increased HbF expression in 
our individuals with an HPFH phenotype.   
 
Recent reports have identified mutations in the KLF1 gene which are associated 
with a variety of phenotypes in humans.  The work described in chapter 7 
identified KLF1 mutations in patients with increased HbF levels.  Mutations 
predicted to have an effect were found in 11 (8.4%) out of 131 referrals with 
increased HbF levels and one patient with HbSS.  All the mutations identified 
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were heterozygous indicating that a single altered KLF1 allele can elevate HbF. 
Mutations were identified in individuals predominantly of African, Indian and 
Southeast Asian descent demonstrating that KLF1 mutations could be a 
widespread cause of HPFH in malarial regions where haemoglobinopathies are 
common. The identification of a KLF1 mutation in an individual with a 
particularly mild form of sickle cell disease required further investigation.  Apart 
from the inheritance of co-existing α-thalassaemia there was no explanation as 
to why his Hb level was normal and he had an asymptomatic phenotype.  If the 
KLF1 mutation is responsible for his dramatic phenotype amelioration then it 
would be highly significant as it would provide in-vivo evidence that controlled 
reduction of KLF1 expression could be an effective treatment for sickle cell 
disease.  Whole genome SNP array analysis revealed that part of chromosome 
11p showed an area with uniparental disomy (UPD).  These results explained 
why there was no family history of sickle cell disease but did not offer any 
explanation as to why he was asymptomatic. Whole exome sequence analysis 
confirmed the two variants already identified but failed to identify any further 
mutations in other genes which could explain this unusual phenotype. Further 
family studies are required to ascertain the phenotype of the KLF1 mutation on 
its own and with the sickle cell gene.   
 
Finally, the finding that Asian Indian newborns appeared to undergo 
haemoglobin switching earlier than other ethnic groups was investigated in 
chapter 8.  The reason for the increased HbA level observed in Asian Indian 
newborns was unclear.  The ratio of HbA to HbF was studied in 2,286 term 
newborns from a variety of ethnic groups and Asian Indian newborns analysed 
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had higher mean HbA levels at birth compared with the Caucasian and black 
groups.  Statistical analysis showed that there was a sub-group of Asian Indian 
newborns with high HbA levels at birth.  Increased birth weight, gestation and 
chromosomal abnormalities were shown not to be the cause of the high HbA 
levels.  The frequency of γ-thalassaemia which could be responsible for the 
earlier switching in the in the Asian Indian newborns was unknown.  Six Asian 
Indian newborns with high HbA levels were analysed by MLPA for  
γ-thalassaemia and the results failed to show any evidence of deletional  
γ-thalassaemia or a γ-globin gene rearrangement.  The recent referral of an 
Asian Indian family with the 4.9kb γ-thalassaemia deletion mutation indicated 
that these mutations exist within this population.  Therefore 300 adult Asian 
Indian samples were analysed for the deletional 4.9kb γ-thalassaemia mutation 
and all gave a negative result for this deletion.  The frequency of this mutation in 
Asian Indian is therefore low but what cannot be excluded is that other novel 
types of γ-thalassaemia might be prevalent.  This is the first study to identify a 
cohort of Asian Indian newborns undergoing haemoglobin switching earlier than 
other ethnic groups.  It was not possible to identify the precise mechanisms 
involved and large scale DNA studies would need to be carried out to try and 
determine whether γ-globin gene deletions or rearrangements are responsible 
for this finding.   
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9.2 Conclusions 
 
Figure 9.1 shows a summary of the results (chapters 3-7) from the cohort of 
patients with increased HbF levels and patients with a haemoglobinopathy and 
unexplained elevated HbF.  The results determine the frequency of deletional 
and non-deletion HPFH in the UK population which was otherwise unknown.  
As our laboratory is the UK National Haemoglobinopathy Reference Centre 
(NHRL) this study benefitted from being able to research patient samples from a 
wide variety of ethnic groups.  This enabled the identification of the range of 
mutations present in all ethnic groups residing in the UK with the discovery of 
16 novel mutations.  Since the introduction of MLPA for detecting deletions in 
the globin gene clusters many new deletion mutations are being identified 
showing that deletions in these clusters occur more frequently than was first 
thought.   
 
Figure 9.2 shows a summary of results of the frequency of non-deletion HPFH 
(chapters 5-7) in both patients with high HbF only and patients with a 
haemoglobinopathy and an unexplained raised HbF level.  Being able to study 
these two cohorts of patients enabled the determination of whether some 
mutations are associated with disease traits.  One interesting finding was that  
γ-promoter mutations appear to occur more frequently in populations without a 
significant haemoglobinopathy and that it is a likely cause of HPFH in white 
British individuals with only two mutations having been found in this ethnic 
group.  There is a selective advantage for having increased HbF levels as HbF 
provides protection from malaria by the retardation of parasite growth.  
Therefore it is likely that the British γ-promoter mutations have arisen from 
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genetic drift and that similar to British α0-thalassaemia these mutations 
originally came from malarial regions.  Figure 9.2 also shows that KLF1 
mutations are responsible for increased HbF levels in non-deletion HPFH in 
both patients with and without a haemoglobinopathy.  As discussed, mutations 
in the KLF1 gene have been associated with several different phenotypes but 
this study also identified KLF1 mutations with disease traits (HbEE and HbSS).  
Another interesting finding was that mutations in the KLF1 gene were not linked 
to γ-promoter mutations. 
 
This thesis has revealed the genetic factors responsible for an HPFH phenotype 
in 40% of the patient samples studied.  Although the frequency of mutations 
was higher than originally suspected there are still a large proportion of patient 
samples (60%) with an unexplained raised HbF for which no genetic 
determinant could be found.    
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Figure 9.1 Summary of results showing the frequency of deletional and non deletion HPFH in the UK population.   
The numbers in each box represent the number of patients with the each type of HPFH.   
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Figure 9.2 Summary of results showing the frequency of non deletion HPFH in both patients with high HbF only and 
patients with a haemoglobinopathy and an unexplained raised HbF level. The numbers in each box represent the number 
of patients with the each type of HPFH. 
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9.3 Future work 
 
There are still many unanswered questions which require more extensive 
investigations.  It was not possible with the small cohorts of samples in this 
study to fully evaluate the three loci (XmnI-HBG2, HBS1L-MYB, and BCL11A) 
shown in previous large GWAS studies to be responsible for variation in HbF 
levels.  New research has also suggested that further genetic factors might play 
a role in the regulation of HbF (HDAC1/2, miRNA-15A/16-1, PRMT1, TR2, TR4 
and COUP-TFII) (Sankaran, 2011).  The fact that there are so many genetic 
factors recently identified and thought to be involved in the regulation of HbF 
lends promise to this field.  In order to evaluate some of these potential factors 
the use of targeted next-generation sequencing (NGS) could be employed.  
Specific panels designed to screen the regions of interest for rare and common 
mutations causing red cell disorders (rare anaemias, red cell enzymopathies 
and the haemoglobinopathies) could be implemented in specialist centres.  This 
would offer clinicians a one-stop effective test for screening patients and not 
only will discover known mutations but will allow scope for the discovery of new 
mutations and perhaps new genes.   This new era of NGS technology holds a 
number of potential advantages over traditional methods, including the ability to 
fully sequence large numbers of genes (hundreds to thousands) in a single test. 
NGS can detect deletions, insertions, copy number alterations, translocations, 
and exome-wide base substitutions in all the known red cell related genes. 
Continuing advances in NGS technology should provide us with more insight 
into the molecular mechanisms involved with the potential of revealing new 
targets for therapeutic intervention. 
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APPENDICES 
APPENDIX 1: Diagram showing the principle of the MLPA 
technique 
 
 
Outline of the MLPA reaction (adapted and modified from Schouten et al., 2002 
and www.mrc-holland.com) 
 
 
 
 
 
1).  Annealing of  50 probe sets
covering 500kb of β gene cluster
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APPENDIX 2: Schematic representation of β-globin gene cluster 
MLPA probe set designed by Harteveld et al (2005). 
 
 
The genes throughout the β-globin gene cluster are represented by light blue 
boxes.  The three (green, blue and red) probe set positions in the cluster are 
indicated by the coloured arrows.  The bottom diagram shows a closer 
representation of the probes whose target sequence is in the region where the 
δ- and β-globin genes are found. (adapted and modified from Harteveld  
et al., 2005) 
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APPENDIX 3: Pyrosequencing assay design rs 11886868 
 
a) Pyromark Assay Design Software 2.0 showing the primer set properties for 
SNP rs 11886868 
 
 
chr2:60720083+60720375  
 
Primer Set 1  Score: 100  
General Warnings    
 
F1    
 
R1    
 
S1    
 
 
 PCR Product  Forward PCR Primer, F1 Reverse PCR Primer, R1 Sequencing Primer, S1  
Length, bp  183  18  21  20  
Position, 5'- 3'   17 - 34  199 - 179  142 - 161  
Warnings          
Tm, ºC   69.2  69.3  52.0  
%GC  44.3  50.0  42.9  30.0  
Sequence to Analyze   
 
b) Results of pyrosequencing rs 11886868:  i) wild type (TT) ii) heterozygote 
(TC) and iii) homozygote (CC) samples. 
 
 
 
i)        ii) 
          
 
iii) 
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APPENDIX 4: Pyrosequencing assay design rs 9399137 
 
a) Pyromark Assay Design Software 2.0 showing the primer set properties for 
SNP rs 9399137 
 
 
chr6:135418885+135419101  
 
Primer Set 1  Score: 100  
General Warnings    
 
F1    
 
R1    
 
S1    
 
 
 PCR Product  Forward PCR Primer, F1 Reverse PCR Primer, R1 Sequencing Primer, S1  
Length, bp  94  24  21  18  
Position, 5'- 3'   66 - 89  159 - 139  152 - 135  
Warnings          
Tm, ºC   71.2  71.2  51.7  
%GC  33.0  41.7  42.9  33.3  
Sequence to Analyze   
 
 b) Results of pyrosequencing rs 11886868:  i) wild type (TT) ii) heterozygote 
(TC) and iii) homozygote (CC) samples. 
 
 
 
i)      ii) 
 
       
 
 
iii) 
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APPENDIX 5: Statistical analysis 
 
Chapter 6 required the use of two statistical tests, one-way ANOVA and 
Dunnett’s test.  Chapter 8 analysed data using an independent t-test.  All 
statistics were performed using the software package Analyse-it®.   
 
ANOVA 
Analysis of variance (ANOVA) test was used to analyse the differences 
between the group means and their associated "variation" in HbF among the 
groups. ANOVA provides a statistical test of whether or not the means of 
several groups are equal, and therefore generalizes the t-test to more than two 
groups. ANOVAs are useful in comparing three or more means (groups or 
variables) for statistical significance. 
 
Dunnett’s test 
ANOVA is able to say whether there was an overall difference between the 
groups analysed but cannot tell which specific groups differed.  Therefore a 
further test is required.  The Dunnett’s test was chosen as it is the most 
powerful method at performing pair-wise comparisons.  This test is able to make 
comparisons between the groups and also compares groups against a control 
(in this study the wild type allele). 
 
Independent t-test 
The independent t-test compares the means between two unrelated groups on 
the same continuous, dependent variable. 
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